US20170296740A1 - Modular combination of medication infusion and analyte monitoring - Google Patents
Modular combination of medication infusion and analyte monitoring Download PDFInfo
- Publication number
- US20170296740A1 US20170296740A1 US15/582,878 US201715582878A US2017296740A1 US 20170296740 A1 US20170296740 A1 US 20170296740A1 US 201715582878 A US201715582878 A US 201715582878A US 2017296740 A1 US2017296740 A1 US 2017296740A1
- Authority
- US
- United States
- Prior art keywords
- analyte
- infusion device
- patient
- sensor
- infusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M2005/14268—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body with a reusable and a disposable component
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
- A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3561—Range local, e.g. within room or hospital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3592—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/36—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests with means for eliminating or preventing injection or infusion of air into body
- A61M5/365—Air detectors
Definitions
- the present disclosure related to methods and systems for integrating infusion systems and analyte monitoring systems. More specifically, the present disclosure related to methods and systems for providing modular combination for integrated infusion and analyte monitoring systems.
- Type 1 diabetes must periodically be administered with insulin to sustain their physiological conditions.
- these patents administer doses of either fast acting or slow acting insulin using needle type syringes, for example, prior to meals, and/or at a suitable time during the course of each day contemporaneously with the blood glucose level testing using fingerstick testing, for example. If insulin is not suitable administered, the diabetic patients risk serious if not fatal damage to the body.
- the patient inserts a cannula which is connected to an infusion tubing attached to an external pump, and insulin is administered based on a preprogrammed basal profiles.
- the external infusion devices presently available include computational capability to determine suitable bolus doses such as carbohydrate bolus and correction bolus, for example, to be administered in conjunction with the infusion device executing the patient's basal profile.
- the basal profiles are generally determined by the parent's physician or caretaker and are based on a number of factors including the patient's insulin sensitivity and physiological condition which are diagnosed by the patient's physician, for example, and are typically intended to as accurately estimate the patient's glucose levels over a predetermined time period during which the patient is infusing insulin.
- the glucose levels may be estimated based on the patient's periodic discrete testing using a test strip and a blood glucose meter such as Freestyle® Glucose Meter available from Abbott Diabetes Care, Inc., of Alameda, Calif. Such estimations are, however, prone to error, and do not accurately mirror the patient's actual physiological condition.
- each aspect of the infusion and the analyte monitoring require components that are configured to execute the associated functions related to, for example, the control and management of insulin delivery and analyte monitoring.
- these components are prone to failure or otherwise periodic replacement due to ordinary usage.
- a modular system including medication delivery unit such as an insulin pump, and an analyte monitoring device such as a continuous glucose monitoring system, that would allow for component based replacement when one or more aspects of the overall therapy management system fails or requires replacement.
- FIG. 1 illustrates an integrated infusion device and analyte monitoring system in accordance with one embodiment of the present disclosure
- FIG. 2 illustrates an integrated infusion device and analyte monitoring system in accordance with another embodiment of the present disclosure
- FIG. 3 illustrates an integrated infusion device and analyte monitoring system in accordance with yet another embodiment of the present disclosure
- FIG. 4 illustrates an integrated infusion device and analyte monitoring system in accordance with still another embodiment of the present disclosure
- FIG. 5 illustrates an integrated infusion device and analyte monitoring system in accordance with still a further embodiment of the present disclosure
- FIG. 6 illustrates an integrated infusion device and monitoring system in accordance with yet still a further embodiment of the present disclosure
- FIG. 7 A illustrates the integrated infusion device and monitoring system shown in FIG. 6 in further detail in one embodiment of the present disclosure
- FIGS. 7B-7C illustrate the analog front end circuitry located at the patient interface and the pump assembly, respectively, of the integrated infusion device and monitoring system shown in FIG. 7A in accordance with one embodiment of the present disclosure
- FIGS. 8A-8C illustrate a passive sensor configuration for use in a continuous analyte monitoring system, and two embodiments of an active sensor configuration for use at the patient interface in the integrated infusion device and monitoring system, respectively, in accordance with one embodiment of the present disclosure
- FIG. 9 illustrates an integrated infusion device and analyte monitoring system with the infusion device and the monitoring system transmitter integrated into a single patch worn by the patient in accordance with one embodiment of the present disclosure
- FIG. 10 is a detailed view of the infusion device cannula integrated with analyte monitoring system sensor electrodes in accordance with one embodiment of the present disclosure
- FIG. 11A illustrates a component perspective view of the infusion device cannula integrated with analyte monitoring system sensor electrodes in accordance with another embodiment of the present disclosure
- FIG. 11B illustrates a top planar view of the analyte monitoring system transmitter unit integrated with infusion device in accordance with one embodiment of the present disclosure
- FIG. 12A-12C each illustrate a cross sectional view of the infusion device cannula integrated with continuous analyte monitoring system sensor electrodes of FIG. 10 in accordance with the various embodiments respectively, of the present disclosure
- FIG. 13 is a timing chart for illustrating the temporal spacing of blood glucose measurement and insulin delivery by the migrated infusion device and monitoring system in one embodiment
- FIGS. 14A-14C illustrates modular combination of medication delivery and physiological condition monitoring system in accordance with one embodiment
- FIGS. 15A-15C illustrates modular combination of medication delivery and physiological condition monitoring system in accordance with another embodiment
- FIG. 16 illustrates a top planar view of a modular sensor component in accordance with one embodiment
- FIG. 17 illustrates modular combination of medication delivery and physiological condition monitoring system in accordance with yet another embodiment.
- FIG. 1 illustrates an integrated infusion device and analyte monitoring system in accordance with one embodiment of the present disclosure.
- the integrated infusion device and analyte monitoring system 100 in one embodiment of the present disclosure includes an infusion device 110 connected to an infusion tubing 130 for liquid transport or infusion, and which is further coupled to a cannula 170 .
- the cannula 170 is configured to be mountable coupled to a transmitter unit 150 , where the transmitter unit 150 is also mountable coupled to an analyte sensor 160 .
- an analyte monitor unit 120 which is configured to wirelessly communicate with the transmitter unit over a communication path 140 .
- the transmitter unit 150 is configured for unidirectional wireless communication over the communication path 140 to the analyte monitor unit 120 .
- the analyte monitor unit 120 may be configured to include a transceiver unit (not shown) for bidirectional communication over the communication path 140 .
- the transmitter unit 150 in one embodiment may be configured to periodically or continuously transmit signals associated with analyte levels defected by the analyte sensor 160 to the analyte monitor unit 120 .
- the analyte monitor unit 120 may be configured to receive the signals from the transmitter unit 150 and in one embodiment, is configured to perform data storage and processing based on one or more preprogrammed or predetermined processes.
- the analyte monitor unit 120 is configured to store the received signals associated with analyte levels in a data storage unit (not shown).
- the analyte monitor unit 120 may be configured to process the signals associated with the analyte levels to generate trend indication by, for example, visual display of a line chart or an angular icon based display for output display on its display unit 121 . Additional information may be output displayed on the display unit 121 of the analyte monitor unit 120 including, but not limited to, the substantially contemporaneous and monitored real time analyte level of the patient received from the transmitter unit 150 as detected by the sensor 160 .
- the real time monitored analyte level may be displayed in a numeric format or in any other suitable format which provides the patient with the accurate measurement of the substantially real time analyte level detected by the sensor 160 .
- Analytes that may be monitored or determined by the sensor 160 include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin.
- concentration of drugs such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be determined.
- the sensor 160 may include a short term (for example, 3 day, 5 day or 7 day use) analyte sensor which is replaced after its intended useful life.
- the sensor 100 is configured to be positioned subcutaneous to the skin of the patient such that at least a portion of the analyte sensor is maintained in fluid contact with the patient's analyte such as, for example, interstitial fluid or blood.
- the cannula 170 which is configured to similarly be positioned under the patient's skin is connected to the infusion tubing 130 of the infusion device 110 so as to deliver medication such as insulin to the patient.
- the cannula 170 is configured to be replaced with the replacement of the sensor 160 .
- the cannula 170 and the sensor 160 may be configured to be subcutaneously positioned under the skin of the patient using an insertion mechanism (not shown) such as an insertion gun which may include, for example, a spring biased or loaded insertion mechanism to substantially accurately position the cannula 170 and the sensor 160 under the patient's skin.
- an insertion mechanism such as an insertion gun which may include, for example, a spring biased or loaded insertion mechanism to substantially accurately position the cannula 170 and the sensor 160 under the patient's skin.
- the cannula 170 and the sensor 160 may be subcutaneously positioned with substantially little or no perceived pain by the patient.
- the cannula 170 and/or the sensor 160 may be configured to be manually inserted by the patient through the patient's skin.
- an adhesive layer 180 which is configured to adhere to the skin of the patient for the duration of the time period during which the sensor 160 and the cannula 170 are subcutaneously positioned.
- the transmitter unit 150 may be mounted after the subcutaneous positioning of the sensor 160 and the cannula 150 so as to be in electrical contact with the sensor electrodes.
- the infusion tubing 130 may be configured to operatively couple to the housing of the transmitter unit 150 so as to be accurately positioned for alignment with the cannula 170 and to provide a substantially water tight seal.
- Exemplary analyte systems that may be employed are described in, for example, U.S. Pat. Nos. 6,134,461, 6,175,752, 6,121,611, 6,560,471, 6,746,582, and elsewhere.
- the infusion device 110 may include capabilities to program basal profiles, calculation of bolus doses including, but not limited to correction bolus, carbohydrate bolus, extended bolus, and dual bolus, which may be performed by the patient using the infusion device 110 , and may be based on one or more factors including the patient's insulin sensitivity, insulin on board, intended carbohydrate intake (for example, for the carbohydrate bolus calculation prior to a meal), the patient's measured or detected glucose level, and the patient's glucose trend information.
- the bolus calculation capabilities may also be provided in the analyte monitor unit 120 .
- the analyte monitor unit 120 is configured with a substantially compact housing that can be easily carried by the patient.
- the infusion device 110 similarly may be configured as a substantially compact device which can be easily and conveniently worn on the patient's clothing (for example, housed in a holster or a carrying device worn or clipped to the patient's belt or other parts of the clothing).
- the analyte monitor unit 120 and/or the infusion device 110 may include a user interface such as information input mechanism by the patient as well as data output including, for example, the display unit 121 on the analyte monitor unit 120 , or similarly a display unit 111 on the infusion device 110 .
- One or more audio output devices such as, for example, speakers or buzzers may be integrated with the housing of the infusion device 110 and/or the analyte monitor unit 120 so as to output audible alerts or alarms based on the occurrence of one or more predetermined conditions associated with the infusion device 110 or the analyte monitor unit 120 .
- the infusion device 110 may be configured to output an audible alarm or alert to the patient upon detection of an occlusion in the infusion tubing 130 or the occurrence of a timed event such as a reminder to prime the infusion tubing upon replacement of the cannula 170 , and the like.
- the analyte monitor unit 120 may be similarly configured to output an audible alarm or alert when a predetermined condition or a pre-programmed event occurs, such as, for example, a reminder to replace the sensor 160 after its useful life (of, for example, 3 days, 5 days or 7 days, or more), or one or more alerts associated with the data received from the transmitter unit 150 corresponding to the patient's monitored analyte levels.
- alerts or alarms may include a warning alert to the patient that the detected analyte level is beyond a predetermined threshold level, or the trend of the detected analyte levels within a given time period is indicative of a significant condition such as potential hyperglycemia or hypoglycemia, which require attention or corrective action.
- audible alarms and/or alerts are described above for illustrative purposed only, that within the scope of the present disclosure, other events or conditions may be programmed into the infusion device 110 or the analyte monitor unit 120 or both, so as to alert or notify the patient of the occurrence or the potential occurrence of such events or conditions.
- audible alarms may be output alone, or in combination with one or more of a visual alert such as an output display on the display unit 111 , 121 of the infusion device 110 or the analyte monitor unit 120 , respectively, or vibratory alert which would provide a tactile indication to the patient of the associated alarm and/or alert.
- a visual alert such as an output display on the display unit 111 , 121 of the infusion device 110 or the analyte monitor unit 120 , respectively, or vibratory alert which would provide a tactile indication to the patient of the associated alarm and/or alert.
- analyte monitor unit 120 and one transmitter unit 150 are shown, within the scope of the present disclosure, additional analyte monitor units or transmitter units may be provided such that, for example, the transmitter unit 150 may be configured to transmit to multiple analyte monitor units substantially simultaneously.
- multiple transmitter units coupled to multiple sensors concurrently in fluid contact with the patient's analyte may be configured to transmit to the analyte monitor unit 120 , or to multiple analyte monitor units.
- an additional transmitter unit coupled to an additional sensor may be provided in the integrated infusion device and analyte monitoring system 100 which does not include the cannula 170 , and which may be used to perform functions associated with the sensor 160 such as sensor calibration, sensor data verification, and the like.
- the transmitter unit 150 is configured to transmit the sampled data signals received from the sensor 160 without acknowledgement from the analyte monitor unit 120 that the transmitted sampled data signals have been received.
- the transmitter unit 150 may be configured to transmit the encoded sampled data signals at a fixed rate (e.g., at one minute intervals, or any suitable rate) after the completion of the initial power on procedure.
- the analyte monitor unit 120 may be configured to detect such transmitted encoded sampled data signals at predetermined time intervals.
- the transmitter unit 150 and the analyte monitor unit 120 may be configured for bi-directional communication over the communication path 140 .
- the analyte monitor unit 120 may include two sections.
- the first section of the analyte monitor unit 120 may include an analog interface section that is configured to communicate with the transmitter unit 150 via the communication path 140 .
- the analog interface section may include an RF receiver and an antenna for receiving and amplifying the data signals from the transmitter unit 150 , which are thereafter, demodulated with a local oscillator and filtered through a band-pass filter.
- the second section of the analyte monitor unit 120 may include a data processing section which is configured to process the data signals received from the transmitter unit 150 such as by performing data decoding, error detection and correction, data clock generation, and data bit recovery, for example.
- the analyte monitor unit 120 is configured to detect the presence of the transmitter unit 150 within its range based on, for example, the strength of the detected data signals received from the transmitter unit 150 or predetermined transmitter identification information. Upon successful synchronization with the transmitter unit 150 , the analyte monitor unit 120 is configured to begin receiving from the transmitter unit 150 data signals corresponding to the patient's detected analyte, for example glucose, levels.
- the analyte monitor unit 120 or the infusion device 110 may be configured to further communicate with a data processing terminal (not shown) which may include a desktop computer terminal, a data communication enabled kiosk, a laptop computer, a handheld computing device such as a personal digital assistant (PDAs), or a data communication enable mobile telephone, and the like, each of which may be configure for data communication via a wired or a wireless connection.
- a data processing terminal for example may include physician's terminal and/or a bedside terminal in a hospital environment.
- the communication path 140 for data communication between the transmitter unit 150 and the analyte monitor unit 120 of FIG. 1 may include an RF communication link, Bluetooth communication link, infrared communication link, or any other type of suitable wireless communication connection between two or more electronic devices.
- the data communication link may also include a wired cable connection such as, for example, but not limited to an RS232 connection, USB connection, or serial cable connection.
- the analyte monitor unit 120 or the infusion device 110 may also include a test strip port configured to receive a blood glucose test strip for discrete sampling of the patient's blood for glucose level determination.
- a test strip port configured to receive a blood glucose test strip for discrete sampling of the patient's blood for glucose level determination.
- An example of the functionality of blood glucose test strip meter unit may be found in Freestyle® Blood Glucose Meter available from the assignee of the present disclosure, Abbott Diabetes Care, Inc.
- the cannula 170 for infusing insulin or other suitable medication is integrated with the adhesive patch 180 for the sensor 160 and the transmitter unit 150 of the analyte monitoring system. Accordingly, only one on-skin patch can be worn by the patient (for example, on the skin of the abdomen) rather than two separate patches for the infusion device cannula 170 , and the analyte monitoring system sensor 160 (with the transmitter unit 150 ).
- the Type-1 diabetic patient may conveniently implement infusion therapy in conjunction with real time glucose monitoring while minimizing potential skin irritation on the adhesive patch 180 site on the patient's skin, and thus provide more insertion sites with less irritation.
- the integrated infusion device and analyte monitoring system 100 as shown in FIG. 1 may be configured such that the infusion tubing 130 may be disconnected from the infusion device 110 as well as from the housing of the transmitter 150 (or the adhesive patch 180 ) such that, optionally, the patient may configure the system as continuous analyte monitoring system while disabling the infusion device 110 functionality. Likewise, a patient may configure the system as an infusion device while disabling the continuous analyte monitoring system functions.
- the patient may better manage the physiological conditions associated with diabetes by having substantially continuous real time glucose data, trend information based on the substantially continuous real time glucose data, and accordingly, modify or adjust the infusion levels delivered by the infusion device 110 from the pre-programmed basal profiles that the infusion device 110 is configured to implement.
- FIG. 2 illustrates an integrated infusion device and analyte monitoring system in accordance with another embodiment of the present disclosure.
- the integrated infusion device and analyte monitoring system 200 in one embodiment of the present disclosure includes an integrated infusion device and analyte monitor unit 210 which is coupled to an infusion tubing 220 connected to the cannula 260 .
- a transmitter unit 240 which is in electrical contact with an analyte sensor 250 , where the cannula 260 and the analyte sensor 250 are subcutaneously postitioned under the skin of the patient, and retained in position by an adhesive layer or patch 270 .
- the integrated infusion device and analyte monitor unit 210 is configured to wirelessly communicate with the transmitter unit 240 over a communicatin path 230 such as an RF communication link.
- a communicatin path 230 such as an RF communication link.
- the transmitter unit 240 may be configure to transmit signals corresponding to the detected analyte levels received from the analyte sensor 250 to the integrated infusion device and analyte monitor 210 for data analysis and processing.
- the patient may conveniently receive real time glucose levels from the transmitter unit 240 and accordingly, determine whether to modify the existing basal profile(s) in accordance with which insulin is delivered to the patient.
- the functionalities of the analyte monitor unit may be integrated within the compact housing of the infusion device to provide additional convenience to the patient, for example, by providing the real time glucose data as well as other relevant information such as glucose trend data to the user interface of the infusion device, so that the patient may readily and easily determine any suitable modification to the infusion rate of the insulin pump.
- each component shown in FIG. 2 including the cannula 260 , the analyte sensor 250 , the transmitter unit 240 , the adhesive layer 270 , the communication path 230 , as well as the infusion tubing 220 and the functionalities of the infusion device and the analyte monitor are substantially similar to the corresponding respective component as described above in conjunction with FIG. 1 .
- the additional convenience may be provided to the patient in maintaining and enhancing diabetes management by, for example, having a single integrated device such as the integrated infusion device and analyte monitor unit 210 which would allow the patient to easily manipulate and manage insulin therapy using a single user interface system of the integrated infusion device and analyte monitor unit 210 .
- a single integrated device such as the integrated infusion device and analyte monitor unit 210 which would allow the patient to easily manipulate and manage insulin therapy using a single user interface system of the integrated infusion device and analyte monitor unit 210 .
- the patient may be provided with the additional convenience in managing diabetes and improving insulin therapy.
- FIG. 3 illustrates as integrated infusion device and analyte monitoring system in accordance with yet another embodiment of the present disclosure.
- the integrated infusion device and analyte monitoring system 300 in one embodiment of the present disclosure includes an infusion device 310 connected to an infusion tubing 340 coupled to a cannula 370 .
- the cannula 370 is configured to be positioned subcutaneously under the patient's skin and substantially retained in position by an adhesive layer 380 .
- an analyte sensor 360 also positioned subcutaneously under the patient's skin and maintained in fluid contact with the patient's analyte.
- a transmitter unit 350 is provided so as to be electrically coupled to the analyte sensor 360 electrodes. Also, as can be seen from FIG 3 , in one embodiment, the infusion tubing 340 is connected to the housing of the transmitter unit 350 so as to connect to the cannula 370 disposed under the patient's skin.
- an analyte monitor unit 320 configured to wirelessly communicate with the transmitter unit 350 to receive data therefrom associated with the analyte levels of the patient detected by the analyte sensor 360 .
- the infusion device 310 does not include a user interface such as a display unit and/or an input unit such as buttons or a jog dial.
- the user interface and control mechanism is provided on the analyte monitoring unit 320 such that the analyte monitoring unit 320 is configured to wirelessly control the operation of the infusion device 310 and further, to suitably program the infusion device 310 to execute pre-programmed basal profile(s), and to otherwise control the functionality of the infusion device 310 .
- all of the programming and control mechanism for the infusion device 310 is provided in the analyte monitoring unit 320 such that when the patient is wearing the infusion device 310 , it may be worn discreetly under clothing near the infusion site on the patient's skin (such as abdomen), while still providing convenient access to the patient for controlling the infusion device 310 through the analyte monitoring unit 320 .
- each component shown in FIG. 3 including the cannula 370 , the analyte sensor 360 , the transmitter unit 350 , the adhesive layer 380 , the communication path 320 , as well as the infusion tubing 340 and the functionalities of the infusion device and the analyte monitoring unit 320 are substantially similar to the corresponding respective component as described above in conjunction with FIG. 1 .
- the infusion device 30 in the embodiment shown in FIG. 3 is configured with a transceiver or an equivalent communication mechanism to communicate with the analyte monitoring unit 320 .
- configuration of the infusion device 310 without a user interface provides a smaller and lighter housing and configuration for the infusion device 310 which would enhance the comfort in wearing and/or carrying the infusion device 310 with the patient.
- the control and programming functions of the infusion device 310 is provided on the analyte monitoring unit 320 , the patient may conveniently program and/or control the functions and operations of the infusion device 310 without being tethered to the infusion tubing 340 attached to the cannula 370 which is positioned under the patient's skin.
- the programming and control of the infusion device 310 is remotely performed on the analyte monitoring unit 320 , the infusion tubing 304 may be shorter and thus less cumbersome.
- FIG. 4 illustrates an integrated infusion device and analyte monitoring system in accordance with still another embodiment of the present disclosure.
- the integrated infusion device and analyte monitoring system 400 in one embodiment of the present disclosure includes an infusion device 410 configured to wirelessly communicate with an analyte monitoring unit 420 over a communication path 430 such as an RF (radio frequency) link.
- the infusion device 410 is connected to an infusion tubing 440 which has provided therein integral wires connected to the analyte sensor electrodes.
- the measure analyte levels of the patient is received by the infusion device 410 via the infusion tubing 440 and transmitted to the analyte monitoring unit 420 for further processing and analysis.
- the integrated infusion device and analyte monitoring system 400 includes a patch 450 provided with a cannula 470 and an analyte sensor 460 .
- the cannula 470 is configured to deliver or infuse medication such as insulin from the infusion device 410 to the patient. That is, in one embodiment, the cannula 470 and the analyte sensor 460 are configured to be positioned subcutaneous to the patient's skin.
- the analyte sensor 460 is configured to be positioned to be in fluid contact with the patient's analyte.
- the analyte sensor 460 is electrically coupled to integral wires provided within the infusion tubing 440 so as to provide signals corresponding to the measured or detected analyte levels of the patient to the infusion device 410 .
- the infusion device 410 is configured to perform date analysis and storage, such that the infusion device 410 may be configured to display the real time measured glucose levels to the patient on its display unit 411 .
- the infusion device 410 is configured to wirelessly transmit the received signals from the analyte sensor 460 to the analyte monitoring unit 420 for data analysis, display, and/or storage and the analyte monitoring unit 420 may be configured to remotely control the functions and features of the infusion device 410 providing additional user convenience and discreteness.
- the patch 450 may be configured to be substantially small without a transmitter unit mounted thereon, and provided with a relatively small surface area to be attached to the patient's skin.
- the pattern may be provided with added comfort in having a substantially compact housing mounted on the skirt (attached with an adhesive layer, for example), to infuse medication such as insulin, and for continuous analyte monitoring with the analyte sensor 460 .
- FIG. 5 illustrates an integrated infusion device and analyte monitoring system in accordance with still a further embodiment of the present disclosure.
- the integrated infusion device and analyte monitoring system 500 of FIG. 5 includes an integrated infusion device and analyte monitoring unit 510 .
- one user interface is provided to the user including the display unit 511 and input buttons 512 provided on the housing of the integrated infusion device and analyte monitoring unit 510 .
- an adhesive patch 530 is provided to retain the subcutaneous position of a cannula 550 and the analyte sensor 540 in the desired positions under the patient's skin.
- the integrated infusion device and analyte monitoring unit 510 may be provided with wireless or wired communication capability so to communicate with a remote terminal such as a physician's computer terminal over a wireless communication path such as RF communication link, or over a cable connection such as a USB connection, for example.
- a remote terminal such as a physician's computer terminal
- a wireless communication path such as RF communication link
- a cable connection such as a USB connection
- FIG. 6 illustrates an integrated infusion device and monitoring system in accordance with yet still a further embodiment of the present disclosure.
- the integrated infusion device and analyte monitoring system 600 is provided with an infusion device without a user interface, and configured to wirelessly communicate with an analyte monitoring unit 620 over a communication path 630 such as an RF link.
- the infusion device 610 which may be provided in a compact housing since it does not incorporate the components associated with a user interface, is connected to an infusion tubing 640 having disposed therein integral wires correspondingly connected to the electrodes of analyte sensor 660 in fluid contact with the patient's analyte.
- the compact adhesive patch 650 in one embodiment is configured to retain cannula 670 and the analyte sensor 660 in the desired position under the skin of the patient.
- the analyte monitoring unit 620 is configured to control and program the infusion device 610 over the communication link 630 . In this manner, the control and programming functions of the infusion device 610 may be remotely performed by the analyte monitoring unit 620 , providing convenience to the patient.
- FIG. 7A illustrates the integrated infusion device and monitoring system shown in FIG. 6 in further detail in one embodiment of the present disclosure
- FIGS. 7A-7B illustrate the analog front end circuitry located at the patient interface and the pump assembly, respectively, of the integrated infusion device and monitoring system shown in FIG. 7A in accordance with one embodiment of the present disclosure.
- an infusion device 710 connected to an infusion tubing 720 with integral wires provided therein for connection to the electrodes of the analyte sensor is shown.
- the infusion tubing 720 is further connected to an adhesive patch 730 which is configured to retain cannula 750 and analyte sensor 740 in the desired subcutaneous portion under the skin of the patient.
- the infusion device 710 may be provided with a first analog front end circuitry unit 711
- the adhesive patch may be provided with a second analog front end circuitry unit 731
- the integral wires from the analyte sensor 740 is configured to extend from the infusion device 710 to the adhesive layer 730 via the infusion tubing 720 . Since the analyte sensor 740 in one embodiment is a passive component, the signals on the working electrode and the reference electrodes of the analyte sensors are subject to noise given the high impendence of the electrodes and the length of the integral wires (in excess of a few centimeters). The noise in turn may potentially adversely affect the signals on the working and reference electrodes which may distort the measured analyte levels detected by the analyte sensor 740 .
- the signals from the working and reference electrodes may be converted to low impedance signals to minimize adverse impact from the noise.
- the infusion device 710 may be provided with a first analog front end circuitry unit 711
- the adhesive patch 730 may be provided with a second analog front end circuitry unit 731 as discussed in further detail below in conjunction with FIGS. 7B and 7C .
- the second analog front end circuitry unit 731 disposed on the adhesive patch 730 on the patient's skin in one embodiment includes an a trans-impedance amplifier (current to voltage converter or “I-to-V”) 731 A configured to convert the working electrode (W) current to a voltage (Vw), and to provide a guard signal (G), and a servo segment 731 B to drive the counter electrode (C) voltage (Ve) based on the reference electrode (R) voltage. Also shown in FIG.
- I-to-V current to voltage converter
- LPF Low-Pass Filter
- ⁇ C microcontroller
- the second analog front end circuitry unit 731 may be implemented by a pair of operational amplifiers ( 731 A and 731 B), four resistors (R 1 , R 2 , R 3 , Rf), and a bypass capacitor (Cb).
- the I-to-F stage using operational amplifier 731 A is generated by the action of the input current from the working electrode (W) flowing through the feedback resistor (Rf) and creating a voltage differential that is driven by the operational amplifier 731 A as the low impedance signal Vw.
- the offset for the Vw signal is established by the resistor divider comprised of R 1 , R 2 and R 3 which also creates the voltage of the guard signal (G)—a signal that is at the same potential or voltage as the working electrode (W).
- the servo drives the counter electrode (C) voltage to the sensor so that the reference electrode (R) is at the second value set by the resistor divider comprised of resistors R 1 , R 2 and R 3 .
- the bypass capacitor (Cb) may be a small, low equivalent series resistance (ESR) capacitor, such as a 0.1 uF (100 nF) multi-layer ceramic (MLC) capacitor, that acts to provide local energy and reduce noise on the circuit.
- ESR equivalent series resistance
- the voltage source for this circuit may be provided by the potential difference between V+ and V ⁇ where, for example, V+ may be 5V and V ⁇ may be ground (GND) or V+ may be +3V and V ⁇ may be ⁇ 3V.
- the operational amplifiers 731 A, 731 B may be acquired as a dual operational amplifier integrated circuit (IC) in a single, small 8-pin, surface mount technology (SMT) package such as the OPA2349 in a SOT23-8 package (3 mm by 3 mm). Similar dual operational amplifier products may be available in even smaller ball-grid array (BGA) packages and as bare die that may be mounted directly to the circuit substrate, such as a printed circuit board (PCB) or flex circuit, using techniques such as “flip-chip” and wire-bond.
- IC integrated circuit
- SMT surface mount technology
- Similar dual operational amplifier products may be available in even smaller ball-grid array (BGA) packages and as bare die that may be mounted directly to the circuit substrate, such as a printed circuit board (PCB) or flex circuit, using techniques such as “flip-chip” and wire-bond.
- PCB printed circuit board
- the analyte sensor described above in conjunction with the Figures may include one or more working electrodes and a reference electrode or a reference/counter electrode disposed on a substrate, and further, may optionally include a separate counter electrode.
- the various electrodes of the sensor as well as the substrate and the dielectric layers may be provided in a stacked, side by side, or layered configuration or construction.
- the sensor may include a substrate layer and a first conducting layer such as a carbon trace deposed on at least a portion of the substrate layer, and which may comprise the working electrode. Also shown disposed on at least a portion of the first conducting layer is a sensing layer.
- a first insulation layer such as a first dielectric layer may be disposed or stacked on at least a portion of the first conducting layer, and further, a second conducting layer such as another carbon trace may be disposed or stacked on top of at least a portion of the first insulation layer (or dielectric layer).
- the second conducting layer may comprise the reference electrode, and in one aspect, may include a layer of silver/silver chloride (Ag/AgCl).
- a second insulation layer such as a dielectric layer in one embodiment may be disposed or stacked on at least a portion of the second conducting layer.
- a third conducting layer which may include carbon trace and that may comprise the counter electrode may be disposed on at least a portion of the second insulation layer.
- a third insulation layer may be disposed or stacked on at least a portion of the third conducting layer.
- the analyte sensor may be configured in a stacked, side by side or layered construction or configuration such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer).
- some or all of the electrodes of the analyte sensor may be provided on the same side of the substrate in a stacked construction as described above, or alternatively, may be provided in a co-planar manner such that each electrode is disposed on the same plane on the substrate, however, with a dielectric material or insulation material disposed between the conducting layers/electrodes.
- the one or more conducting layers such as the electrodes of the sensor may be disposed on opposing sides of the substrate.
- FIGS. 8A-8C illustrate a passive sensor configuration for use in a continuous analyte monitoring system, and two embodiments of an active sensor configuration for use at the patient interface in the integrated infusion device and monitoring system, respectively, in accordance with one embodiment of the present disclosure.
- analyte sensor 810 includes working electrode 811 , a guard trace 812 , a reference electrode 813 , and a counter electrode 814 .
- the “tail” segment 815 of the analyte sensor 810 is configured to be positioned subcutaneously under the patient's skin so as to be in fluid contact with the patient.
- analyte sensor 820 is provided with the analog front end portion 821 where the four contacts shown are V+, V ⁇ , Vw, and Ve signals in accordance with one embodiment in place of the working electrode 811 , a guard trace 812 , a reference electrode 813 , and a counter electrode 814 , respectively.
- these signals of the active analyte sensor 820 are low impedance and thus less subject to noise than the passive sensor signals.
- the analyte sensor 820 configuration may include a flex circuit.
- an active sensor of similar construction to the active sensor 820 of FIG. 11B but with much smaller dimensions is shown. More specifically, analyte sensor 830 is provided with four contacts configured for direct wire bonding rather than a mechanical contact system as indicated by the large contact areas on the previous two sensor configurations shown in FIGS. 8A-8B . Since the shape of the analyte sensor 830 is reduced, the sensor 830 may be wrapped around the cannula (for example, cannula 470 of FIG. 4 ) and thus only a single entry site may be required for the patient analyte monitoring and insulin infusion. Moreover, within the scope of the present disclosure, additional sensor/cannula configurations may be provided where the sensor circuitry and cannula are created as a single assembly such as a cannula with the circuit 831 fabricated on the surface.
- FIG. 9 illustrates an integrated infusion device and analyte monitoring system with the infusion device and the monitoring system transmitter integrated into a single patch worn by the patient in accordance with one embodiment of the present disclosure.
- the integrated infusion device and analyte monitoring system 900 includes an integrated patch pump and transmitter unit 910 provided on an adhesive layer 960 , and which is configured to be placed on the skin of the patient, so as to securely position cannula 950 and analyte sensor 940 subcutaneously under the skin of the patient.
- the housing of the integrated infusion pump and transmitter unit 910 is configured in one embodiment to include the infusion mechanism to deliver medication such as insulin to the patient via the cannula 950 .
- the integrated patch pump and transmitter unit 910 is configured transmit signals associated with the detected analyte levels measured by the analyte sensor 940 , over a wireless communication path 930 such as an RF link.
- the signals are transmitted from the on body integrated patch pump and transmitter unit 910 to a controller unit 920 which is configured to control the operation of the integrated patch pump and transmitter unit 910 , as well as to receive the transmitted signals from the integrated patch pump and transmitter unit 910 which correspond to the detected analyte levels of the patient.
- the infusion mechanism of the integrated patch pump and transmitter unit 910 may include the infusion device of the type described in U.S. Pat. No. 6,916,159 assigned to the assignee of the present disclosure Abbott Diabetes Care, Inc.
- the wireless communication path 930 may be replaced by a set of wires to provide a wired connection to she controller unit 920 .
- the integrated infusion device and analyte monitoring system 900 does not use an infusion tubing which may provide additional comfort and convenience to the patient by providing additional freedom from having to wear a cumbersome tubing.
- FIG. 10 is a detailed view of the infusion device cannula integrated with analyte monitoring system sensor electrodes in accordance with one embodiment of the present disclosure.
- an infusion device cannula with analyte sensor electrodes 1020 disposed therein, and mounted to an adhesive patch 1010 so as to retain its position securely in the patient.
- the cannula with analyte sensor electrodes 1020 include sensor electrodes 1021 , 1022 , 1023 (which may correspond to working, reference and counter electrodes, respectively) each of which are provided within the cannula tip 1020 , and further, positioned so as to maintain fluid contact with the patient's analyte.
- some or all of the electrodes of the analyte sensor may be wrapped around the cannula, stacked on one or more inner and/or outer surfaces of the cannula.
- FIG. 12A-12C each illustrate a cross sectional view of the infusion device cannula integrated with continuous analyte monitoring system sensor electrodes of FIG. 10 in accordance with the various embodiments respectively, of the present disclosure.
- the wire and tubing are provided in parallel such that the tubing wall 1020 , the tube bore for insulin flow 1024 , the wire outer casing 1020 and the individual insulated wires 1021 , 1022 , 1023 are substantially provided as shown in FIG. 12A .
- each of the three insulated wires are provided with an insulation layer 1020 of tubing wall individually surrounding each insulated wire 1021 , 1022 , 1023 , and further, where the three insulated wires 1021 , 1022 , 1023 are in turn surrounded by the tubing wall 1020 .
- the insulated wires 1021 , 1022 , 1023 respectively connected to the sensor electrodes are co-extruded into tubing wall 1020 , with the tube bore 1024 for insulin delivery and the insulated wires 1021 , 1022 , 1023 configured substantially as shown in the FIG 12B .
- FIG. 12B in one embodiment of the present disclosure, the insulated wires 1021 , 1022 , 1023 respectively connected to the sensor electrodes are co-extruded into tubing wall 1020 , with the tube bore 1024 for insulin delivery and the insulated wires 1021 , 1022 , 1023 configured substantially as shown in the FIG 12B .
- each of the insulated wires 1021 , 1022 , 1023 are wrapped around the tubing 1020 and covered with a sheath 1210 , thus providing the tubing wall 1020 , the tubing bore 1024 for insulin delivery, the individual insulated wires 1021 , 1022 , 1023 , and the outer protective sheath 1210 , which may also serve as an electromagnetic shield to eliminate electronic noise as substantially shown is the Figure.
- the embodiments shown in FIGS. 12A and 12C may have a larger cross-sectional area (thus a larger hole needed to be punctured on the skin of the patient), but are likely easier to manufacture, more reliable and easier to make connection to the analyte sensor electronics).
- an optical data transmission i.e. fiber optics
- insulin delivery tubing between sensor and pump may be provided instead of integral wires as discussed above.
- FIG. 11A illustrates a component perspective view of the infusion device cannula integrated with analyte monitoring system sensor electrodes in accordance with another embodiment of the present disclosure
- FIG. 11B illustrates a top planar view of the analyte monitoring system transmitter unit integrated with infusion device in accordance with one embodiment of the present disclosure
- integrated analyte sensor and infusion device cannula 1100 comprise five laminated layers including a top insulation layer 1101 , a conductive layer 1102 with electrode traces disposed thereon, followed by three layer substrate with integrated infusion cannula 1103 .
- the three layer substrate with integrated infusion cannula 1103 includes a separation/insulation layer 1103 A to insulate the sensor electrodes from the infusion cannula, a channel layer 1103 B configured to guide the flow of the insulin or any other suitable medication, and an inlet/outlet layer 1103 C. Also shown in FIG. 11A is an assembled view of the integrated analyte sensor and infusion device cannula 1100 .
- a patch pump as shown in one embodiment is provided with a transmitter unit 1110 and an insulin pump 1130 coupled to insulin reservoir 1120 , and operatively coupled or mounted to the transmitter unit 1110 .
- the analyte sensor contacts 1140 which are configured to establish electrical contact with the respective electrodes of the integrated infusion cannula and analyte sensor 1100 .
- insulin port 1150 which is connected to the channel layer 1103 B of the integrated infusion device cannula and analyte sensor 1100 .
- the patch pump may be worn by the patient on skin and which includes the insulin infusion mechanism as well as the analyte sensor and transmitter unit.
- FIG. 13 is a timing chart for illustrating the temporal spacing of blood glucose measurement and insulin delivery by the integrated infusion device and monitoring system in one embodiment. More specifically, insulin pumps typically deliver insulin in a periodic manner with the period of delivery in the range of 2 to 3 minutes and the duration of delivery at each period being on the order of a few seconds or less. The amount of insulin that is delivered each period may be varied depending on the overall insulin delivery rate that is desired.
- the analyte data is collected continuously (as, for example, a continuous current of glucose oxidation) but is typically reported to the user periodically.
- the analyte reporting period is typically 1 to 10 minutes and glucose oxidation current needs to be collected for 10 to 30 seconds in order to generate a reportable glucose value (to allow for filtering etc.).
- analyte monitoring and insulin delivery may necessitate placement of an analyte sensor in close proximity to an insulin infusion cannula on the body.
- Such close proximity engenders the possibility of insulin delivery interfering with the analyte measurements.
- glucose measurement in this area would not be representative of the glucose concentration in the body as a whole. Accordingly, in one embodiment of the present disclosure, there is provided a method for temporal spacing of blood glucose measurements and insulin delivery to mitigate the possible interference between insulin infusion and glucose measurements.
- the temporal spacing of analyte measurement and insulin delivery may include providing a large a temporal space from after insulin delivery and before taking an analyte measurement. Since both analyte measurement and insulin delivery are performed periodically, a maximum spacing in time may be achieved if analyte measurement substantially immediately precedes insulin delivery. During the time between insulin delivery and the subsequent glucose measurement, infused insulin has time to diffuse and be transported away from the infusion site due to normal circulation of interstitial fluid. An example timeline of temporally spaced analyte measurement and insulin delivery is shown in FIG 13 . If multiple analyte measurements are taken between insulin delivery points, there should always be a reading just prior to insulin delivery and as well just after insulin delivery to minimize the affect of injected insulin on the glucose measurement readings.
- readings are typically taken periodically for simplicity in processing, a reading may be taken out of time with other readings and sealed appropriately for the overall reading average. Similarly, the insulin delivery point may be delayed slightly until after the reading with little or no affect as the readings typically occur much more frequently than the infusions, which are intended to act over longer periods of time.
- other timing considerations may be considered depending on the environment in which the integrated infusion device and analyte monitoring system is used by the patient, within the scope of the present disclosure to minimize potential error on measured analyte levels and/or introduce noise or potential adverse effects to the infusion rates of the infusion device.
- fluctuation in the power supplies of the infusion device and/or the analyte monitoring system including, for example, batteries or related power distribution circuitry may introduce electrical noise effects which may adversely affect the measured readings associated with the analyte monitoring system.
- the analyte monitoring system when configured to be in an active state so as to be transmitting or receiving data, or when the pump cycle of the infusion device is active, the power supply may be affected by the load from the data transmission/reception, or the pumping cycle.
- the adverse effect of the power supply in addition to noise from other components of the electronic circuitry may introduce undesirable noise and adversely affect the accuracy of the analyte sensor measurements.
- the transmitter unit 150 may be configured to monitor the timing or occurrence of the measured analyte level received from the analyte sensor 160 and the data transmission timing of the transmitter unit 150 such that the two events do not substantially overlap or occur at substantially the same time.
- the analyte monitor unit 120 may be configured to compare the timing of the analyte sensor 160 measurement and the timing of the data transmission from the transmitter unit 150 , and to discard data analyte related data received from the transmitter unit 150 which coincide with the timing of the analyte measurements by the analyte sensor 160 .
- air bubble detection in the insulin tubing may be provided, by monitoring fluid motion that would also detect the absence of fluid such as that due to an air bubble in the line.
- the flow sensor may be configured to generate zero current when an air bubble is present.
- colorization of insulin may be provided for air bubble detection in the tubing. Since pharmaceutical insulin is a clear colorless liquid, it is difficult to visually discriminate between insulin and air in tubing that carries insulin from the insulin pump to the cannula. By providing a color tint to the insulin it would be much easier to visually identify air bubbles in the tubing and be able to remove them before they cause problems.
- An insulin tint in one embodiment is biocompatible and insulin compatible.
- the various components of the integrated system may need periodic replacement, where the components may require replacement at different times during the usage of the integrated system.
- the infusion device cannula may require replacement after about each 3-days of usage, while the analyte sensor for use in the analyte monitoring system may not require replacement until at least about five or seven days of usage.
- the components of the integrated system may be provided as replaceable modular components such that one or more components may be replaced at different times during the usage of the integrated system without substantially impacting the remaining portion of the integrated system.
- FIGS. 14A-14C illustrate modular combination of medication delivery and physiological condition monitoring system in accordance with one embodiment.
- an on-body patch pump housing 1401 may be provided on the skin surface 1404 of the patient, such that the cannula 1402 is positioned transcutaneously through the patient's skin surface 1404 into the patient's body.
- a connection port 1403 provided on the housing 1401 of the patch pump.
- the connection port 1403 in one embodiment may be configured to couple to an end cap 1405 ( FIG. 14B ) if the patch pump is used as a pump alone, or alternatively may be configured to couple to an analyte sensor connector portion 1406 when used as an integrated system with an analyte monitoring system.
- the analyte sensor may include a connector portion 1406 which is configured to couple to the connection port 1403 of the patch pump housing to establish a substantially water tight seal, an anchor portion 1407 which is configured to securely position the analyte sensor on the skin surface 1404 of the patient, and the tip portion 1408 which is trancutaneously positioned through the skin surface 1404 of the patient so as to be in fluid contact with the patient's analyte.
- the analyte sensor may be provided as a modular component which may be used in conjunction with the patch pump as an integrated system.
- the patient may select to use the patch pump alone without the continuous monitoring aspect of the integrated system.
- the modular system described herein may be easily used as a stand alone pump, where the end cap may be configured to provide a substantially water tight seal to the housing 1401 of the patch pump.
- the patch pump may be used in conjunction with the analyte monitoring system wherein the patch pump housing 1401 may be configured to couple to the sensor connector portion 1406 , establishing electrical contact between the sensor electrodes to the respective internal electronic components within the patch pump housing 1401 .
- the electronic components associated with the analyte monitoring system including the transmitter unit, processing unit and other components of analyte monitoring system may be provided substantially within the housing of the patch pump 1401 .
- the integrated system may be used as a stand along infusion device, the patch pump and the analyte sensor may be replaced or changed independent of each other, and without substantially increasing the profile or the on-body size of the overall system, the sensor may be inserted or positioned in the patient independent of the patch pump, and also removed independent of the pump housing 1401 .
- FIGS. 15A-15C illustrates modular combination of medication delivery and physiological condition monitoring system in accordance with another embodiment.
- the integrated system is provided with a patch pump housing 1501 which is configured for positioning on the skin surface 1504 of the patient, and which is operatively coupled to a transcutaneously positioned cannula 1502 for medication delivery to the patient.
- connection port 1503 of the patch pump is provided substantially on the top surface of the pump housing 1501 , such that, when desired, the analyte sensor connector portion 1506 may be coupled to the patch pump via the connection port 1503 from the top surface of the patch pump.
- a cap or a plug 1505 may be provided to seal (for example, water tight seal) the connection port 1503 when the patch pump housing 1501 is not connected to an analyte sensor, and thus for use as a stand alone infusion device.
- the cap or plug 1505 may include any suitable configuration, preferably to include a low profile physical dimension so as to maintain the low profile configuration of the on-body patch pump housing 1501 .
- connection port 1503 is configured to establish electrical connect with the various electrodes of the analyte sensor while providing a water tight seal at the connection.
- the analyte sensor includes an anchor potion 1507 configured to securely position the sensor on the skin surface 1504 of the patient, and a tip portion 1508 which is configured for transcutaneous placement for fluid contact with the patient's analyte.
- connection port of the patch pump may be provided on any location of the patch pump housing.
- connection port providing a water tight seal when connected with an end cap (to establish closure), or with an analyte sensor (to use the patch pump in an integrated system with analyte monitoring) may be provided on the bottom, side, or any other surface of the patch pump housing.
- FIG. 16 illustrates a top planar view of a modular sensor component in accordance with one embodiment. More particularly, FIG. 16 illustrates the analyte sensor of FIGS. 14A-14C or 15A-15C in one embodiment. As shown, the connector portion 1506 of the analyte sensor is provided substantially on one end of the analyte sensor, while the sensing portion 1508 (for transcutaneous placement) of the analyte sensor is provided substantially on the other end of the sensor. Also shown in FIG. 16 is the anchor portion 1507 which in one embodiment is configured with a relatively larger width compared to other portions of the sensor.
- the anchor portion 1507 may be configured to substantially securely retain the analyte sensor on the skin surface of patient.
- one or more of the patch pump housing and the analyte sensor may be provided with an adhesive layer on the bottom surface to secure positioning on the patient's skin surface during usage.
- the analyte sensor may comprise a flex circuit so as to provide a low profile when worn on the body of the patient.
- FIG. 17 illustrates modular combination of medication delivery and physiological condition monitoring system in accordance with yet another embodiment.
- the patch pump 1701 is provided with a connection port 1703 and positioned on the patient's skirt surface 1704 so as to securely retain the transcutaneously positioned cannula 1702 at the desired depth under the skin layer of the patient.
- a connection device 1706 which in one embodiment is provided with a pump connector 1705 and a sensor connector 1707 . More specifically, in one embodiment, a separate modular component is provided and secured on the skin surface 1704 of the patient, and may be configured to connect to both the patch pump 1701 as well as the analyte sensor.
- the connection device 1706 may be configured to further couple to other components or devices as may be desired.
- connection device 1706 is configured to establish electrical connection between the sensor and the patch pump such that the detected analyte levels from the tip portion 1710 of the analyte sensor is received by the suitable electronic control circuitry within the patch pump housing 1701 .
- the analyte monitoring associated electronic components such as data processing units, transmitter units, and the like, may be provided within the connection device 1706 .
- the patch pump housing 1701 may be further optimized in size.
- connection device 1706 is configured in one embodiment to include the pump connector 1705 which, in one embodiment is configured to couple to the connection port 1703 of the pump to establish electrical contact and a substantially water tight seal. Furthermore the connection device 1706 may be further configured to include a sensor connector portion 1707 which is configured to receive or connect to the connector portion 1708 of the sensor so as to establish electrical contact with the various electrodes of the sensor. That is, in one embodiment, the connector portion 1707 of the connection device 1706 may be configured to couple to the sensor connector portion 1708 .
- the sensor connection portion 1708 is configured in one embodiment to establish electrical contact with the connection device 1706 to transfer or otherwise relay the signal level information associated with the detected analyte levels of the patient for further processing.
- modular components or devices which comprise an integrated medication delivery and analyte monitoring system, where each component may be independently replace, removed, or used on its own, and further, where the modular components may be used together as an integrated system for medication delivery and analyte monitoring.
- a modular system for providing integrated medication delivery and physiological condition monitoring in one aspect includes a first modular component configured for medication delivery, and a second modular component configured to analyte level detection, where the second modular component is connectable to the first modular component to establish electrical contact with the first modular component, where a substantially water tight seal is formed when the first and second modular component are connected, and further where one of the first modular component and the second modular component is configured for replacement independent of the other component, and a third modular component connectable to the first modular component when the first modular component is disconnected with the second modular component.
- the first modular component may include a connection port for coupling to either one of the second modular component or the third modular component.
- the first modular component may include a low profile infusion device.
- the second modular component may include an analyte sensor.
- a water tight seal may be formed when the first and third modular components are connected.
- the first modular component in still another aspect may be configured to deliver medication to a patient at a first location in the patient, and further, wherein the second modular component is configured to detect analyte level of the patient at a second location in the patient, where the first and second locations may be separated by a predetermined distance, for example, approximately 12 inches.
- the first modular component in another aspect may include a reusable portion and a disposable portion, where either of the second or third modular components is connectable to the reusable portion of the first modular component.
- the disposable portion of the first modular component may include one or more of an infusion set, or a reservoir containing the medication for delivery.
- the reusable portion of the first modular component may include a processing unit to control the operation of one or more of the first modular component or the second modular component.
- the system may include a communication unit disposed in one or more of the first modular component or the second modular component, the communication unit configured to transmit to or receive data from a remote location.
- the remote location may include one or more of a portable control unit, a computer terminal, a server terminal, a mobile telephone, or a personal digital assistant.
- the communication unit may be configured to transmit one or more signals corresponding to a respective one or more analyte levels to the remote location.
- the communication unit may be configured to receive a flow instruction command to control delivery of the medication.
- the communication unit may be configured to wirelessly communicate over one or more of an Rf communication link, a Bluetooth communication link, or an infrared communication link.
- the second modular component in a further aspect may include an inner wall and an outer wall, a plurality of electrodes disposed between the inner wall and the outer wall, and a fluid delivery channel formed by the inner wall, where the plurality of electrodes may include an analyte sensor.
- a method in accordance with another embodiment may include providing a first modular component for medication delivery, providing a second modular component configured to analyte level detection, the second modular component connectable to the first modular component to establish electrical contact with the first modular component, forming a substantially water tight seal when the first and second modular components are connected, and providing a third modular component connectable to the first modular component when the first modular component is disconnected with the second modular component, where one of the first modular component and the second modular components are configured for replacement independent of the other component.
- the method may include delivering medication to a patient, and monitoring analyte level of the patient substantially concurrently to the medication delivery.
- a modular system for providing integrated medication delivery and physiological condition monitoring in accordance with still another aspect includes a replaceable first modular component configured to deliver medication, a replaceable second modular component configured to analyte level detection, where the second modular component is connectable to the first modular component to establish electrical contact with the first modular component, and a third modular component connectable to the first modular component when the first modular component is disconnected from the second modular component, where a substantially water tight seal is formed when the first and second modular components are connected or when the first and third modular components are connected.
- the one of the first modular component and the second modular components may be configured for replacement independent of the other component.
- the first modular component may include a connection port to couple to either one of the second modular component or the third modular component, and further, where the third modular component may include a cap configured to couple to the connection port of the first modular component.
- the cap may include an end cap or a plug.
- the analyte level monitored may include glucose level.
- the first modular component may include a low profile infusion device.
- the second modular component may include an analyte sensor.
- the first modular component may be configured to deliver medication to a patient at a first location in the patient, and further, where the second modular component may be configured to detect analyte level of the patient at a second location in the patient.
- first and second locations are separated by a predetermined distance.
- the first modular component may include a reusable portion and a disposable portion, where either of the second or third modular components are connectable to the reusable portion of the first modular component.
- the disposable portion of the first modular component may include one or more of an infusion set, or a reservoir containing the medication for delivery.
- the reusable portion of the first modular component may include a processing unit to control the operation of one of more of the first modular component or the second modular component.
- the system may include a communication unit disposed in one or more of the first modular component or the second modular component, the communication unit configured to transmit to or receive data from a remote location, an further, where the remote location may include one of more of a portable control unit, a computer terminal, a server terminal, a mobile telephone, or a personal digital assistant.
- the communication unit may be configured to transmit one or more signals corresponding to a respective one or more analyte levels to the remote location.
- the communication unit may be configured to receive a flow instruction command to control delivery of the medication.
- the communication unit may be configured to wirelessly communicate over one or more of an RF communication link, a Bluetooth communication link, or an infrared communication link.
- the second modular component may include an inner wall and an outer wall, a plurality of electrodes disposed between the inner wall and the outer wall, and a fluid delivery channel formed by the inner wall.
- the plurality of electrodes may comprise an analyte sensor.
- a method in accordance with another aspect includes positioning a replaceable first modular component on a skin surface of a user, connecting a replaceable second modular component to a predetermined location on the first modular component during a first time period, wherein a water tight seal is formed between the first modular component and the second modular component, and connecting a third modular component to the predetermined location first modular component during a second time period, where a water tight seal is formed between the first modular component and the second modular component, and further where the first time period and the second time period are nonoverlapping.
- the method may include delivering medication to the user, and monitoring analyte level of the user.
- a kit in still another aspect may include an infusion device configured to deliver medication, the infusion device including a port, an analyte monitoring device configured to monitor an analyte level of a user, the analyte monitoring device connectable to the port of the infusion device during a first predetermined time period, and a cap connectable to the port of the infusion device during a second predetermined time period, where the first and second predetermined time periods are nonoverlapping.
- the infusion device may include an on-body patch pump.
- the cap provides a water tight seal on the port when connected to the infusion device.
- the analyte monitoring device provides a water tight seal on the port when connected to the infusion device.
- a system including an infusion device and an analyte monitoring unit includes an infusion device, an on-body unit including a data transmission section, the on-body unit further coupled to the infusion device, the on-body unit configured to receive one or more signals corresponding to a respective one or more analyte levels, and further, the on-body unit configured to infuse a fluid received from the infusion device, and a receiver unit operatively coupled to the on-body unit the receiver unit configured to receive data from the on-body unit, wherein the received data is associated with the analyte level.
- the system may further include an analyte sensor at least a first portion of which is in fluid contact with an analyte of a patient, and further, where at a second portion of the analyte sensor is in signal communication with the data transmission section.
- the data transmission section may in one embodiment be configured to transmit the one or more signals corresponding to a respective one or more analyte levels substantially periodically at one or more predetermined time intervals, where the one of more predetermined time intervals may include one or more of approximately 30 seconds, approximately one minute, or approximately 90 seconds.
- the on-body unit may include a cannula at least a portion of which is subcutaneously positioned under a skin layer, and further, may also include an infusion tubing connected to the infusion device to deliver the fluid to the on-body unit.
- the infusion tubing and the on-body unit in a further aspect may be connected in a substantially water tight seal.
- the infusion tubing may be configured to operatively couple to the cannula to deliver the fluid.
- the on-body unit may be configured to wirelessly transmit the one or more signals corresponding to the respective one or more analyte levels to the receiver unit, where the on-body unit and the receiver may be configured to wirelessly communicate over one or more of an RF communication link, a Bluetooth communication link, or an infrared communication link.
- the infusion device in a further embodiment may be configured to control the delivery rate of the fluid based on the one or more signals corresponding to the respective one or more analyte levels received by the receiver unit, and further, where the infusion device may be configured to determine a modified deliver protocol for delivering fluid such as insulin based on information associated with the one or more signals corresponding to the respective one or more analyte levels.
- the modified delivery protocol may include one or more of a correction bolus, a modified basal profile, a carbohydrate bolus, and extended bolus, or combinations thereof.
- the receiver unit in one embodiment may be configured to wirelessly communicate with the infusion device.
- the receiver unit may be integrated into a housing of the infusion device.
- a method of integrating analyte monitoring and fluid infusion in another embodiment of the present disclosure includes infusing a fluid at a predetermined delivery rate, detecting one or more unable levels, transmitting one or more signals associated with the respective detected one or more analyte levels, and determining a modified delivery rate based on the transmitted one or more signals.
- the one or more signals may be transmitted substantially immediately after the associated respective one or more analyte levels are detected.
- the transmitting step in one embodiment may include wirelessly transmitting the one or more signals which wirelessly transmitted over one or more of an RF communication link, a Bluetooth communication link, an infrared communication link, or combinations thereof.
- the method in a further aspect may also include the steps of receiving the transmitted one or more signals, and displaying the received one or more signals.
- the method may also include the step of displaying the modified delivery rate.
- the method may also include the step of implementing the modified delivery rate, where the predetermined delivery rate may include one or more basal delivery rates.
- the modified delivery rate in a further embodiment may include one or more of a correction bolus, a modified basal profile, a carbohydrate bolus, an extended bolus, or combinations thereof.
- An apparatus including an analyte sensor and a fluid delivery channel in yet another embodiment of the present disclosure includes a fluid delivery unit having an inner wall and an outer wall, and a plurality of electrodes disposed between the inner wall and the outer wall of the fluid delivery unit, where a portion of the fluid delivery unit and a portion of the plurality of electrodes are subcutaneously positioned under a skin layer.
- the plurality of electrodes may comprise an analyte sensor, including, for example, one or more of a working electrode, a counter electrode, a reference electrode, or combinations thereof.
- the fluid delivery unit may include a channel for delivering a fluid such as insulin, the channel substantially formed by the inner wall.
- An apparatus including an analyte sensor and a fluid delivery channel in accordance with still another embodiment of the present disclosure includes a first tubing having a first tubing channel, and a second tubing having a second tubing channel including a plurality of electrodes disposed within the second tubing channel, where at least a portion of the first tubing and at least a portion of the second tubing are subcutaneously positioned under a skin layer.
- the plurality of the electrodes may be substantially and entirely insulated from each other.
- first tubing and the second tubing may be integrally formal such that an outer surface of the first tubing is substantially in contact with an outer surface of the second tubing.
- a system including an infusion device and an analyte monitoring unit in accordance with still another embodiment of the present disclosure includes an infusion and monitoring device, an on-body unit including a data transmission section, the on-body unit further coupled to the infusion and monitoring device, the on-body unit configured to receive one or more signals corresponding to a respective one or more analyte levels, and further, the on-body unit configured to infuse a fluid received from the infusion and monitoring device, and a connector coupled at a first end to the infusion device, and further, coupled at a second end to the on-body unit, the connector configured to channel the fluid from the infusion device to the on-body unit, and further, configured to provide the one or more signals corresponding to the respective one or more analyte levels to the infusion and monitoring device.
- the infusion and monitoring device may be configured to execute fluid delivery to a patient, and further, to detect analyte levels of the patient over a predetermined time period.
- the infusion and monitoring device may include a contnuous glucose monitoring system.
- the infusion and monitoring device may include an insulin pump.
- a method of fluid delivery and analyte monitoring in accordance with still another embodiment of the present disclosure includes determining a delivery profile for fluid infusion, wherein the delivery profile including a plurality of predetermined discrete fluid infusion each temporally separated by a predetermined time period, and sampling an analyte level substantially immediately prior to each predetermined discrete fluid infusion.
- the method may further include the step of sampling an analyte level substantially immediately after each predetermined discrete fluid infusion.
Abstract
Methods and systems for providing modular components in an integrated infusion device and analyte monitoring system where the components are independently repleaceable are provided.
Description
- The present application claims priority to U.S. application Ser. No. 12/032,593 filed Feb. 15, 2008 (issued as U.S. Pat. No. 9,636,450), which claims priority under 35 U.S.C. 119(e) to U.S. provisional patent application No. 60/890,497 filed Feb. 19, 2007, entitled “Modular Combination of Medication Infusion And Analyte Monitoring”, and assigned to the Assignee of the present application, Abbott Diabetes Care, Inc. of Alameda, Calif., the disclosure of which in incorporation herein by reference for all purposes.
- The present disclosure related to methods and systems for integrating infusion systems and analyte monitoring systems. More specifically, the present disclosure related to methods and systems for providing modular combination for integrated infusion and analyte monitoring systems.
- Type 1 diabetes must periodically be administered with insulin to sustain their physiological conditions. Typically, these patents administer doses of either fast acting or slow acting insulin using needle type syringes, for example, prior to meals, and/or at a suitable time during the course of each day contemporaneously with the blood glucose level testing using fingerstick testing, for example. If insulin is not suitable administered, the diabetic patients risk serious if not fatal damage to the body.
- Continued development and improvement in the external infusion pump therapy in recent years have drawn much appeal to the diabetic patients for, among others, improved management of diabetes by better regulating and controlling the intake of insulin. Typically, the patient inserts a cannula which is connected to an infusion tubing attached to an external pump, and insulin is administered based on a preprogrammed basal profiles. Moreover, the external infusion devices presently available include computational capability to determine suitable bolus doses such as carbohydrate bolus and correction bolus, for example, to be administered in conjunction with the infusion device executing the patient's basal profile.
- The basal profiles are generally determined by the parent's physician or caretaker and are based on a number of factors including the patient's insulin sensitivity and physiological condition which are diagnosed by the patient's physician, for example, and are typically intended to as accurately estimate the patient's glucose levels over a predetermined time period during which the patient is infusing insulin. The glucose levels may be estimated based on the patient's periodic discrete testing using a test strip and a blood glucose meter such as Freestyle® Glucose Meter available from Abbott Diabetes Care, Inc., of Alameda, Calif. Such estimations are, however, prone to error, and do not accurately mirror the patient's actual physiological condition.
- Furthermore, each aspect of the infusion and the analyte monitoring require components that are configured to execute the associated functions related to, for example, the control and management of insulin delivery and analyte monitoring. In addition, these components are prone to failure or otherwise periodic replacement due to ordinary usage. In view of the foregoing, it would be desirable to have a modular system including medication delivery unit such as an insulin pump, and an analyte monitoring device such as a continuous glucose monitoring system, that would allow for component based replacement when one or more aspects of the overall therapy management system fails or requires replacement.
- In accordance with the various embodiments of the present disclosure, there are provided method and system for modular combination of medication delivery and physiological condition monitoring.
- These and other objects, features and advantages of the present disclosure will become more fully apparent from the following detailed description of the embodiments, the appended claims and the accompanying drawings.
-
FIG. 1 illustrates an integrated infusion device and analyte monitoring system in accordance with one embodiment of the present disclosure; -
FIG. 2 illustrates an integrated infusion device and analyte monitoring system in accordance with another embodiment of the present disclosure; -
FIG. 3 illustrates an integrated infusion device and analyte monitoring system in accordance with yet another embodiment of the present disclosure; -
FIG. 4 illustrates an integrated infusion device and analyte monitoring system in accordance with still another embodiment of the present disclosure; -
FIG. 5 illustrates an integrated infusion device and analyte monitoring system in accordance with still a further embodiment of the present disclosure; -
FIG. 6 illustrates an integrated infusion device and monitoring system in accordance with yet still a further embodiment of the present disclosure; -
FIG. 7 A illustrates the integrated infusion device and monitoring system shown inFIG. 6 in further detail in one embodiment of the present disclosure, whileFIGS. 7B-7C illustrate the analog front end circuitry located at the patient interface and the pump assembly, respectively, of the integrated infusion device and monitoring system shown inFIG. 7A in accordance with one embodiment of the present disclosure; -
FIGS. 8A-8C illustrate a passive sensor configuration for use in a continuous analyte monitoring system, and two embodiments of an active sensor configuration for use at the patient interface in the integrated infusion device and monitoring system, respectively, in accordance with one embodiment of the present disclosure; -
FIG. 9 illustrates an integrated infusion device and analyte monitoring system with the infusion device and the monitoring system transmitter integrated into a single patch worn by the patient in accordance with one embodiment of the present disclosure; -
FIG. 10 is a detailed view of the infusion device cannula integrated with analyte monitoring system sensor electrodes in accordance with one embodiment of the present disclosure; -
FIG. 11A illustrates a component perspective view of the infusion device cannula integrated with analyte monitoring system sensor electrodes in accordance with another embodiment of the present disclosure, whileFIG. 11B illustrates a top planar view of the analyte monitoring system transmitter unit integrated with infusion device in accordance with one embodiment of the present disclosure; -
FIG. 12A-12C each illustrate a cross sectional view of the infusion device cannula integrated with continuous analyte monitoring system sensor electrodes ofFIG. 10 in accordance with the various embodiments respectively, of the present disclosure; -
FIG. 13 is a timing chart for illustrating the temporal spacing of blood glucose measurement and insulin delivery by the migrated infusion device and monitoring system in one embodiment; -
FIGS. 14A-14C illustrates modular combination of medication delivery and physiological condition monitoring system in accordance with one embodiment; -
FIGS. 15A-15C illustrates modular combination of medication delivery and physiological condition monitoring system in accordance with another embodiment; -
FIG. 16 illustrates a top planar view of a modular sensor component in accordance with one embodiment; and -
FIG. 17 illustrates modular combination of medication delivery and physiological condition monitoring system in accordance with yet another embodiment. -
FIG. 1 illustrates an integrated infusion device and analyte monitoring system in accordance with one embodiment of the present disclosure. Referring toFIG. 1 , the integrated infusion device andanalyte monitoring system 100 in one embodiment of the present disclosure includes aninfusion device 110 connected to aninfusion tubing 130 for liquid transport or infusion, and which is further coupled to acannula 170. As can be seen fromFIG. 1 , thecannula 170 is configured to be mountable coupled to atransmitter unit 150, where thetransmitter unit 150 is also mountable coupled to ananalyte sensor 160. Also provided is ananalyte monitor unit 120 which is configured to wirelessly communicate with the transmitter unit over acommunication path 140. - Referring to
FIG. 1 , in one embodiment of the present disclosure, thetransmitter unit 150 is configured for unidirectional wireless communication over thecommunication path 140 to theanalyte monitor unit 120. In one embodiment, theanalyte monitor unit 120 may be configured to include a transceiver unit (not shown) for bidirectional communication over thecommunication path 140. Thetransmitter unit 150 in one embodiment may be configured to periodically or continuously transmit signals associated with analyte levels defected by theanalyte sensor 160 to theanalyte monitor unit 120. Theanalyte monitor unit 120 may be configured to receive the signals from thetransmitter unit 150 and in one embodiment, is configured to perform data storage and processing based on one or more preprogrammed or predetermined processes. - For example, in one embodiment, the
analyte monitor unit 120 is configured to store the received signals associated with analyte levels in a data storage unit (not shown). Alternatively, or in addition, theanalyte monitor unit 120 may be configured to process the signals associated with the analyte levels to generate trend indication by, for example, visual display of a line chart or an angular icon based display for output display on itsdisplay unit 121. Additional information may be output displayed on thedisplay unit 121 of theanalyte monitor unit 120 including, but not limited to, the substantially contemporaneous and monitored real time analyte level of the patient received from thetransmitter unit 150 as detected by thesensor 160. The real time monitored analyte level may be displayed in a numeric format or in any other suitable format which provides the patient with the accurate measurement of the substantially real time analyte level detected by thesensor 160. - Analytes that may be monitored or determined by the
sensor 160 include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be determined. - Referring back to
FIG. 1 , thesensor 160 may include a short term (for example, 3 day, 5 day or 7 day use) analyte sensor which is replaced after its intended useful life. Moreover, in one embodiment, thesensor 100 is configured to be positioned subcutaneous to the skin of the patient such that at least a portion of the analyte sensor is maintained in fluid contact with the patient's analyte such as, for example, interstitial fluid or blood. In addition, thecannula 170 which is configured to similarly be positioned under the patient's skin is connected to theinfusion tubing 130 of theinfusion device 110 so as to deliver medication such as insulin to the patient. Moreover, in one embodiment, thecannula 170 is configured to be replaced with the replacement of thesensor 160. - In one aspect of the present disclosure, the
cannula 170 and thesensor 160 may be configured to be subcutaneously positioned under the skin of the patient using an insertion mechanism (not shown) such as an insertion gun which may include, for example, a spring biased or loaded insertion mechanism to substantially accurately position thecannula 170 and thesensor 160 under the patient's skin. In this manner, thecannula 170 and thesensor 160 may be subcutaneously positioned with substantially little or no perceived pain by the patient. Alternatively, thecannula 170 and/or thesensor 160 may be configured to be manually inserted by the patient through the patient's skin. After positioning thecannula 170 and thesensor 160, they may be substantially firmly retained in position by anadhesive layer 180 which is configured to adhere to the skin of the patient for the duration of the time period during which thesensor 160 and thecannula 170 are subcutaneously positioned. - Moreover, in one embodiment, the
transmitter unit 150 may be mounted after the subcutaneous positioning of thesensor 160 and thecannula 150 so as to be in electrical contact with the sensor electrodes. Similarly, theinfusion tubing 130 may be configured to operatively couple to the housing of thetransmitter unit 150 so as to be accurately positioned for alignment with thecannula 170 and to provide a substantially water tight seal. Exemplary analyte systems that may be employed are described in, for example, U.S. Pat. Nos. 6,134,461, 6,175,752, 6,121,611, 6,560,471, 6,746,582, and elsewhere. - Referring back to
FIG. 1 , theinfusion device 110 may include capabilities to program basal profiles, calculation of bolus doses including, but not limited to correction bolus, carbohydrate bolus, extended bolus, and dual bolus, which may be performed by the patient using theinfusion device 110, and may be based on one or more factors including the patient's insulin sensitivity, insulin on board, intended carbohydrate intake (for example, for the carbohydrate bolus calculation prior to a meal), the patient's measured or detected glucose level, and the patient's glucose trend information. In a further embodiment, the bolus calculation capabilities may also be provided in theanalyte monitor unit 120. - In one embodiment, the
analyte monitor unit 120 is configured with a substantially compact housing that can be easily carried by the patient. In addition, theinfusion device 110 similarly may be configured as a substantially compact device which can be easily and conveniently worn on the patient's clothing (for example, housed in a holster or a carrying device worn or clipped to the patient's belt or other parts of the clothing). Referring yet again toFIG. 1 , theanalyte monitor unit 120 and/or theinfusion device 110 may include a user interface such as information input mechanism by the patient as well as data output including, for example, thedisplay unit 121 on theanalyte monitor unit 120, or similarly a display unit 111 on theinfusion device 110. - One or more audio output devices such as, for example, speakers or buzzers may be integrated with the housing of the
infusion device 110 and/or theanalyte monitor unit 120 so as to output audible alerts or alarms based on the occurrence of one or more predetermined conditions associated with theinfusion device 110 or theanalyte monitor unit 120. For example, theinfusion device 110 may be configured to output an audible alarm or alert to the patient upon detection of an occlusion in theinfusion tubing 130 or the occurrence of a timed event such as a reminder to prime the infusion tubing upon replacement of thecannula 170, and the like. - The
analyte monitor unit 120 may be similarly configured to output an audible alarm or alert when a predetermined condition or a pre-programmed event occurs, such as, for example, a reminder to replace thesensor 160 after its useful life (of, for example, 3 days, 5 days or 7 days, or more), or one or more alerts associated with the data received from thetransmitter unit 150 corresponding to the patient's monitored analyte levels. Such alerts or alarms may include a warning alert to the patient that the detected analyte level is beyond a predetermined threshold level, or the trend of the detected analyte levels within a given time period is indicative of a significant condition such as potential hyperglycemia or hypoglycemia, which require attention or corrective action. It is to be noted that the examples of audible alarms and/or alerts are described above for illustrative purposed only, that within the scope of the present disclosure, other events or conditions may be programmed into theinfusion device 110 or theanalyte monitor unit 120 or both, so as to alert or notify the patient of the occurrence or the potential occurrence of such events or conditions. - In addition, within the scope of the present disclosure, audible alarms may be output alone, or in combination with one or more of a visual alert such as an output display on the
display unit 111, 121 of theinfusion device 110 or theanalyte monitor unit 120, respectively, or vibratory alert which would provide a tactile indication to the patient of the associated alarm and/or alert. - Moreover, referring yet again to
FIG. 1 , while oneanalyte monitor unit 120 and onetransmitter unit 150 are shown, within the scope of the present disclosure, additional analyte monitor units or transmitter units may be provided such that, for example, thetransmitter unit 150 may be configured to transmit to multiple analyte monitor units substantially simultaneously. Alternatively, multiple transmitter units coupled to multiple sensors concurrently in fluid contact with the patient's analyte may be configured to transmit to theanalyte monitor unit 120, or to multiple analyte monitor units. For example, an additional transmitter unit coupled to an additional sensor may be provided in the integrated infusion device andanalyte monitoring system 100 which does not include thecannula 170, and which may be used to perform functions associated with thesensor 160 such as sensor calibration, sensor data verification, and the like. - In one embodiment, the
transmitter unit 150 is configured to transmit the sampled data signals received from thesensor 160 without acknowledgement from theanalyte monitor unit 120 that the transmitted sampled data signals have been received. For example, thetransmitter unit 150 may be configured to transmit the encoded sampled data signals at a fixed rate (e.g., at one minute intervals, or any suitable rate) after the completion of the initial power on procedure. Likewise, theanalyte monitor unit 120 may be configured to detect such transmitted encoded sampled data signals at predetermined time intervals. Alternatively, thetransmitter unit 150 and theanalyte monitor unit 120 may be configured for bi-directional communication over thecommunication path 140. - Additionally, in one aspect, the
analyte monitor unit 120 may include two sections. The first section of theanalyte monitor unit 120 may include an analog interface section that is configured to communicate with thetransmitter unit 150 via thecommunication path 140. In one embodiment, the analog interface section may include an RF receiver and an antenna for receiving and amplifying the data signals from thetransmitter unit 150, which are thereafter, demodulated with a local oscillator and filtered through a band-pass filter. The second section of theanalyte monitor unit 120 may include a data processing section which is configured to process the data signals received from thetransmitter unit 150 such as by performing data decoding, error detection and correction, data clock generation, and data bit recovery, for example. - In operation, upon completing the power-on procedure, the
analyte monitor unit 120 is configured to detect the presence of thetransmitter unit 150 within its range based on, for example, the strength of the detected data signals received from thetransmitter unit 150 or predetermined transmitter identification information. Upon successful synchronization with thetransmitter unit 150, theanalyte monitor unit 120 is configured to begin receiving from thetransmitter unit 150 data signals corresponding to the patient's detected analyte, for example glucose, levels. - Referring again to
FIG. 1 , theanalyte monitor unit 120 or theinfusion device 110, or both may be configured to further communicate with a data processing terminal (not shown) which may include a desktop computer terminal, a data communication enabled kiosk, a laptop computer, a handheld computing device such as a personal digital assistant (PDAs), or a data communication enable mobile telephone, and the like, each of which may be configure for data communication via a wired or a wireless connection. The data processing terminal for example may include physician's terminal and/or a bedside terminal in a hospital environment. - The
communication path 140 for data communication between thetransmitter unit 150 and theanalyte monitor unit 120 ofFIG. 1 may include an RF communication link, Bluetooth communication link, infrared communication link, or any other type of suitable wireless communication connection between two or more electronic devices. The data communication link may also include a wired cable connection such as, for example, but not limited to an RS232 connection, USB connection, or serial cable connection. - Referring yet again to
FIG. 1 , in a further aspect of the present disclosure, theanalyte monitor unit 120 or the infusion device 110 (or both) may also include a test strip port configured to receive a blood glucose test strip for discrete sampling of the patient's blood for glucose level determination. An example of the functionality of blood glucose test strip meter unit may be found in Freestyle® Blood Glucose Meter available from the assignee of the present disclosure, Abbott Diabetes Care, Inc. - In the manner described above, in one embodiment of the present disclosure, the
cannula 170 for infusing insulin or other suitable medication is integrated with theadhesive patch 180 for thesensor 160 and thetransmitter unit 150 of the analyte monitoring system. Accordingly, only one on-skin patch can be worn by the patient (for example, on the skin of the abdomen) rather than two separate patches for theinfusion device cannula 170, and the analyte monitoring system sensor 160 (with the transmitter unit 150). Thus, the Type-1 diabetic patient may conveniently implement infusion therapy in conjunction with real time glucose monitoring while minimizing potential skin irritation on theadhesive patch 180 site on the patient's skin, and thus provide more insertion sites with less irritation. - In addition, the integrated infusion device and
analyte monitoring system 100 as shown inFIG. 1 may be configured such that theinfusion tubing 130 may be disconnected from theinfusion device 110 as well as from the housing of the transmitter 150 (or the adhesive patch 180) such that, optionally, the patient may configure the system as continuous analyte monitoring system while disabling theinfusion device 110 functionality. Likewise, a patient may configure the system as an infusion device while disabling the continuous analyte monitoring system functions. - Moreover, in accordance with one embodiment of the present disclosure, the patient may better manage the physiological conditions associated with diabetes by having substantially continuous real time glucose data, trend information based on the substantially continuous real time glucose data, and accordingly, modify or adjust the infusion levels delivered by the
infusion device 110 from the pre-programmed basal profiles that theinfusion device 110 is configured to implement. -
FIG. 2 illustrates an integrated infusion device and analyte monitoring system in accordance with another embodiment of the present disclosure. Referring toFIG. 2 , the integrated infusion device and analyte monitoring system 200 in one embodiment of the present disclosure includes an integrated infusion device andanalyte monitor unit 210 which is coupled to an infusion tubing 220 connected to thecannula 260. Also shown inFIG. 2 is atransmitter unit 240 which is in electrical contact with ananalyte sensor 250, where thecannula 260 and theanalyte sensor 250 are subcutaneously postitioned under the skin of the patient, and retained in position by an adhesive layer or patch 270. - Referring to
FIG. 2 , the integrated infusion device andanalyte monitor unit 210 is configured to wirelessly communicate with thetransmitter unit 240 over a communicatin path 230 such as an RF communication link. Compared with the embodiment shown inFIG. 1 , it can be seen that in the embodiment shown inFIG. 2 , the infusion device and the analyte monitor are integrated into asingle housing 210. In this manner, thetransmitter unit 240 may be configure to transmit signals corresponding to the detected analyte levels received from theanalyte sensor 250 to the integrated infusion device and analyte monitor 210 for data analysis and processing. - Accordingly, the patient may conveniently receive real time glucose levels from the
transmitter unit 240 and accordingly, determine whether to modify the existing basal profile(s) in accordance with which insulin is delivered to the patient. In this manner, the functionalities of the analyte monitor unit may be integrated within the compact housing of the infusion device to provide additional convenience to the patient, for example, by providing the real time glucose data as well as other relevant information such as glucose trend data to the user interface of the infusion device, so that the patient may readily and easily determine any suitable modification to the infusion rate of the insulin pump. - In one embodiment, the configurations of each component shown in
FIG. 2 including thecannula 260, theanalyte sensor 250, thetransmitter unit 240, the adhesive layer 270, the communication path 230, as well as the infusion tubing 220 and the functionalities of the infusion device and the analyte monitor are substantially similar to the corresponding respective component as described above in conjunction withFIG. 1 . - Accordingly, in one embodiment of the present disclosure, the additional convenience may be provided to the patient in maintaining and enhancing diabetes management by, for example, having a single integrated device such as the integrated infusion device and
analyte monitor unit 210 which would allow the patient to easily manipulate and manage insulin therapy using a single user interface system of the integrated infusion device andanalyte monitor unit 210. Indeed, by providing the information associated with both the glucose levels and insulin infusion in a single device, the patient may be provided with the additional convenience in managing diabetes and improving insulin therapy. -
FIG. 3 illustrates as integrated infusion device and analyte monitoring system in accordance with yet another embodiment of the present disclosure. Referring toFIG. 3 , the integrated infusion device andanalyte monitoring system 300 in one embodiment of the present disclosure includes aninfusion device 310 connected to aninfusion tubing 340 coupled to acannula 370. Thecannula 370 is configured to be positioned subcutaneously under the patient's skin and substantially retained in position by anadhesive layer 380. Also retained in position, as discussed above and similar to the embodiments described in conjunction withFIGS. 1-2 , is ananalyte sensor 360 also positioned subcutaneously under the patient's skin and maintained in fluid contact with the patient's analyte. A transmitter unit 350 is provided so as to be electrically coupled to theanalyte sensor 360 electrodes. Also, as can be seen fromFIG 3 , in one embodiment, theinfusion tubing 340 is connected to the housing of the transmitter unit 350 so as to connect to thecannula 370 disposed under the patient's skin. - Referring to
FIG. 3 , also provided is an analyte monitor unit 320 configured to wirelessly communicate with the transmitter unit 350 to receive data therefrom associated with the analyte levels of the patient detected by theanalyte sensor 360. Referring toFIG. 3 , in one embodiment theinfusion device 310 does not include a user interface such as a display unit and/or an input unit such as buttons or a jog dial. Instead, the user interface and control mechanism is provided on the analyte monitoring unit 320 such that the analyte monitoring unit 320 is configured to wirelessly control the operation of theinfusion device 310 and further, to suitably program theinfusion device 310 to execute pre-programmed basal profile(s), and to otherwise control the functionality of theinfusion device 310. - More specifically, all of the programming and control mechanism for the
infusion device 310 is provided in the analyte monitoring unit 320 such that when the patient is wearing theinfusion device 310, it may be worn discreetly under clothing near the infusion site on the patient's skin (such as abdomen), while still providing convenient access to the patient for controlling theinfusion device 310 through the analyte monitoring unit 320. - In addition, in one embodiment, the configurations of each component shown in
FIG. 3 including thecannula 370, theanalyte sensor 360, the transmitter unit 350, theadhesive layer 380, the communication path 320, as well as theinfusion tubing 340 and the functionalities of the infusion device and the analyte monitoring unit 320 are substantially similar to the corresponding respective component as described above in conjunction withFIG. 1 . However, theinfusion device 30 in the embodiment shown inFIG. 3 is configured with a transceiver or an equivalent communication mechanism to communicate with the analyte monitoring unit 320. - In this manner, in one embodiment of the present disclosure, configuration of the
infusion device 310 without a user interface provides a smaller and lighter housing and configuration for theinfusion device 310 which would enhance the comfort in wearing and/or carrying theinfusion device 310 with the patient. Moreover, since the control and programming functions of theinfusion device 310 is provided on the analyte monitoring unit 320, the patient may conveniently program and/or control the functions and operations of theinfusion device 310 without being tethered to theinfusion tubing 340 attached to thecannula 370 which is positioned under the patient's skin. In addition, since the programming and control of theinfusion device 310 is remotely performed on the analyte monitoring unit 320, the infusion tubing 304 may be shorter and thus less cumbersome. -
FIG. 4 illustrates an integrated infusion device and analyte monitoring system in accordance with still another embodiment of the present disclosure. Referring toFIG. 4 , the integrated infusion device andanalyte monitoring system 400 in one embodiment of the present disclosure includes aninfusion device 410 configured to wirelessly communicate with an analyte monitoring unit 420 over acommunication path 430 such as an RF (radio frequency) link. In addition, as can be further seen fromFIG. 4 , theinfusion device 410 is connected to aninfusion tubing 440 which has provided therein integral wires connected to the analyte sensor electrodes. As discussed in further detail below, the measure analyte levels of the patient is received by theinfusion device 410 via theinfusion tubing 440 and transmitted to the analyte monitoring unit 420 for further processing and analysis. - More specifically, referring to
FIG. 4 , the integrated infusion device andanalyte monitoring system 400 includes apatch 450 provided with acannula 470 and ananalyte sensor 460. Thecannula 470 is configured to deliver or infuse medication such as insulin from theinfusion device 410 to the patient. That is, in one embodiment, thecannula 470 and theanalyte sensor 460 are configured to be positioned subcutaneous to the patient's skin. Theanalyte sensor 460 is configured to be positioned to be in fluid contact with the patient's analyte. - In this manner, the
analyte sensor 460 is electrically coupled to integral wires provided within theinfusion tubing 440 so as to provide signals corresponding to the measured or detected analyte levels of the patient to theinfusion device 410. In one embodiment, theinfusion device 410 is configured to perform date analysis and storage, such that theinfusion device 410 may be configured to display the real time measured glucose levels to the patient on itsdisplay unit 411. In addition to or alternatively, theinfusion device 410 is configured to wirelessly transmit the received signals from theanalyte sensor 460 to the analyte monitoring unit 420 for data analysis, display, and/or storage and the analyte monitoring unit 420 may be configured to remotely control the functions and features of theinfusion device 410 providing additional user convenience and discreteness. - Referring back to
FIG. 4 , in one embodiment, thepatch 450 may be configured to be substantially small without a transmitter unit mounted thereon, and provided with a relatively small surface area to be attached to the patient's skin. In this manner, the pattern may be provided with added comfort in having a substantially compact housing mounted on the skirt (attached with an adhesive layer, for example), to infuse medication such as insulin, and for continuous analyte monitoring with theanalyte sensor 460. -
FIG. 5 illustrates an integrated infusion device and analyte monitoring system in accordance with still a further embodiment of the present disclosure. As compared with the embodiment shown inFIG. 4 , the integrated infusion device andanalyte monitoring system 500 ofFIG. 5 includes an integrated infusion device andanalyte monitoring unit 510. Accordingly, one user interface is provided to the user including thedisplay unit 511 andinput buttons 512 provided on the housing of the integrated infusion device andanalyte monitoring unit 510. Also shown inFIG. 5 are infusion tubing 520 with integral wires disposed therein and connected to an analyte sensor 540 electrodes in fluid contact with the patient's analyte. Moreover, as can be seen fromFIG. 5 , an adhesive patch 530 is provided to retain the subcutaneous position of acannula 550 and the analyte sensor 540 in the desired positions under the patient's skin. - Optionally, the integrated infusion device and
analyte monitoring unit 510 may be provided with wireless or wired communication capability so to communicate with a remote terminal such as a physician's computer terminal over a wireless communication path such as RF communication link, or over a cable connection such as a USB connection, for example. Referring back toFIG. 5 , in one embodiment of the present disclosure, the diabetic patient using an infusion therapy is provided with fewer components to handle or manipulate further simplifying insulin therapy and glucose level monitoring and management. -
FIG. 6 illustrates an integrated infusion device and monitoring system in accordance with yet still a further embodiment of the present disclosure. Referring toFIG. 6 , the integrated infusion device and analyte monitoring system 600 is provided with an infusion device without a user interface, and configured to wirelessly communicate with ananalyte monitoring unit 620 over acommunication path 630 such as an RF link. The infusion device 610 which may be provided in a compact housing since it does not incorporate the components associated with a user interface, is connected to an infusion tubing 640 having disposed therein integral wires correspondingly connected to the electrodes ofanalyte sensor 660 in fluid contact with the patient's analyte. In addition, the compact adhesive patch 650 in one embodiment is configured to retaincannula 670 and theanalyte sensor 660 in the desired position under the skin of the patient. - Similar to the embodiment shown in
FIG. 3 , theanalyte monitoring unit 620 is configured to control and program the infusion device 610 over thecommunication link 630. In this manner, the control and programming functions of the infusion device 610 may be remotely performed by theanalyte monitoring unit 620, providing convenience to the patient. -
FIG. 7A illustrates the integrated infusion device and monitoring system shown inFIG. 6 in further detail in one embodiment of the present disclosure, whileFIGS. 7A-7B illustrate the analog front end circuitry located at the patient interface and the pump assembly, respectively, of the integrated infusion device and monitoring system shown inFIG. 7A in accordance with one embodiment of the present disclosure. Referring toFIG. 7A , aninfusion device 710 connected to aninfusion tubing 720 with integral wires provided therein for connection to the electrodes of the analyte sensor is shown. Theinfusion tubing 720 is further connected to anadhesive patch 730 which is configured to retain cannula 750 and analyte sensor 740 in the desired subcutaneous portion under the skin of the patient. - Referring to
FIG. 7A , in one embodiment of the present disclosure, theinfusion device 710 may be provided with a first analog front end circuitry unit 711, while the adhesive patch may be provided with a second analog frontend circuitry unit 731. The integral wires from the analyte sensor 740 is configured to extend from theinfusion device 710 to theadhesive layer 730 via theinfusion tubing 720. Since the analyte sensor 740 in one embodiment is a passive component, the signals on the working electrode and the reference electrodes of the analyte sensors are subject to noise given the high impendence of the electrodes and the length of the integral wires (in excess of a few centimeters). The noise in turn may potentially adversely affect the signals on the working and reference electrodes which may distort the measured analyte levels detected by the analyte sensor 740. - Given the length of the integral wire which corresponds to the length of the
infusion tubing 720, in one embodiment, the signals from the working and reference electrodes may be converted to low impedance signals to minimize adverse impact from the noise. Accordingly, theinfusion device 710 may be provided with a first analog front end circuitry unit 711, while theadhesive patch 730 may be provided with a second analog frontend circuitry unit 731 as discussed in further detail below in conjunction withFIGS. 7B and 7C . - Referring now to
FIG. 7B , the second analog frontend circuitry unit 731 disposed on theadhesive patch 730 on the patient's skin, in one embodiment includes an a trans-impedance amplifier (current to voltage converter or “I-to-V”) 731A configured to convert the working electrode (W) current to a voltage (Vw), and to provide a guard signal (G), and a servo segment 731B to drive the counter electrode (C) voltage (Ve) based on the reference electrode (R) voltage. Also shown inFIG. 7B is a Low-Pass Filter (LPF) and gain stage 711A that follow each of the I-to-V and servo stages, and which is configured in one embodiment to drive an A/D (Analog-to-Digital) converter unit 711C whose results are read by a controller such as a central processing unit (CPU) 711D. The A/D converter unit 711C and theCPU 711D and other peripherals may be combined into a single integrated circuit (IC) known as a microcontroller (μC) such as the MSP430 product line. - Referring now to
FIG. 7C , in one embodiment, the second analog frontend circuitry unit 731 may be implemented by a pair of operational amplifiers (731A and 731B), four resistors (R1, R2, R3, Rf), and a bypass capacitor (Cb). the I-to-F stage usingoperational amplifier 731A is generated by the action of the input current from the working electrode (W) flowing through the feedback resistor (Rf) and creating a voltage differential that is driven by theoperational amplifier 731A as the low impedance signal Vw. The offset for the Vw signal is established by the resistor divider comprised of R1, R2 and R3 which also creates the voltage of the guard signal (G)—a signal that is at the same potential or voltage as the working electrode (W). - The servo, using operational amplifier 731B, in one embodiment, drives the counter electrode (C) voltage to the sensor so that the reference electrode (R) is at the second value set by the resistor divider comprised of resistors R1, R2 and R3. This maintains the working electrode (W) voltage above the reference electrode (R) by a set amount know as the “Poise Voltage” (i.e 40 mV). The bypass capacitor (Cb) may be a small, low equivalent series resistance (ESR) capacitor, such as a 0.1 uF (100 nF) multi-layer ceramic (MLC) capacitor, that acts to provide local energy and reduce noise on the circuit. The voltage source for this circuit may be provided by the potential difference between V+ and V− where, for example, V+ may be 5V and V− may be ground (GND) or V+ may be +3V and V− may be −3V.
- In one embodiment, the
operational amplifiers 731A, 731B, may be acquired as a dual operational amplifier integrated circuit (IC) in a single, small 8-pin, surface mount technology (SMT) package such as the OPA2349 in a SOT23-8 package (3 mm by 3 mm). Similar dual operational amplifier products may be available in even smaller ball-grid array (BGA) packages and as bare die that may be mounted directly to the circuit substrate, such as a printed circuit board (PCB) or flex circuit, using techniques such as “flip-chip” and wire-bond. - In one aspect, the analyte sensor described above in conjunction with the Figures may include one or more working electrodes and a reference electrode or a reference/counter electrode disposed on a substrate, and further, may optionally include a separate counter electrode. Indeed, in one aspect, the various electrodes of the sensor as well as the substrate and the dielectric layers may be provided in a stacked, side by side, or layered configuration or construction. For example, in one aspect, the sensor may include a substrate layer and a first conducting layer such as a carbon trace deposed on at least a portion of the substrate layer, and which may comprise the working electrode. Also shown disposed on at least a portion of the first conducting layer is a sensing layer.
- A first insulation layer such as a first dielectric layer may be disposed or stacked on at least a portion of the first conducting layer, and further, a second conducting layer such as another carbon trace may be disposed or stacked on top of at least a portion of the first insulation layer (or dielectric layer). The second conducting layer may comprise the reference electrode, and in one aspect, may include a layer of silver/silver chloride (Ag/AgCl).
- Further, a second insulation layer such as a dielectric layer in one embodiment may be disposed or stacked on at least a portion of the second conducting layer. Further, a third conducting layer which may include carbon trace and that may comprise the counter electrode may be disposed on at least a portion of the second insulation layer. Finally, a third insulation layer may be disposed or stacked on at least a portion of the third conducting layer. In this manner, the analyte sensor may be configured in a stacked, side by side or layered construction or configuration such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer).
- Additionally, within the scope of the present disclosure, some or all of the electrodes of the analyte sensor may be provided on the same side of the substrate in a stacked construction as described above, or alternatively, may be provided in a co-planar manner such that each electrode is disposed on the same plane on the substrate, however, with a dielectric material or insulation material disposed between the conducting layers/electrodes. Furthermore, in still another aspect, the one or more conducting layers such as the electrodes of the sensor may be disposed on opposing sides of the substrate.
- Referring again to the Figures,
FIGS. 8A-8C illustrate a passive sensor configuration for use in a continuous analyte monitoring system, and two embodiments of an active sensor configuration for use at the patient interface in the integrated infusion device and monitoring system, respectively, in accordance with one embodiment of the present disclosure. Referring toFIG. 8A , analyte sensor 810 includes workingelectrode 811, a guard trace 812, areference electrode 813, and a counter electrode 814. In one embodiment, the “tail” segment 815 of the analyte sensor 810 is configured to be positioned subcutaneously under the patient's skin so as to be in fluid contact with the patient. - Referring now to
FIG. 8B ,analyte sensor 820 is provided with the analogfront end portion 821 where the four contacts shown are V+, V−, Vw, and Ve signals in accordance with one embodiment in place of the workingelectrode 811, a guard trace 812, areference electrode 813, and a counter electrode 814, respectively. In this manner, in one embodiment of the present disclosure, these signals of theactive analyte sensor 820 are low impedance and thus less subject to noise than the passive sensor signals. Moreover, in one embodiment, theanalyte sensor 820 configuration may include a flex circuit. - Referring now to
FIG. 8C , in a further embodiment, an active sensor of similar construction to theactive sensor 820 ofFIG. 11B but with much smaller dimensions is shown. More specifically, analyte sensor 830 is provided with four contacts configured for direct wire bonding rather than a mechanical contact system as indicated by the large contact areas on the previous two sensor configurations shown inFIGS. 8A-8B . Since the shape of the analyte sensor 830 is reduced, the sensor 830 may be wrapped around the cannula (for example,cannula 470 ofFIG. 4 ) and thus only a single entry site may be required for the patient analyte monitoring and insulin infusion. Moreover, within the scope of the present disclosure, additional sensor/cannula configurations may be provided where the sensor circuitry and cannula are created as a single assembly such as a cannula with the circuit 831 fabricated on the surface. -
FIG. 9 illustrates an integrated infusion device and analyte monitoring system with the infusion device and the monitoring system transmitter integrated into a single patch worn by the patient in accordance with one embodiment of the present disclosure. Referring toFIG. 9 , the integrated infusion device and analyte monitoring system 900 includes an integrated patch pump andtransmitter unit 910 provided on anadhesive layer 960, and which is configured to be placed on the skin of the patient, so as to securely positioncannula 950 and analyte sensor 940 subcutaneously under the skin of the patient. The housing of the integrated infusion pump andtransmitter unit 910 is configured in one embodiment to include the infusion mechanism to deliver medication such as insulin to the patient via thecannula 950. - In addition, the integrated patch pump and
transmitter unit 910 is configured transmit signals associated with the detected analyte levels measured by the analyte sensor 940, over awireless communication path 930 such as an RF link. The signals are transmitted from the on body integrated patch pump andtransmitter unit 910 to acontroller unit 920 which is configured to control the operation of the integrated patch pump andtransmitter unit 910, as well as to receive the transmitted signals from the integrated patch pump andtransmitter unit 910 which correspond to the detected analyte levels of the patient. - Referring back to
FIG. 9 , in one embodiment the infusion mechanism of the integrated patch pump andtransmitter unit 910 may include the infusion device of the type described in U.S. Pat. No. 6,916,159 assigned to the assignee of the present disclosure Abbott Diabetes Care, Inc. In addition, while a wireless communication over thecommunication path 930 is shown inFIG. 9 , thewireless communication path 930 may be replaced by a set of wires to provide a wired connection to shecontroller unit 920. - In this manner, in one embodiment of the present disclosure, the integrated infusion device and analyte monitoring system 900 does not use an infusion tubing which may provide additional comfort and convenience to the patient by providing additional freedom from having to wear a cumbersome tubing.
-
FIG. 10 is a detailed view of the infusion device cannula integrated with analyte monitoring system sensor electrodes in accordance with one embodiment of the present disclosure. Referring toFIG. 10 , there is shown an infusion device cannula withanalyte sensor electrodes 1020 disposed therein, and mounted to anadhesive patch 1010 so as to retain its position securely in the patient. More specifically, as can be seen fromFIG. 10 , the cannula withanalyte sensor electrodes 1020 includesensor electrodes cannula tip 1020, and further, positioned so as to maintain fluid contact with the patient's analyte. In one aspect, some or all of the electrodes of the analyte sensor may be wrapped around the cannula, stacked on one or more inner and/or outer surfaces of the cannula. -
FIG. 12A-12C each illustrate a cross sectional view of the infusion device cannula integrated with continuous analyte monitoring system sensor electrodes ofFIG. 10 in accordance with the various embodiments respectively, of the present disclosure. Referring toFIG. 12A , in one embodiment, the wire and tubing are provided in parallel such that thetubing wall 1020, the tube bore forinsulin flow 1024, the wireouter casing 1020 and the individualinsulated wires FIG. 12A . More specifically, it can be seen from the Figure that each of the three insulated wires are provided with aninsulation layer 1020 of tubing wall individually surrounding eachinsulated wire insulated wires tubing wall 1020. - Referring now to
FIG. 12B in one embodiment of the present disclosure, theinsulated wires tubing wall 1020, with thetube bore 1024 for insulin delivery and theinsulated wires FIG 12B . Referring now toFIG. 12C , in still a further embodiment of the present disclosure, each of theinsulated wires tubing 1020 and covered with asheath 1210, thus providing thetubing wall 1020, thetubing bore 1024 for insulin delivery, the individualinsulated wires protective sheath 1210, which may also serve as an electromagnetic shield to eliminate electronic noise as substantially shown is the Figure. - Referring again to the Figures, the embodiments shown in
FIGS. 12A and 12C may have a larger cross-sectional area (thus a larger hole needed to be punctured on the skin of the patient), but are likely easier to manufacture, more reliable and easier to make connection to the analyte sensor electronics). Additionally, within the scope of the present disclosure, an optical data transmission (i.e. fiber optics) along insulin delivery tubing between sensor and pump may be provided instead of integral wires as discussed above. -
FIG. 11A illustrates a component perspective view of the infusion device cannula integrated with analyte monitoring system sensor electrodes in accordance with another embodiment of the present disclosure, whileFIG. 11B illustrates a top planar view of the analyte monitoring system transmitter unit integrated with infusion device in accordance with one embodiment of the present disclosure. Referring toFIGS. 11A-11B , in one embodiment of the present disclosure, integrated analyte sensor andinfusion device cannula 1100 comprise five laminated layers including a top insulation layer 1101, aconductive layer 1102 with electrode traces disposed thereon, followed by three layer substrate withintegrated infusion cannula 1103. - In one embodiment, the three layer substrate with
integrated infusion cannula 1103 includes a separation/insulation layer 1103A to insulate the sensor electrodes from the infusion cannula, a channel layer 1103B configured to guide the flow of the insulin or any other suitable medication, and an inlet/outlet layer 1103C. Also shown inFIG. 11A is an assembled view of the integrated analyte sensor andinfusion device cannula 1100. - Referring now to
FIG. 11B , it can be seen that a patch pump as shown in one embodiment is provided with atransmitter unit 1110 and an insulin pump 1130 coupled toinsulin reservoir 1120, and operatively coupled or mounted to thetransmitter unit 1110. Also shown inFIG. 11B is theanalyte sensor contacts 1140 which are configured to establish electrical contact with the respective electrodes of the integrated infusion cannula andanalyte sensor 1100. Also shown inFIG. 11B is insulin port 1150 which is connected to the channel layer 1103B of the integrated infusion device cannula andanalyte sensor 1100. - In this manner, in one embodiment of the present disclosure, the patch pump may be worn by the patient on skin and which includes the insulin infusion mechanism as well as the analyte sensor and transmitter unit.
-
FIG. 13 is a timing chart for illustrating the temporal spacing of blood glucose measurement and insulin delivery by the integrated infusion device and monitoring system in one embodiment. More specifically, insulin pumps typically deliver insulin in a periodic manner with the period of delivery in the range of 2 to 3 minutes and the duration of delivery at each period being on the order of a few seconds or less. The amount of insulin that is delivered each period may be varied depending on the overall insulin delivery rate that is desired. The analyte data is collected continuously (as, for example, a continuous current of glucose oxidation) but is typically reported to the user periodically. The analyte reporting period is typically 1 to 10 minutes and glucose oxidation current needs to be collected for 10 to 30 seconds in order to generate a reportable glucose value (to allow for filtering etc.). - Indeed, the integration of analyte monitoring and insulin delivery may necessitate placement of an analyte sensor in close proximity to an insulin infusion cannula on the body. Such close proximity engenders the possibility of insulin delivery interfering with the analyte measurements. For example, if insulin infusion should result in a localized decrease in the glucose concentration in the area of the body near the infusion site, then glucose measurement in this area would not be representative of the glucose concentration in the body as a whole. Accordingly, in one embodiment of the present disclosure, there is provided a method for temporal spacing of blood glucose measurements and insulin delivery to mitigate the possible interference between insulin infusion and glucose measurements.
- In accordance with one embodiment, the temporal spacing of analyte measurement and insulin delivery may include providing a large a temporal space from after insulin delivery and before taking an analyte measurement. Since both analyte measurement and insulin delivery are performed periodically, a maximum spacing in time may be achieved if analyte measurement substantially immediately precedes insulin delivery. During the time between insulin delivery and the subsequent glucose measurement, infused insulin has time to diffuse and be transported away from the infusion site due to normal circulation of interstitial fluid. An example timeline of temporally spaced analyte measurement and insulin delivery is shown in
FIG 13 . If multiple analyte measurements are taken between insulin delivery points, there should always be a reading just prior to insulin delivery and as well just after insulin delivery to minimize the affect of injected insulin on the glucose measurement readings. - Although readings are typically taken periodically for simplicity in processing, a reading may be taken out of time with other readings and sealed appropriately for the overall reading average. Similarly, the insulin delivery point may be delayed slightly until after the reading with little or no affect as the readings typically occur much more frequently than the infusions, which are intended to act over longer periods of time. In addition, other timing considerations may be considered depending on the environment in which the integrated infusion device and analyte monitoring system is used by the patient, within the scope of the present disclosure to minimize potential error on measured analyte levels and/or introduce noise or potential adverse effects to the infusion rates of the infusion device.
- More specifically, fluctuation in the power supplies of the infusion device and/or the analyte monitoring system including, for example, batteries or related power distribution circuitry may introduce electrical noise effects which may adversely affect the measured readings associated with the analyte monitoring system. For example, when the analyte monitoring system is configured to be in an active state so as to be transmitting or receiving data, or when the pump cycle of the infusion device is active, the power supply may be affected by the load from the data transmission/reception, or the pumping cycle. The adverse effect of the power supply in addition to noise from other components of the electronic circuitry may introduce undesirable noise and adversely affect the accuracy of the analyte sensor measurements.
- Accordingly, the transmitter unit 150 (
FIG. 1 ) for example, may be configured to monitor the timing or occurrence of the measured analyte level received from theanalyte sensor 160 and the data transmission timing of thetransmitter unit 150 such that the two events do not substantially overlap or occur at substantially the same time. Alternatively, the analyte monitor unit 120 (FIG. 1 ) may be configured to compare the timing of theanalyte sensor 160 measurement and the timing of the data transmission from thetransmitter unit 150, and to discard data analyte related data received from thetransmitter unit 150 which coincide with the timing of the analyte measurements by theanalyte sensor 160. - Moreover in one embodiment, air bubble detection in the insulin tubing may be provided, by monitoring fluid motion that would also detect the absence of fluid such as that due to an air bubble in the line. In one embodiment, the flow sensor may be configured to generate zero current when an air bubble is present.
- In addition, colorization of insulin may be provided for air bubble detection in the tubing. Since pharmaceutical insulin is a clear colorless liquid, it is difficult to visually discriminate between insulin and air in tubing that carries insulin from the insulin pump to the cannula. By providing a color tint to the insulin it would be much easier to visually identify air bubbles in the tubing and be able to remove them before they cause problems. An insulin tint in one embodiment is biocompatible and insulin compatible.
- In certain embodiments, the various components of the integrated system, for example, of the infusion device and analyte monitoring system 100 (
FIG. 1 ) may need periodic replacement, where the components may require replacement at different times during the usage of the integrated system. For example, the infusion device cannula may require replacement after about each 3-days of usage, while the analyte sensor for use in the analyte monitoring system may not require replacement until at least about five or seven days of usage. Accordingly, in one embodiment, the components of the integrated system may be provided as replaceable modular components such that one or more components may be replaced at different times during the usage of the integrated system without substantially impacting the remaining portion of the integrated system. - More particularly,
FIGS. 14A-14C illustrate modular combination of medication delivery and physiological condition monitoring system in accordance with one embodiment. Referring toFIGS. 14A-14C , an on-bodypatch pump housing 1401 may be provided on the skin surface 1404 of the patient, such that thecannula 1402 is positioned transcutaneously through the patient's skin surface 1404 into the patient's body. Further shown is a connection port 1403 provided on thehousing 1401 of the patch pump. As discussed in further detail below, the connection port 1403 in one embodiment may be configured to couple to an end cap 1405 (FIG. 14B ) if the patch pump is used as a pump alone, or alternatively may be configured to couple to an analytesensor connector portion 1406 when used as an integrated system with an analyte monitoring system. - Referring to the Figures, as can be seen, the analyte sensor may include a
connector portion 1406 which is configured to couple to the connection port 1403 of the patch pump housing to establish a substantially water tight seal, an anchor portion 1407 which is configured to securely position the analyte sensor on the skin surface 1404 of the patient, and thetip portion 1408 which is trancutaneously positioned through the skin surface 1404 of the patient so as to be in fluid contact with the patient's analyte. - In this manner, in one embodiment, the analyte sensor may be provided as a modular component which may be used in conjunction with the patch pump as an integrated system. Alternatively, as discussed above, the patient may select to use the patch pump alone without the continuous monitoring aspect of the integrated system. In this case, the modular system described herein may be easily used as a stand alone pump, where the end cap may be configured to provide a substantially water tight seal to the
housing 1401 of the patch pump. - Alternatively, the patch pump may be used in conjunction with the analyte monitoring system wherein the
patch pump housing 1401 may be configured to couple to thesensor connector portion 1406, establishing electrical contact between the sensor electrodes to the respective internal electronic components within thepatch pump housing 1401. In this case, the electronic components associated with the analyte monitoring system, including the transmitter unit, processing unit and other components of analyte monitoring system may be provided substantially within the housing of thepatch pump 1401. - In this manner, in certain aspects of the present disclosure, the integrated system may be used as a stand along infusion device, the patch pump and the analyte sensor may be replaced or changed independent of each other, and without substantially increasing the profile or the on-body size of the overall system, the sensor may be inserted or positioned in the patient independent of the patch pump, and also removed independent of the
pump housing 1401. -
FIGS. 15A-15C illustrates modular combination of medication delivery and physiological condition monitoring system in accordance with another embodiment. Referring to the Figures, similar to the embodiment shown inFIGS. 14A-14C , the integrated system is provided with a patch pump housing 1501 which is configured for positioning on the skin surface 1504 of the patient, and which is operatively coupled to a transcutaneously positioned cannula 1502 for medication delivery to the patient. - In the embodiment shown in
FIGS. 15A-15C , the connection port 1503 of the patch pump is provided substantially on the top surface of the pump housing 1501, such that, when desired, the analytesensor connector portion 1506 may be coupled to the patch pump via the connection port 1503 from the top surface of the patch pump. Alternatively, as shown inFIG. 15B , in one aspect, a cap or a plug 1505 may be provided to seal (for example, water tight seal) the connection port 1503 when the patch pump housing 1501 is not connected to an analyte sensor, and thus for use as a stand alone infusion device. In one aspect, the cap or plug 1505 may include any suitable configuration, preferably to include a low profile physical dimension so as to maintain the low profile configuration of the on-body patch pump housing 1501. - As before, in particular embodiments, the connection port 1503 is configured to establish electrical connect with the various electrodes of the analyte sensor while providing a water tight seal at the connection. Referring again to the Figures, the analyte sensor includes an anchor potion 1507 configured to securely position the sensor on the skin surface 1504 of the patient, and a
tip portion 1508 which is configured for transcutaneous placement for fluid contact with the patient's analyte. - While the embodiments described above include connection port of the patch pump housing provided on an end surface or a top surface of the pump housing, within the scope of the present disclosure, the connection port of the patch pump may be provided on any location of the patch pump housing. For example, within the scope of the present disclosure, the connection port providing a water tight seal when connected with an end cap (to establish closure), or with an analyte sensor (to use the patch pump in an integrated system with analyte monitoring), may be provided on the bottom, side, or any other surface of the patch pump housing.
-
FIG. 16 illustrates a top planar view of a modular sensor component in accordance with one embodiment. More particularly,FIG. 16 illustrates the analyte sensor ofFIGS. 14A-14C or 15A-15C in one embodiment. As shown, theconnector portion 1506 of the analyte sensor is provided substantially on one end of the analyte sensor, while the sensing portion 1508 (for transcutaneous placement) of the analyte sensor is provided substantially on the other end of the sensor. Also shown inFIG. 16 is the anchor portion 1507 which in one embodiment is configured with a relatively larger width compared to other portions of the sensor. - In this manner, the anchor portion 1507 may be configured to substantially securely retain the analyte sensor on the skin surface of patient. Furthermore, one or more of the patch pump housing and the analyte sensor may be provided with an adhesive layer on the bottom surface to secure positioning on the patient's skin surface during usage. In a further aspect, the analyte sensor may comprise a flex circuit so as to provide a low profile when worn on the body of the patient.
-
FIG. 17 illustrates modular combination of medication delivery and physiological condition monitoring system in accordance with yet another embodiment. Referring toFIG. 17 , thepatch pump 1701 is provided with a connection port 1703 and positioned on the patient's skirt surface 1704 so as to securely retain the transcutaneously positioned cannula 1702 at the desired depth under the skin layer of the patient. Also shown in the Figure is a connection device 1706 which in one embodiment is provided with apump connector 1705 and a sensor connector 1707. More specifically, in one embodiment, a separate modular component is provided and secured on the skin surface 1704 of the patient, and may be configured to connect to both thepatch pump 1701 as well as the analyte sensor. Moreover, within the scope of the present disclosure, the connection device 1706 may be configured to further couple to other components or devices as may be desired. - Referring back to
FIG. 17 , in one aspect, the connection device 1706 is configured to establish electrical connection between the sensor and the patch pump such that the detected analyte levels from thetip portion 1710 of the analyte sensor is received by the suitable electronic control circuitry within thepatch pump housing 1701. In an alternate embodiment, the analyte monitoring associated electronic components such as data processing units, transmitter units, and the like, may be provided within the connection device 1706. In this case, thepatch pump housing 1701 may be further optimized in size. - Referring yet again to
FIG. 17 , the connection device 1706 is configured in one embodiment to include thepump connector 1705 which, in one embodiment is configured to couple to the connection port 1703 of the pump to establish electrical contact and a substantially water tight seal. Furthermore the connection device 1706 may be further configured to include a sensor connector portion 1707 which is configured to receive or connect to theconnector portion 1708 of the sensor so as to establish electrical contact with the various electrodes of the sensor. That is, in one embodiment, the connector portion 1707 of the connection device 1706 may be configured to couple to thesensor connector portion 1708. Accordingly, when thesensor tip 1710 is inserted through the skin surface 1704 of the patient and in fluid contact with the patient's analytes, and retained securely in place by the adhesive tab potion 1709, thesensor connection portion 1708 is configured in one embodiment to establish electrical contact with the connection device 1706 to transfer or otherwise relay the signal level information associated with the detected analyte levels of the patient for further processing. - In this manner, in one aspect of the present disclosure, there are provided modular components or devices which comprise an integrated medication delivery and analyte monitoring system, where each component may be independently replace, removed, or used on its own, and further, where the modular components may be used together as an integrated system for medication delivery and analyte monitoring.
- Accordingly, a modular system for providing integrated medication delivery and physiological condition monitoring in one aspect includes a first modular component configured for medication delivery, and a second modular component configured to analyte level detection, where the second modular component is connectable to the first modular component to establish electrical contact with the first modular component, where a substantially water tight seal is formed when the first and second modular component are connected, and further where one of the first modular component and the second modular component is configured for replacement independent of the other component, and a third modular component connectable to the first modular component when the first modular component is disconnected with the second modular component.
- In one aspect, the first modular component may include a connection port for coupling to either one of the second modular component or the third modular component.
- The first modular component may include a low profile infusion device.
- The second modular component may include an analyte sensor.
- Further, in one aspect, a water tight seal may be formed when the first and third modular components are connected.
- The first modular component in still another aspect may be configured to deliver medication to a patient at a first location in the patient, and further, wherein the second modular component is configured to detect analyte level of the patient at a second location in the patient, where the first and second locations may be separated by a predetermined distance, for example, approximately 12 inches.
- The first modular component in another aspect may include a reusable portion and a disposable portion, where either of the second or third modular components is connectable to the reusable portion of the first modular component.
- The disposable portion of the first modular component may include one or more of an infusion set, or a reservoir containing the medication for delivery.
- The reusable portion of the first modular component may include a processing unit to control the operation of one or more of the first modular component or the second modular component.
- In yet still another aspect, the system may include a communication unit disposed in one or more of the first modular component or the second modular component, the communication unit configured to transmit to or receive data from a remote location.
- The remote location may include one or more of a portable control unit, a computer terminal, a server terminal, a mobile telephone, or a personal digital assistant.
- The communication unit may be configured to transmit one or more signals corresponding to a respective one or more analyte levels to the remote location.
- In another aspect, the communication unit may be configured to receive a flow instruction command to control delivery of the medication.
- Further, in still another aspect, the communication unit may be configured to wirelessly communicate over one or more of an Rf communication link, a Bluetooth communication link, or an infrared communication link.
- The second modular component in a further aspect may include an inner wall and an outer wall, a plurality of electrodes disposed between the inner wall and the outer wall, and a fluid delivery channel formed by the inner wall, where the plurality of electrodes may include an analyte sensor.
- A method in accordance with another embodiment may include providing a first modular component for medication delivery, providing a second modular component configured to analyte level detection, the second modular component connectable to the first modular component to establish electrical contact with the first modular component, forming a substantially water tight seal when the first and second modular components are connected, and providing a third modular component connectable to the first modular component when the first modular component is disconnected with the second modular component, where one of the first modular component and the second modular components are configured for replacement independent of the other component.
- In another aspect, the method may include delivering medication to a patient, and monitoring analyte level of the patient substantially concurrently to the medication delivery.
- A modular system for providing integrated medication delivery and physiological condition monitoring in accordance with still another aspect includes a replaceable first modular component configured to deliver medication, a replaceable second modular component configured to analyte level detection, where the second modular component is connectable to the first modular component to establish electrical contact with the first modular component, and a third modular component connectable to the first modular component when the first modular component is disconnected from the second modular component, where a substantially water tight seal is formed when the first and second modular components are connected or when the first and third modular components are connected.
- The one of the first modular component and the second modular components may be configured for replacement independent of the other component.
- The first modular component may include a connection port to couple to either one of the second modular component or the third modular component, and further, where the third modular component may include a cap configured to couple to the connection port of the first modular component.
- The cap may include an end cap or a plug.
- The analyte level monitored may include glucose level.
- The first modular component may include a low profile infusion device.
- The second modular component may include an analyte sensor.
- The first modular component may be configured to deliver medication to a patient at a first location in the patient, and further, where the second modular component may be configured to detect analyte level of the patient at a second location in the patient.
- In yet a further aspect, the first and second locations are separated by a predetermined distance.
- The first modular component may include a reusable portion and a disposable portion, where either of the second or third modular components are connectable to the reusable portion of the first modular component.
- The disposable portion of the first modular component may include one or more of an infusion set, or a reservoir containing the medication for delivery.
- The reusable portion of the first modular component may include a processing unit to control the operation of one of more of the first modular component or the second modular component.
- Also the system may include a communication unit disposed in one or more of the first modular component or the second modular component, the communication unit configured to transmit to or receive data from a remote location, an further, where the remote location may include one of more of a portable control unit, a computer terminal, a server terminal, a mobile telephone, or a personal digital assistant.
- The communication unit may be configured to transmit one or more signals corresponding to a respective one or more analyte levels to the remote location.
- Also, the communication unit may be configured to receive a flow instruction command to control delivery of the medication.
- The communication unit may be configured to wirelessly communicate over one or more of an RF communication link, a Bluetooth communication link, or an infrared communication link.
- In still yet another aspect, the second modular component may include an inner wall and an outer wall, a plurality of electrodes disposed between the inner wall and the outer wall, and a fluid delivery channel formed by the inner wall.
- The plurality of electrodes may comprise an analyte sensor.
- A method in accordance with another aspect includes positioning a replaceable first modular component on a skin surface of a user, connecting a replaceable second modular component to a predetermined location on the first modular component during a first time period, wherein a water tight seal is formed between the first modular component and the second modular component, and connecting a third modular component to the predetermined location first modular component during a second time period, where a water tight seal is formed between the first modular component and the second modular component, and further where the first time period and the second time period are nonoverlapping.
- The method may include delivering medication to the user, and monitoring analyte level of the user.
- A kit in still another aspect may include an infusion device configured to deliver medication, the infusion device including a port, an analyte monitoring device configured to monitor an analyte level of a user, the analyte monitoring device connectable to the port of the infusion device during a first predetermined time period, and a cap connectable to the port of the infusion device during a second predetermined time period, where the first and second predetermined time periods are nonoverlapping.
- The infusion device may include an on-body patch pump.
- The cap provides a water tight seal on the port when connected to the infusion device.
- The analyte monitoring device provides a water tight seal on the port when connected to the infusion device.
- In still yet a further aspect, a system including an infusion device and an analyte monitoring unit includes an infusion device, an on-body unit including a data transmission section, the on-body unit further coupled to the infusion device, the on-body unit configured to receive one or more signals corresponding to a respective one or more analyte levels, and further, the on-body unit configured to infuse a fluid received from the infusion device, and a receiver unit operatively coupled to the on-body unit the receiver unit configured to receive data from the on-body unit, wherein the received data is associated with the analyte level.
- The system may further include an analyte sensor at least a first portion of which is in fluid contact with an analyte of a patient, and further, where at a second portion of the analyte sensor is in signal communication with the data transmission section.
- The data transmission section may in one embodiment be configured to transmit the one or more signals corresponding to a respective one or more analyte levels substantially periodically at one or more predetermined time intervals, where the one of more predetermined time intervals may include one or more of approximately 30 seconds, approximately one minute, or approximately 90 seconds.
- In one aspect, the on-body unit may include a cannula at least a portion of which is subcutaneously positioned under a skin layer, and further, may also include an infusion tubing connected to the infusion device to deliver the fluid to the on-body unit. The infusion tubing and the on-body unit in a further aspect may be connected in a substantially water tight seal.
- In yet another embodiment, the infusion tubing may be configured to operatively couple to the cannula to deliver the fluid.
- The on-body unit may be configured to wirelessly transmit the one or more signals corresponding to the respective one or more analyte levels to the receiver unit, where the on-body unit and the receiver may be configured to wirelessly communicate over one or more of an RF communication link, a Bluetooth communication link, or an infrared communication link.
- In addition, the infusion device in a further embodiment may be configured to control the delivery rate of the fluid based on the one or more signals corresponding to the respective one or more analyte levels received by the receiver unit, and further, where the infusion device may be configured to determine a modified deliver protocol for delivering fluid such as insulin based on information associated with the one or more signals corresponding to the respective one or more analyte levels.
- In yet another aspect, the modified delivery protocol may include one or more of a correction bolus, a modified basal profile, a carbohydrate bolus, and extended bolus, or combinations thereof.
- The receiver unit in one embodiment may be configured to wirelessly communicate with the infusion device.
- In a further embodiment, the receiver unit may be integrated into a housing of the infusion device.
- A method of integrating analyte monitoring and fluid infusion in another embodiment of the present disclosure includes infusing a fluid at a predetermined delivery rate, detecting one or more unable levels, transmitting one or more signals associated with the respective detected one or more analyte levels, and determining a modified delivery rate based on the transmitted one or more signals.
- In one aspect, the one or more signals may be transmitted substantially immediately after the associated respective one or more analyte levels are detected.
- Moreover, the transmitting step in one embodiment may include wirelessly transmitting the one or more signals which wirelessly transmitted over one or more of an RF communication link, a Bluetooth communication link, an infrared communication link, or combinations thereof.
- The method in a further aspect may also include the steps of receiving the transmitted one or more signals, and displaying the received one or more signals.
- Moreover, the method may also include the step of displaying the modified delivery rate. In addition, the method may also include the step of implementing the modified delivery rate, where the predetermined delivery rate may include one or more basal delivery rates.
- The modified delivery rate in a further embodiment may include one or more of a correction bolus, a modified basal profile, a carbohydrate bolus, an extended bolus, or combinations thereof.
- An apparatus including an analyte sensor and a fluid delivery channel in yet another embodiment of the present disclosure includes a fluid delivery unit having an inner wall and an outer wall, and a plurality of electrodes disposed between the inner wall and the outer wall of the fluid delivery unit, where a portion of the fluid delivery unit and a portion of the plurality of electrodes are subcutaneously positioned under a skin layer.
- In nee aspect, the plurality of electrodes may comprise an analyte sensor, including, for example, one or more of a working electrode, a counter electrode, a reference electrode, or combinations thereof.
- The fluid delivery unit may include a channel for delivering a fluid such as insulin, the channel substantially formed by the inner wall.
- An apparatus including an analyte sensor and a fluid delivery channel in accordance with still another embodiment of the present disclosure includes a first tubing having a first tubing channel, and a second tubing having a second tubing channel including a plurality of electrodes disposed within the second tubing channel, where at least a portion of the first tubing and at least a portion of the second tubing are subcutaneously positioned under a skin layer.
- In one embodiment, the plurality of the electrodes may be substantially and entirely insulated from each other.
- In another embodiment the first tubing and the second tubing may be integrally formal such that an outer surface of the first tubing is substantially in contact with an outer surface of the second tubing.
- A system including an infusion device and an analyte monitoring unit in accordance with still another embodiment of the present disclosure includes an infusion and monitoring device, an on-body unit including a data transmission section, the on-body unit further coupled to the infusion and monitoring device, the on-body unit configured to receive one or more signals corresponding to a respective one or more analyte levels, and further, the on-body unit configured to infuse a fluid received from the infusion and monitoring device, and a connector coupled at a first end to the infusion device, and further, coupled at a second end to the on-body unit, the connector configured to channel the fluid from the infusion device to the on-body unit, and further, configured to provide the one or more signals corresponding to the respective one or more analyte levels to the infusion and monitoring device.
- In one aspect, the infusion and monitoring device may be configured to execute fluid delivery to a patient, and further, to detect analyte levels of the patient over a predetermined time period.
- In a further aspect, the infusion and monitoring device may include a contnuous glucose monitoring system.
- In still another aspect, the infusion and monitoring device may include an insulin pump.
- A method of fluid delivery and analyte monitoring in accordance with still another embodiment of the present disclosure includes determining a delivery profile for fluid infusion, wherein the delivery profile including a plurality of predetermined discrete fluid infusion each temporally separated by a predetermined time period, and sampling an analyte level substantially immediately prior to each predetermined discrete fluid infusion.
- The method may further include the step of sampling an analyte level substantially immediately after each predetermined discrete fluid infusion.
- All references cited above herein, in addition to the background and summary sections, are hereby incorporated by reference into the detailed description of the preferred embodiments as disclosing alternative embodiments and components.
- Various other modifications and alternations in the structure and method of operation of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments.
Claims (8)
1. A method, comprising:
positioning a replaceable first modular component on a skin surface of a user;
connecting a replaceable second modular component to a predetermined location on the first modular component during a first time period, wherein a water tight seal is formed between the first modular component and the second modular component;
connecting a third modular component to the predetermined location first modular component during a second time period, wherein a water tight seal is formed between the first modular component and the third modular component;
wherein the first time period and the second time period are nonoverlapping.
2. The method of claim 1 including:
delivering medication to the user; and
monitoring analyte level of the user.
3. The method of claim 1 wherein the analyte includes glucose.
4. A kit, comprising:
an infusion device configured to deliver medication, the infusion device including a port;
an analyte monitoring device configured to monitor an analyte level of a user, the analyte monitoring device connectable to the port of the infusion device during a first predetermined time period;
a cap connectable to the port of the infusion device during a second predetermined time period;
wherein the first and second predetermined time periods are overlapping.
5. The kit of claim 4 wherein the analyte includes glucose.
6. The kit of claim 4 wherein the infusion device includes an on-body patch pump.
7. The kit of claim 4 wherein the cap provides a water tight seal on the port when connected to the infusion device.
8. The kit of claim 4 wherein the analyte monitoring device provides a water tight seal on the port when connected to the infusion device.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/582,878 US20170296740A1 (en) | 2007-02-19 | 2017-05-01 | Modular combination of medication infusion and analyte monitoring |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89049707P | 2007-02-19 | 2007-02-19 | |
US12/032,593 US9636450B2 (en) | 2007-02-19 | 2008-02-15 | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US15/582,878 US20170296740A1 (en) | 2007-02-19 | 2017-05-01 | Modular combination of medication infusion and analyte monitoring |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/032,593 Continuation US9636450B2 (en) | 2004-12-29 | 2008-02-15 | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170296740A1 true US20170296740A1 (en) | 2017-10-19 |
Family
ID=39707320
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/032,593 Active 2030-02-15 US9636450B2 (en) | 2004-12-29 | 2008-02-15 | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US12/826,662 Abandoned US20100274112A1 (en) | 2007-02-19 | 2010-06-29 | Modular Combination Of Medication Infusion And Analyte Monitoring |
US15/582,878 Abandoned US20170296740A1 (en) | 2007-02-19 | 2017-05-01 | Modular combination of medication infusion and analyte monitoring |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/032,593 Active 2030-02-15 US9636450B2 (en) | 2004-12-29 | 2008-02-15 | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US12/826,662 Abandoned US20100274112A1 (en) | 2007-02-19 | 2010-06-29 | Modular Combination Of Medication Infusion And Analyte Monitoring |
Country Status (7)
Country | Link |
---|---|
US (3) | US9636450B2 (en) |
EP (1) | EP2125096A4 (en) |
CN (2) | CN103055378A (en) |
BR (1) | BRPI0807515A2 (en) |
CA (1) | CA2678565A1 (en) |
RU (1) | RU2480251C2 (en) |
WO (1) | WO2008103620A2 (en) |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US6989891B2 (en) | 2001-11-08 | 2006-01-24 | Optiscan Biomedical Corporation | Device and method for in vitro determination of analyte concentrations within body fluids |
US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US7727181B2 (en) | 2002-10-09 | 2010-06-01 | Abbott Diabetes Care Inc. | Fluid delivery device with autocalibration |
US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
USD902408S1 (en) | 2003-11-05 | 2020-11-17 | Abbott Diabetes Care Inc. | Analyte sensor control unit |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US8774886B2 (en) | 2006-10-04 | 2014-07-08 | Dexcom, Inc. | Analyte sensor |
US8571624B2 (en) | 2004-12-29 | 2013-10-29 | Abbott Diabetes Care Inc. | Method and apparatus for mounting a data transmission device in a communication system |
US9259175B2 (en) | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
US20090105569A1 (en) | 2006-04-28 | 2009-04-23 | Abbott Diabetes Care, Inc. | Introducer Assembly and Methods of Use |
US8613703B2 (en) | 2007-05-31 | 2013-12-24 | Abbott Diabetes Care Inc. | Insertion devices and methods |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US9743862B2 (en) | 2011-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Systems and methods for transcutaneously implanting medical devices |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US9636450B2 (en) * | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US9351669B2 (en) | 2009-09-30 | 2016-05-31 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US20100331646A1 (en) * | 2009-06-30 | 2010-12-30 | Abbott Diabetes Care Inc. | Health Management Devices and Methods |
US8029441B2 (en) | 2006-02-28 | 2011-10-04 | Abbott Diabetes Care Inc. | Analyte sensor transmitter unit configuration for a data monitoring and management system |
US7731657B2 (en) | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US8333714B2 (en) | 2006-09-10 | 2012-12-18 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US8251907B2 (en) | 2005-02-14 | 2012-08-28 | Optiscan Biomedical Corporation | System and method for determining a treatment dose for a patient |
US7768408B2 (en) | 2005-05-17 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing data management in data monitoring system |
US20090227855A1 (en) | 2005-08-16 | 2009-09-10 | Medtronic Minimed, Inc. | Controller device for an infusion pump |
US7737581B2 (en) | 2005-08-16 | 2010-06-15 | Medtronic Minimed, Inc. | Method and apparatus for predicting end of battery life |
EP1762259B1 (en) * | 2005-09-12 | 2010-09-08 | Unomedical A/S | Inserter for an infusion set with a first and second spring units |
CA2636034A1 (en) | 2005-12-28 | 2007-10-25 | Abbott Diabetes Care Inc. | Medical device insertion |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US9211379B2 (en) | 2006-02-28 | 2015-12-15 | Unomedical A/S | Inserter for infusion part and infusion part provided with needle protector |
US7801582B2 (en) | 2006-03-31 | 2010-09-21 | Abbott Diabetes Care Inc. | Analyte monitoring and management system and methods therefor |
KR20090028701A (en) | 2006-06-09 | 2009-03-19 | 우노메디컬 에이/에스 | Mounting pad |
JP5241714B2 (en) | 2006-07-07 | 2013-07-17 | プロテウス デジタル ヘルス, インコーポレイテッド | Smart parenteral delivery system |
JP2009545341A (en) * | 2006-08-02 | 2009-12-24 | ウノメディカル アクティーゼルスカブ | Cannula and delivery device |
US8206296B2 (en) | 2006-08-07 | 2012-06-26 | Abbott Diabetes Care Inc. | Method and system for providing integrated analyte monitoring and infusion system therapy management |
WO2008114220A2 (en) * | 2007-03-19 | 2008-09-25 | Insuline Medical Ltd. | Device for drug delivery and associated connections thereto |
US9220837B2 (en) | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
CN104069567A (en) | 2007-03-19 | 2014-10-01 | 茵苏莱恩医药有限公司 | Drug delivery device |
WO2008114224A2 (en) * | 2007-03-19 | 2008-09-25 | Insuline Medical Ltd. | Method and device for substance measurement |
US8622991B2 (en) | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
EP1987761B1 (en) * | 2007-05-03 | 2019-10-23 | F. Hoffmann-La Roche AG | Tube-like sensor for proving an analyte |
US8597190B2 (en) | 2007-05-18 | 2013-12-03 | Optiscan Biomedical Corporation | Monitoring systems and methods with fast initialization |
US8088098B2 (en) * | 2007-06-25 | 2012-01-03 | Medingo, Ltd. | Tailored basal insulin delivery system and method |
US8641618B2 (en) | 2007-06-27 | 2014-02-04 | Abbott Diabetes Care Inc. | Method and structure for securing a monitoring device element |
US20120046533A1 (en) * | 2007-08-29 | 2012-02-23 | Medtronic Minimed, Inc. | Combined sensor and infusion sets |
US9656019B2 (en) | 2007-10-02 | 2017-05-23 | Medimop Medical Projects Ltd. | Apparatuses for securing components of a drug delivery system during transport and methods of using same |
US7967795B1 (en) | 2010-01-19 | 2011-06-28 | Lamodel Ltd. | Cartridge interface assembly with driving plunger |
WO2009044401A2 (en) | 2007-10-02 | 2009-04-09 | Yossi Gross | External drug pump |
US9345836B2 (en) | 2007-10-02 | 2016-05-24 | Medimop Medical Projects Ltd. | Disengagement resistant telescoping assembly and unidirectional method of assembly for such |
US10420880B2 (en) | 2007-10-02 | 2019-09-24 | West Pharma. Services IL, Ltd. | Key for securing components of a drug delivery system during assembly and/or transport and methods of using same |
EP2211974A4 (en) | 2007-10-25 | 2013-02-27 | Proteus Digital Health Inc | Fluid transfer port information system |
EP2231229A1 (en) | 2007-12-18 | 2010-09-29 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
CA2713485A1 (en) | 2008-02-13 | 2009-08-20 | Unomedical A/S | Sealing between a cannula part and a fluid path |
CA2715628A1 (en) | 2008-02-21 | 2009-08-27 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8924159B2 (en) * | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8876755B2 (en) | 2008-07-14 | 2014-11-04 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
US9393369B2 (en) | 2008-09-15 | 2016-07-19 | Medimop Medical Projects Ltd. | Stabilized pen injector |
EP2355758A2 (en) | 2008-11-07 | 2011-08-17 | Insuline Medical Ltd. | Device and method for drug delivery |
US9801575B2 (en) | 2011-04-15 | 2017-10-31 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
AU2009331635A1 (en) | 2008-12-22 | 2011-06-23 | Unomedical A/S | Medical device comprising adhesive pad |
US8152779B2 (en) | 2008-12-30 | 2012-04-10 | Medimop Medical Projects Ltd. | Needle assembly for drug pump |
US9375529B2 (en) * | 2009-09-02 | 2016-06-28 | Becton, Dickinson And Company | Extended use medical device |
US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
EP2229967B1 (en) | 2009-03-17 | 2020-04-15 | F.Hoffmann-La Roche Ag | Cannula assembly and ambulatory infusion system with a pressure sensor made of stacked coplanar layers |
US20100256466A1 (en) * | 2009-04-02 | 2010-10-07 | Avraham Shekalim | Metabolite Management System |
US8315885B2 (en) | 2009-04-14 | 2012-11-20 | Baxter International Inc. | Therapy management development platform |
US8467972B2 (en) | 2009-04-28 | 2013-06-18 | Abbott Diabetes Care Inc. | Closed loop blood glucose control algorithm analysis |
US8613892B2 (en) | 2009-06-30 | 2013-12-24 | Abbott Diabetes Care Inc. | Analyte meter with a moveable head and methods of using the same |
US8731639B2 (en) | 2009-07-20 | 2014-05-20 | Optiscan Biomedical Corporation | Adjustable connector, improved fluid flow and reduced clotting risk |
US8731638B2 (en) | 2009-07-20 | 2014-05-20 | Optiscan Biomedical Corporation | Adjustable connector and dead space reduction |
EP4289355A3 (en) | 2009-07-23 | 2024-02-28 | Abbott Diabetes Care Inc. | Continuous analyte measurement system |
JP2013500805A (en) | 2009-08-07 | 2013-01-10 | ウノメディカル・アー/エス | Dosing device having a sensor and one or more cannulas |
AU2010286917B2 (en) | 2009-08-31 | 2016-03-10 | Abbott Diabetes Care Inc. | Medical devices and methods |
US10071198B2 (en) | 2012-11-02 | 2018-09-11 | West Pharma. Servicees IL, Ltd. | Adhesive structure for medical device |
US8157769B2 (en) | 2009-09-15 | 2012-04-17 | Medimop Medical Projects Ltd. | Cartridge insertion assembly for drug delivery system |
US10071196B2 (en) | 2012-05-15 | 2018-09-11 | West Pharma. Services IL, Ltd. | Method for selectively powering a battery-operated drug-delivery device and device therefor |
US8348898B2 (en) | 2010-01-19 | 2013-01-08 | Medimop Medical Projects Ltd. | Automatic needle for drug pump |
RU2012136152A (en) * | 2010-01-22 | 2014-02-27 | Лайфскен, Инк. | METHOD AND SYSTEM OF ANALYTES TESTING |
HUE054269T2 (en) | 2010-01-28 | 2021-08-30 | Hoffmann La Roche | Modular infusion set with an integrated electrically powered functional component |
SG182825A1 (en) | 2010-02-01 | 2012-09-27 | Proteus Biomedical Inc | Data gathering system |
KR20120114368A (en) | 2010-02-01 | 2012-10-16 | 프로테우스 디지털 헬스, 인코포레이티드 | Two-wrist data gathering system |
USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
CA3096110C (en) | 2010-03-24 | 2023-11-14 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
EP2552513B1 (en) | 2010-03-30 | 2014-03-19 | Unomedical A/S | Medical device |
US9452261B2 (en) | 2010-05-10 | 2016-09-27 | Medimop Medical Projects Ltd. | Low volume accurate injector |
US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
EP2433663A1 (en) | 2010-09-27 | 2012-03-28 | Unomedical A/S | Insertion system |
EP2436412A1 (en) | 2010-10-04 | 2012-04-04 | Unomedical A/S | A sprinkler cannula |
US8919452B2 (en) | 2010-11-08 | 2014-12-30 | Baker Hughes Incorporated | Casing spears and related systems and methods |
WO2012134589A1 (en) | 2011-02-09 | 2012-10-04 | Becton, Dickinson And Company | Self-contained torsion spring inserter for drug delivery infusion set |
CN203898932U (en) | 2011-02-09 | 2014-10-29 | 贝克顿·迪金森公司 | Subcutaneous injection apparatus |
USD702834S1 (en) | 2011-03-22 | 2014-04-15 | Medimop Medical Projects Ltd. | Cartridge for use in injection device |
EP2763723B1 (en) | 2011-10-05 | 2016-04-13 | Unomedical A/S | Inserter for simultaneous insertion of multiple transcutaneous parts |
EP2583715A1 (en) | 2011-10-19 | 2013-04-24 | Unomedical A/S | Infusion tube system and method for manufacture |
US9440051B2 (en) | 2011-10-27 | 2016-09-13 | Unomedical A/S | Inserter for a multiplicity of subcutaneous parts |
FI3831283T3 (en) | 2011-12-11 | 2023-06-01 | Abbott Diabetes Care Inc | Analyte sensor devices, connections, and methods |
CN104245014B (en) | 2012-01-31 | 2017-05-24 | 麦迪麦珀医疗项目有限公司 | Time dependent drug delivery apparatus |
AT512504B1 (en) * | 2012-03-22 | 2013-09-15 | Seibersdorf Labor Gmbh | Apparatus and method for determining the capacity |
US9072827B2 (en) | 2012-03-26 | 2015-07-07 | Medimop Medical Projects Ltd. | Fail safe point protector for needle safety flap |
US10668213B2 (en) | 2012-03-26 | 2020-06-02 | West Pharma. Services IL, Ltd. | Motion activated mechanisms for a drug delivery device |
US9463280B2 (en) | 2012-03-26 | 2016-10-11 | Medimop Medical Projects Ltd. | Motion activated septum puncturing drug delivery device |
US9421323B2 (en) | 2013-01-03 | 2016-08-23 | Medimop Medical Projects Ltd. | Door and doorstop for portable one use drug delivery apparatus |
US9011164B2 (en) | 2013-04-30 | 2015-04-21 | Medimop Medical Projects Ltd. | Clip contact for easy installation of printed circuit board PCB |
US9889256B2 (en) | 2013-05-03 | 2018-02-13 | Medimop Medical Projects Ltd. | Sensing a status of an infuser based on sensing motor control and power input |
US9442089B2 (en) | 2013-12-23 | 2016-09-13 | Lifescan Scotland Limited | Analyte meter test strip detection |
WO2015102745A1 (en) | 2013-12-31 | 2015-07-09 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
US10850028B2 (en) * | 2014-09-15 | 2020-12-01 | Sanofi | Triggering injection status information display on a mobile device via tapping the housing of a skin-attachable drug injection device |
US10251813B2 (en) | 2015-03-04 | 2019-04-09 | West Pharma. Services IL, Ltd. | Flexibly mounted cartridge alignment collar for drug delivery device |
US9795534B2 (en) | 2015-03-04 | 2017-10-24 | Medimop Medical Projects Ltd. | Compliant coupling assembly for cartridge coupling of a drug delivery device |
US10293120B2 (en) | 2015-04-10 | 2019-05-21 | West Pharma. Services IL, Ltd. | Redundant injection device status indication |
US9744297B2 (en) | 2015-04-10 | 2017-08-29 | Medimop Medical Projects Ltd. | Needle cannula position as an input to operational control of an injection device |
AU2016260547B2 (en) | 2015-05-14 | 2020-09-03 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
US10213139B2 (en) | 2015-05-14 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for assembling an applicator and sensor control device |
US10149943B2 (en) | 2015-05-29 | 2018-12-11 | West Pharma. Services IL, Ltd. | Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly |
PL3101571T3 (en) * | 2015-06-03 | 2018-09-28 | F. Hoffmann-La Roche Ag | Measurement system for measuring the concentration of an analyte with a subcutaneous analyte sensor |
US11207465B2 (en) | 2015-06-04 | 2021-12-28 | West Pharma. Services Il. Ltd. | Cartridge insertion for drug delivery device |
US10576207B2 (en) | 2015-10-09 | 2020-03-03 | West Pharma. Services IL, Ltd. | Angled syringe patch injector |
US9987432B2 (en) | 2015-09-22 | 2018-06-05 | West Pharma. Services IL, Ltd. | Rotation resistant friction adapter for plunger driver of drug delivery device |
JP7017512B2 (en) | 2015-10-09 | 2022-02-08 | ウェスト ファーマ サービシーズ イスラエル リミテッド | Bending fluid path type accessories for filled fluid containers |
JP6720465B2 (en) * | 2016-01-14 | 2020-07-08 | オプテックス株式会社 | Portable information terminal, control method for portable information terminal, and control program |
CN113041432B (en) | 2016-01-21 | 2023-04-07 | 西医药服务以色列有限公司 | Medicament delivery device comprising a visual indicator |
EP3711793B1 (en) | 2016-01-21 | 2021-12-01 | West Pharma Services IL, Ltd. | A method of connecting a cartridge to an automatic injector |
JP6542481B2 (en) | 2016-01-21 | 2019-07-10 | ウェスト ファーマ サービシーズ イスラエル リミテッド | system |
US11389597B2 (en) | 2016-03-16 | 2022-07-19 | West Pharma. Services IL, Ltd. | Staged telescopic screw assembly having different visual indicators |
CN115177241A (en) * | 2016-05-02 | 2022-10-14 | 德克斯康公司 | System and method for providing alerts optimized for a user |
EP3463526A1 (en) | 2016-06-02 | 2019-04-10 | West Pharma. Services Il, Ltd. | Three position needle retraction |
JP7059251B2 (en) | 2016-08-01 | 2022-04-25 | ウェスト ファーマ サービシーズ イスラエル リミテッド | A spring that prevents the door from closing halfway |
JP6869327B2 (en) | 2016-08-01 | 2021-05-12 | ウェスト ファーマ サービシーズ イスラエル リミテッド | Anti-rotation cartridge |
US11071478B2 (en) | 2017-01-23 | 2021-07-27 | Abbott Diabetes Care Inc. | Systems, devices and methods for analyte sensor insertion |
CN110545862B (en) * | 2017-04-20 | 2022-04-15 | 贝克顿·迪金森公司 | Insulin leak sensor with electronic control to stop insulin flow |
CN110869072B (en) | 2017-05-30 | 2021-12-10 | 西部制药服务有限公司(以色列) | Modular drive mechanism for a wearable injector |
CN114470420A (en) | 2017-12-22 | 2022-05-13 | 西氏医药包装(以色列)有限公司 | Syringe adapted for cartridges of different sizes |
USD1002852S1 (en) | 2019-06-06 | 2023-10-24 | Abbott Diabetes Care Inc. | Analyte sensor device |
US11844925B2 (en) | 2019-06-06 | 2023-12-19 | Medtronic Minimed, Inc. | Fluid infusion systems |
US20220211941A1 (en) * | 2019-07-19 | 2022-07-07 | Medtrum Technologies Inc. | Integrated drug infusion device |
USD999913S1 (en) | 2020-12-21 | 2023-09-26 | Abbott Diabetes Care Inc | Analyte sensor inserter |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800420A (en) * | 1994-11-04 | 1998-09-01 | Elan Medical Technologies Limited | Analyte-controlled liquid delivery device and analyte monitor |
US5858001A (en) * | 1995-12-11 | 1999-01-12 | Elan Medical Technologies Limited | Cartridge-based drug delivery device |
US6068613A (en) * | 1989-06-16 | 2000-05-30 | Kriesel; Marshall S. | Fluid delivery device |
US6186982B1 (en) * | 1998-05-05 | 2001-02-13 | Elan Corporation, Plc | Subcutaneous drug delivery device with improved filling system |
US20020040208A1 (en) * | 2000-10-04 | 2002-04-04 | Flaherty J. Christopher | Data collection assembly for patient infusion system |
US20020072733A1 (en) * | 2000-09-08 | 2002-06-13 | Flaherty J. Christopher | Devices, systems and methods for patient infusion |
US20020123740A1 (en) * | 2000-11-09 | 2002-09-05 | Flaherty J. Christopher | Transcutaneous delivery means |
US20020169439A1 (en) * | 2001-02-22 | 2002-11-14 | Flaherty J. Christopher | Modular infusion device and method |
US20030055380A1 (en) * | 2001-09-19 | 2003-03-20 | Flaherty J. Christopher | Plunger for patient infusion device |
US6589229B1 (en) * | 2000-07-31 | 2003-07-08 | Becton, Dickinson And Company | Wearable, self-contained drug infusion device |
US20040015131A1 (en) * | 2002-07-16 | 2004-01-22 | Flaherty J. Christopher | Flow restriction system and method for patient infusion device |
US20050148865A1 (en) * | 2001-11-09 | 2005-07-07 | Scimed Life Systems, Inc. | Ceramic reinforcement member for MRI devices |
US20060253086A1 (en) * | 2005-05-06 | 2006-11-09 | Medtronic Minimed, Inc. | Medical needles for damping motion |
US20060253085A1 (en) * | 2005-05-06 | 2006-11-09 | Medtronic Minimed, Inc. | Dual insertion set |
Family Cites Families (635)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1191363A (en) | 1968-02-19 | 1970-05-13 | Pavelle Ltd | Improvements in or relating to Electronic Thermostats. |
US3949388A (en) | 1972-11-13 | 1976-04-06 | Monitron Industries, Inc. | Physiological sensor and transmitter |
US3926760A (en) | 1973-09-28 | 1975-12-16 | Du Pont | Process for electrophoretic deposition of polymer |
US4245634A (en) | 1975-01-22 | 1981-01-20 | Hospital For Sick Children | Artificial beta cell |
US4036749A (en) | 1975-04-30 | 1977-07-19 | Anderson Donald R | Purification of saline water |
US4055175A (en) | 1976-05-07 | 1977-10-25 | Miles Laboratories, Inc. | Blood glucose control apparatus |
US4129128A (en) | 1977-02-23 | 1978-12-12 | Mcfarlane Richard H | Securing device for catheter placement assembly |
US4344438A (en) | 1978-08-02 | 1982-08-17 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Optical sensor of plasma constituents |
AU530979B2 (en) | 1978-12-07 | 1983-08-04 | Aus. Training Aids Pty. Ltd., | Detecting position of bullet fired at target |
CS210174B1 (en) | 1979-07-12 | 1982-01-29 | Ivan Emmer | Method of making the electric hygrometric sensor |
US4425920A (en) | 1980-10-24 | 1984-01-17 | Purdue Research Foundation | Apparatus and method for measurement and control of blood pressure |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
DE3138194A1 (en) | 1981-09-25 | 1983-04-14 | Basf Ag, 6700 Ludwigshafen | WATER-INSOLUBLE POROESES PROTEIN MATERIAL, THEIR PRODUCTION AND USE |
DE3278334D1 (en) | 1981-10-23 | 1988-05-19 | Genetics Int Inc | Sensor for components of a liquid mixture |
US4494950A (en) | 1982-01-19 | 1985-01-22 | The Johns Hopkins University | Plural module medication delivery system |
FI831399L (en) | 1982-04-29 | 1983-10-30 | Agripat Sa | KONTAKTLINS AV HAERDAD POLYVINYL ALCOHOL |
EP0098592A3 (en) | 1982-07-06 | 1985-08-21 | Fujisawa Pharmaceutical Co., Ltd. | Portable artificial pancreas |
US4509531A (en) | 1982-07-28 | 1985-04-09 | Teledyne Industries, Inc. | Personal physiological monitor |
US4464170A (en) | 1982-09-29 | 1984-08-07 | Miles Laboratories, Inc. | Blood glucose control apparatus and method |
US4527240A (en) | 1982-12-29 | 1985-07-02 | Kvitash Vadim I | Balascopy method for detecting and rapidly evaluating multiple imbalances within multi-parametric systems |
US5682884A (en) | 1983-05-05 | 1997-11-04 | Medisense, Inc. | Strip electrode with screen printing |
US5509410A (en) | 1983-06-06 | 1996-04-23 | Medisense, Inc. | Strip electrode including screen printing of a single layer |
CA1226036A (en) | 1983-05-05 | 1987-08-25 | Irving J. Higgins | Analytical equipment and sensor electrodes therefor |
CA1219040A (en) | 1983-05-05 | 1987-03-10 | Elliot V. Plotkin | Measurement of enzyme-catalysed reactions |
US4538616A (en) | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
DE3429596A1 (en) | 1984-08-10 | 1986-02-20 | Siemens AG, 1000 Berlin und 8000 München | DEVICE FOR THE PHYSIOLOGICAL FREQUENCY CONTROL OF A PACEMAKER PROVIDED WITH A PICTURE ELECTRODE |
US4847785A (en) | 1985-01-22 | 1989-07-11 | International Business Machines Corp. | Interactive display for trend or bar graph |
US5279294A (en) | 1985-04-08 | 1994-01-18 | Cascade Medical, Inc. | Medical diagnostic system |
US4671288A (en) | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4890620A (en) | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
US4757022A (en) | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4703756A (en) | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
US4731726A (en) | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
US5055171A (en) | 1986-10-06 | 1991-10-08 | T And G Corporation | Ionic semiconductor materials and applications thereof |
US5002054A (en) | 1987-02-25 | 1991-03-26 | Ash Medical Systems, Inc. | Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body |
US4854322A (en) | 1987-02-25 | 1989-08-08 | Ash Medical Systems, Inc. | Capillary filtration and collection device for long-term monitoring of blood constituents |
US4777953A (en) | 1987-02-25 | 1988-10-18 | Ash Medical Systems, Inc. | Capillary filtration and collection method for long-term monitoring of blood constituents |
US4759828A (en) | 1987-04-09 | 1988-07-26 | Nova Biomedical Corporation | Glucose electrode and method of determining glucose |
US4749985A (en) | 1987-04-13 | 1988-06-07 | United States Of America As Represented By The United States Department Of Energy | Functional relationship-based alarm processing |
EP0290683A3 (en) | 1987-05-01 | 1988-12-14 | Diva Medical Systems B.V. | Diabetes management system and apparatus |
GB8725936D0 (en) | 1987-11-05 | 1987-12-09 | Genetics Int Inc | Sensing system |
US4925268A (en) | 1988-07-25 | 1990-05-15 | Abbott Laboratories | Fiber-optic physiological probes |
EP0353328A1 (en) | 1988-08-03 | 1990-02-07 | Dräger Nederland B.V. | A polarographic-amperometric three-electrode sensor |
US5340722A (en) | 1988-08-24 | 1994-08-23 | Avl Medical Instruments Ag | Method for the determination of the concentration of an enzyme substrate and a sensor for carrying out the method |
US4995402A (en) | 1988-10-12 | 1991-02-26 | Thorne, Smith, Astill Technologies, Inc. | Medical droplet whole blood and like monitoring |
US5360404A (en) | 1988-12-14 | 1994-11-01 | Inviro Medical Devices Ltd. | Needle guard and needle assembly for syringe |
US5077476A (en) | 1990-06-27 | 1991-12-31 | Futrex, Inc. | Instrument for non-invasive measurement of blood glucose |
US5068536A (en) | 1989-01-19 | 1991-11-26 | Futrex, Inc. | Method for providing custom calibration for near infrared instruments for measurement of blood glucose |
AT393213B (en) * | 1989-02-08 | 1991-09-10 | Avl Verbrennungskraft Messtech | DEVICE FOR DETERMINING AT LEAST ONE MEDICAL MEASURING SIZE |
EP0385805B1 (en) | 1989-03-03 | 1996-06-05 | Edward W. Stark | Signal processing method and apparatus |
JPH02298855A (en) | 1989-03-20 | 1990-12-11 | Assoc Univ Inc | Electrochemical biosensor using immobilized enzyme and redox polymer |
US4953552A (en) | 1989-04-21 | 1990-09-04 | Demarzo Arthur P | Blood glucose monitoring system |
EP0396788A1 (en) | 1989-05-08 | 1990-11-14 | Dräger Nederland B.V. | Process and sensor for measuring the glucose content of glucosecontaining fluids |
FR2648353B1 (en) | 1989-06-16 | 1992-03-27 | Europhor Sa | MICRODIALYSIS PROBE |
US5431160A (en) | 1989-07-19 | 1995-07-11 | University Of New Mexico | Miniature implantable refillable glucose sensor and material therefor |
US4986271A (en) | 1989-07-19 | 1991-01-22 | The University Of New Mexico | Vivo refillable glucose sensor |
US5264104A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5262035A (en) | 1989-08-02 | 1993-11-16 | E. Heller And Company | Enzyme electrodes |
US5264105A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5320725A (en) | 1989-08-02 | 1994-06-14 | E. Heller & Company | Electrode and method for the detection of hydrogen peroxide |
US5568400A (en) | 1989-09-01 | 1996-10-22 | Stark; Edward W. | Multiplicative signal correction method and apparatus |
US5050612A (en) | 1989-09-12 | 1991-09-24 | Matsumura Kenneth N | Device for computer-assisted monitoring of the body |
US5082550A (en) | 1989-12-11 | 1992-01-21 | The United States Of America As Represented By The Department Of Energy | Enzyme electrochemical sensor electrode and method of making it |
US5342789A (en) | 1989-12-14 | 1994-08-30 | Sensor Technologies, Inc. | Method and device for detecting and quantifying glucose in body fluids |
US5051688A (en) | 1989-12-20 | 1991-09-24 | Rohm Co., Ltd. | Crossed coil meter driving device having a plurality of input parameters |
US5165407A (en) | 1990-04-19 | 1992-11-24 | The University Of Kansas | Implantable glucose sensor |
GB2243211A (en) | 1990-04-20 | 1991-10-23 | Philips Electronic Associated | Analytical instrument and method of calibrating an analytical instrument |
US5202261A (en) | 1990-07-19 | 1993-04-13 | Miles Inc. | Conductive sensors and their use in diagnostic assays |
DE69102140T2 (en) | 1990-09-28 | 1994-09-08 | Pfizer | ACTIVE SUBSTANCE DELIVERY DEVICE CONTAINING A HYDROPHOBIC AGENT. |
US5251126A (en) | 1990-10-29 | 1993-10-05 | Miles Inc. | Diabetes data analysis and interpretation method |
US5293877A (en) | 1990-12-12 | 1994-03-15 | Sherwood Ims, Inc. | Body temperature thermometer and method fo measuring human body temperature utilizing calibration mapping |
US5228449A (en) | 1991-01-22 | 1993-07-20 | Athanasios G. Christ | System and method for detecting out-of-hospital cardiac emergencies and summoning emergency assistance |
US5262305A (en) | 1991-03-04 | 1993-11-16 | E. Heller & Company | Interferant eliminating biosensors |
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
JPH04278450A (en) | 1991-03-04 | 1992-10-05 | Adam Heller | Biosensor and method for analyzing subject |
US5469855A (en) | 1991-03-08 | 1995-11-28 | Exergen Corporation | Continuous temperature monitor |
US5135004A (en) | 1991-03-12 | 1992-08-04 | Incontrol, Inc. | Implantable myocardial ischemia monitor and related method |
US5122925A (en) | 1991-04-22 | 1992-06-16 | Control Products, Inc. | Package for electronic components |
US5231988A (en) | 1991-08-09 | 1993-08-03 | Cyberonics, Inc. | Treatment of endocrine disorders by nerve stimulation |
US5145381A (en) | 1991-08-22 | 1992-09-08 | Amp Incorporated | Wedge driven elastomeric connector |
GB9120144D0 (en) | 1991-09-20 | 1991-11-06 | Imperial College | A dialysis electrode device |
US5322063A (en) | 1991-10-04 | 1994-06-21 | Eli Lilly And Company | Hydrophilic polyurethane membranes for electrochemical glucose sensors |
US5372427A (en) | 1991-12-19 | 1994-12-13 | Texas Instruments Incorporated | Temperature sensor |
US5285792A (en) | 1992-01-10 | 1994-02-15 | Physio-Control Corporation | System for producing prioritized alarm messages in a medical instrument |
US5246867A (en) | 1992-01-17 | 1993-09-21 | University Of Maryland At Baltimore | Determination and quantification of saccharides by luminescence lifetimes and energy transfer |
US5328927A (en) | 1992-03-03 | 1994-07-12 | Merck Sharpe & Dohme, Ltd. | Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
US5711001A (en) | 1992-05-08 | 1998-01-20 | Motorola, Inc. | Method and circuit for acquisition by a radio receiver |
GB9211402D0 (en) | 1992-05-29 | 1992-07-15 | Univ Manchester | Sensor devices |
US5330634A (en) | 1992-08-28 | 1994-07-19 | Via Medical Corporation | Calibration solutions useful for analyses of biological fluids and methods employing same |
US6283761B1 (en) | 1992-09-08 | 2001-09-04 | Raymond Anthony Joao | Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information |
WO1994010553A1 (en) | 1992-10-23 | 1994-05-11 | Optex Biomedical, Inc. | Fibre-optic probe for the measurement of fluid parameters |
US5601435A (en) | 1994-11-04 | 1997-02-11 | Intercare | Method and apparatus for interactively monitoring a physiological condition and for interactively providing health related information |
US5918603A (en) | 1994-05-23 | 1999-07-06 | Health Hero Network, Inc. | Method for treating medical conditions using a microprocessor-based video game |
US5899855A (en) | 1992-11-17 | 1999-05-04 | Health Hero Network, Inc. | Modular microprocessor-based health monitoring system |
US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
US5284425A (en) | 1992-11-18 | 1994-02-08 | The Lee Company | Fluid metering pump |
ZA938555B (en) | 1992-11-23 | 1994-08-02 | Lilly Co Eli | Technique to improve the performance of electrochemical sensors |
CA2149913A1 (en) | 1992-11-24 | 1994-06-09 | James David Keeler | Method and apparatus for operating a neural network with missing and/or incomplete data |
US5410326A (en) | 1992-12-04 | 1995-04-25 | Goldstein; Steven W. | Programmable remote control device for interacting with a plurality of remotely controlled devices |
US5299571A (en) | 1993-01-22 | 1994-04-05 | Eli Lilly And Company | Apparatus and method for implantation of sensors |
GB9304306D0 (en) | 1993-03-03 | 1993-04-21 | Univ Alberta | Glucose sensor |
GB9308294D0 (en) | 1993-04-22 | 1993-06-09 | Gilbarco Ltd | Error detection apparatus for an electro-optic display |
DE59408870D1 (en) | 1993-04-23 | 1999-12-09 | Roche Diagnostics Gmbh | System for stocking and making available test elements |
US5384547A (en) | 1993-08-02 | 1995-01-24 | Motorola, Inc. | Apparatus and method for attenuating a multicarrier input signal of a linear device |
DE4329898A1 (en) | 1993-09-04 | 1995-04-06 | Marcus Dr Besson | Wireless medical diagnostic and monitoring device |
US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
US5997501A (en) | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
US5791344A (en) | 1993-11-19 | 1998-08-11 | Alfred E. Mann Foundation For Scientific Research | Patient monitoring system |
US5497772A (en) | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
US5320715A (en) | 1994-01-14 | 1994-06-14 | Lloyd Berg | Separation of 1-pentanol from cyclopentanol by extractive distillation |
DE4401400A1 (en) | 1994-01-19 | 1995-07-20 | Ernst Prof Dr Pfeiffer | Method and arrangement for continuously monitoring the concentration of a metabolite |
US5543326A (en) | 1994-03-04 | 1996-08-06 | Heller; Adam | Biosensor including chemically modified enzymes |
US5536249A (en) | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
US5390671A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
US5391250A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
US5609575A (en) | 1994-04-11 | 1997-03-11 | Graseby Medical Limited | Infusion pump and method with dose-rate calculation |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
DE4415896A1 (en) | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
US5472317A (en) | 1994-06-03 | 1995-12-05 | Minimed Inc. | Mounting clip for a medication infusion pump |
CA2159052C (en) | 1994-10-28 | 2007-03-06 | Rainer Alex | Injection device |
ES2112069T3 (en) | 1995-02-04 | 1998-03-16 | Baumann & Haldi Sa | INDIVIDUAL SYSTEM OF MEASUREMENT, TREATMENT AND TRANSMISSION OF ESSENTIALLY PHYSIOLOGICAL PARAMETERS. |
US5568806A (en) | 1995-02-16 | 1996-10-29 | Minimed Inc. | Transcutaneous sensor insertion set |
US5586553A (en) | 1995-02-16 | 1996-12-24 | Minimed Inc. | Transcutaneous sensor insertion set |
US5788833A (en) | 1995-03-27 | 1998-08-04 | California Institute Of Technology | Sensors for detecting analytes in fluids |
US5752512A (en) | 1995-05-10 | 1998-05-19 | Massachusetts Institute Of Technology | Apparatus and method for non-invasive blood analyte measurement |
US5628310A (en) | 1995-05-19 | 1997-05-13 | Joseph R. Lakowicz | Method and apparatus to perform trans-cutaneous analyte monitoring |
US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
US7016713B2 (en) | 1995-08-09 | 2006-03-21 | Inlight Solutions, Inc. | Non-invasive determination of direction and rate of change of an analyte |
IE77523B1 (en) * | 1995-09-11 | 1997-12-17 | Elan Med Tech | Medicament delivery device |
US5628890A (en) | 1995-09-27 | 1997-05-13 | Medisense, Inc. | Electrochemical sensor |
US5665222A (en) | 1995-10-11 | 1997-09-09 | E. Heller & Company | Soybean peroxidase electrochemical sensor |
US5972199A (en) | 1995-10-11 | 1999-10-26 | E. Heller & Company | Electrochemical analyte sensors using thermostable peroxidase |
US5711861A (en) | 1995-11-22 | 1998-01-27 | Ward; W. Kenneth | Device for monitoring changes in analyte concentration |
FI960636A (en) | 1996-02-12 | 1997-08-13 | Nokia Mobile Phones Ltd | A procedure for monitoring the health of a patient |
US6790178B1 (en) | 1999-09-24 | 2004-09-14 | Healthetech, Inc. | Physiological monitor and associated computation, display and communication unit |
US5833603A (en) | 1996-03-13 | 1998-11-10 | Lipomatrix, Inc. | Implantable biosensing transponder |
DE19618597B4 (en) | 1996-05-09 | 2005-07-21 | Institut für Diabetestechnologie Gemeinnützige Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm | Method for determining the concentration of tissue glucose |
US5735285A (en) | 1996-06-04 | 1998-04-07 | Data Critical Corp. | Method and hand-held apparatus for demodulating and viewing frequency modulated biomedical signals |
CA2253549C (en) | 1996-06-18 | 2005-10-25 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
JP3581218B2 (en) | 1996-07-03 | 2004-10-27 | 株式会社東芝 | Mobile communication terminal device and its mobile phone and data terminal device |
JP2000515778A (en) | 1996-07-08 | 2000-11-28 | アニマス コーポレーシヨン | Implantable sensors and systems for in vivo measurement and control of body fluid component levels |
US5738220A (en) * | 1996-09-30 | 1998-04-14 | Pacesetter, Inc. | Distal tip protector cap |
US6004278A (en) | 1996-12-05 | 1999-12-21 | Mdc Investment Holdings, Inc. | Fluid collection device with retractable needle |
US6071251A (en) | 1996-12-06 | 2000-06-06 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
US5964993A (en) | 1996-12-19 | 1999-10-12 | Implanted Biosystems Inc. | Glucose sensor |
US6122351A (en) | 1997-01-21 | 2000-09-19 | Med Graph, Inc. | Method and system aiding medical diagnosis and treatment |
US6607509B2 (en) | 1997-12-31 | 2003-08-19 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
US6093172A (en) | 1997-02-05 | 2000-07-25 | Minimed Inc. | Injector for a subcutaneous insertion set |
WO1998035225A1 (en) | 1997-02-06 | 1998-08-13 | E. Heller & Company | Small volume in vitro analyte sensor |
US5980708A (en) | 1997-02-12 | 1999-11-09 | Champagne; Gilles Y. | High sensitivity multiple waveform voltammetric instrument |
WO1998037805A1 (en) | 1997-02-26 | 1998-09-03 | Diasense, Inc. | Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose |
US6159147A (en) | 1997-02-28 | 2000-12-12 | Qrs Diagnostics, Llc | Personal computer card for collection of real-time biological data |
US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US6558321B1 (en) | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US6741877B1 (en) | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US6554795B2 (en) | 1997-03-06 | 2003-04-29 | Medtronic Ave, Inc. | Balloon catheter and method of manufacture |
US6699187B2 (en) | 1997-03-27 | 2004-03-02 | Medtronic, Inc. | System and method for providing remote expert communications and video capabilities for use during a medical procedure |
US6270455B1 (en) | 1997-03-28 | 2001-08-07 | Health Hero Network, Inc. | Networked system for interactive communications and remote monitoring of drug delivery |
US5961451A (en) | 1997-04-07 | 1999-10-05 | Motorola, Inc. | Noninvasive apparatus having a retaining member to retain a removable biosensor |
US5942979A (en) | 1997-04-07 | 1999-08-24 | Luppino; Richard | On guard vehicle safety warning system |
US5797940A (en) | 1997-05-30 | 1998-08-25 | International Technidyne Corporation | Adjustable skin incision device |
US5954643A (en) | 1997-06-09 | 1999-09-21 | Minimid Inc. | Insertion set for a transcutaneous sensor |
US7267665B2 (en) | 1999-06-03 | 2007-09-11 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
JP2002505008A (en) | 1997-06-16 | 2002-02-12 | エラン コーポレーション ピーエルシー | Methods for calibrating and testing sensors for in vivo measurement of analytes and devices for use in such methods |
US6056435A (en) | 1997-06-24 | 2000-05-02 | Exergen Corporation | Ambient and perfusion normalized temperature detector |
US6066243A (en) | 1997-07-22 | 2000-05-23 | Diametrics Medical, Inc. | Portable immediate response medical analyzer having multiple testing modules |
US6232950B1 (en) | 1997-08-28 | 2001-05-15 | E Ink Corporation | Rear electrode structures for displays |
US6764581B1 (en) | 1997-09-05 | 2004-07-20 | Abbott Laboratories | Electrode with thin working layer |
US6259937B1 (en) | 1997-09-12 | 2001-07-10 | Alfred E. Mann Foundation | Implantable substrate sensor |
US6071391A (en) | 1997-09-12 | 2000-06-06 | Nok Corporation | Enzyme electrode structure |
DE19836401A1 (en) | 1997-09-19 | 2000-02-17 | Salcomp Oy Salo | Device for charging accumulators |
US6117290A (en) | 1997-09-26 | 2000-09-12 | Pepex Biomedical, Llc | System and method for measuring a bioanalyte such as lactate |
US5904671A (en) | 1997-10-03 | 1999-05-18 | Navot; Nir | Tampon wetness detection system |
US6736957B1 (en) | 1997-10-16 | 2004-05-18 | Abbott Laboratories | Biosensor electrode mediators for regeneration of cofactors and process for using |
US6119028A (en) | 1997-10-20 | 2000-09-12 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces |
US6088608A (en) | 1997-10-20 | 2000-07-11 | Alfred E. Mann Foundation | Electrochemical sensor and integrity tests therefor |
US6081736A (en) | 1997-10-20 | 2000-06-27 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems adapted for long term use |
FI107080B (en) | 1997-10-27 | 2001-05-31 | Nokia Mobile Phones Ltd | measuring device |
WO1999023939A1 (en) | 1997-11-12 | 1999-05-20 | Lightouch Medical, Inc. | Method for non-invasive measurement of an analyte |
US6482176B1 (en) | 1997-11-27 | 2002-11-19 | Disetronic Licensing Ag | Method and device for controlling the introduction depth of an injection needle |
US6579690B1 (en) | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
US7494816B2 (en) | 1997-12-22 | 2009-02-24 | Roche Diagnostic Operations, Inc. | System and method for determining a temperature during analyte measurement |
CA2484271C (en) | 1997-12-31 | 2007-04-24 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
US6103033A (en) | 1998-03-04 | 2000-08-15 | Therasense, Inc. | Process for producing an electrochemical biosensor |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6024699A (en) | 1998-03-13 | 2000-02-15 | Healthware Corporation | Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients |
US6197181B1 (en) | 1998-03-20 | 2001-03-06 | Semitool, Inc. | Apparatus and method for electrolytically depositing a metal on a microelectronic workpiece |
JPH11296598A (en) | 1998-04-07 | 1999-10-29 | Seizaburo Arita | System and method for predicting blood-sugar level and record medium where same method is recorded |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
GB2337122B (en) | 1998-05-08 | 2002-11-13 | Medisense Inc | Test strip |
PT1077636E (en) | 1998-05-13 | 2004-06-30 | Cygnus Therapeutic Systems | SIGNAL PROCESSING FOR PHYSIOLOGICAL ANALYZES MEDICATION |
CA2332112C (en) | 1998-05-13 | 2004-02-10 | Cygnus, Inc. | Monitoring of physiological analytes |
US6121611A (en) | 1998-05-20 | 2000-09-19 | Molecular Imaging Corporation | Force sensing probe for scanning probe microscopy |
US6493069B1 (en) | 1998-07-24 | 2002-12-10 | Terumo Kabushiki Kaisha | Method and instrument for measuring blood sugar level |
US6458109B1 (en) * | 1998-08-07 | 2002-10-01 | Hill-Rom Services, Inc. | Wound treatment apparatus |
US6248067B1 (en) | 1999-02-05 | 2001-06-19 | Minimed Inc. | Analyte sensor and holter-type monitor system and method of using the same |
US5993423A (en) * | 1998-08-18 | 1999-11-30 | Choi; Soo Bong | Portable automatic syringe device and injection needle unit thereof |
US6558320B1 (en) | 2000-01-20 | 2003-05-06 | Medtronic Minimed, Inc. | Handheld personal data assistant (PDA) with a medical device and method of using the same |
US6359270B1 (en) | 1998-09-04 | 2002-03-19 | Ncr Corporation | Communications module mounting for domestic appliance |
KR20000019716A (en) | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising bioflavonoid compounds for descending blood sugar |
US6740518B1 (en) | 1998-09-17 | 2004-05-25 | Clinical Micro Sensors, Inc. | Signal detection techniques for the detection of analytes |
US5951521A (en) * | 1998-09-25 | 1999-09-14 | Minimed Inc. | Subcutaneous implantable sensor set having the capability to remove deliver fluids to an insertion site |
US6402689B1 (en) | 1998-09-30 | 2002-06-11 | Sicel Technologies, Inc. | Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors |
EP1102559B1 (en) | 1998-09-30 | 2003-06-04 | Cygnus, Inc. | Method and device for predicting physiological values |
US6591125B1 (en) | 2000-06-27 | 2003-07-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
CA2666429A1 (en) | 1998-10-08 | 2000-04-13 | Medtronic Minimed, Inc. | Telemetered characteristic monitor system |
US6602469B1 (en) | 1998-11-09 | 2003-08-05 | Lifestream Technologies, Inc. | Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system |
DE69924749T2 (en) | 1998-11-20 | 2006-04-27 | The University Of Connecticut, Farmington | Generically integrated implantable potentiostat remote sensing device for electrochemical probes |
AU768312B2 (en) | 1998-11-30 | 2003-12-11 | Abbott Laboratories | Analyte test instrument having improved calibration and communication processes |
HUP0104660A2 (en) | 1998-11-30 | 2002-03-28 | Novo Nordisk A/S | A method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions |
US6773671B1 (en) | 1998-11-30 | 2004-08-10 | Abbott Laboratories | Multichemistry measuring device and test strips |
US6161095A (en) | 1998-12-16 | 2000-12-12 | Health Hero Network, Inc. | Treatment regimen compliance and efficacy with feedback |
US7436511B2 (en) | 1999-01-22 | 2008-10-14 | Sensys Medical, Inc. | Analyte filter method and apparatus |
US6561978B1 (en) | 1999-02-12 | 2003-05-13 | Cygnus, Inc. | Devices and methods for frequent measurement of an analyte present in a biological system |
DK1154719T3 (en) | 1999-02-25 | 2012-07-23 | Medtronic Minimed Inc | Sample connector and cable for a glucose monitor |
US6360888B1 (en) | 1999-02-25 | 2002-03-26 | Minimed Inc. | Glucose sensor package system |
US6424847B1 (en) | 1999-02-25 | 2002-07-23 | Medtronic Minimed, Inc. | Glucose monitor calibration methods |
GB9907815D0 (en) | 1999-04-06 | 1999-06-02 | Univ Cambridge Tech | Implantable sensor |
US6285897B1 (en) | 1999-04-07 | 2001-09-04 | Endonetics, Inc. | Remote physiological monitoring system |
US6200265B1 (en) | 1999-04-16 | 2001-03-13 | Medtronic, Inc. | Peripheral memory patch and access method for use with an implantable medical device |
US6669663B1 (en) | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
US6514689B2 (en) | 1999-05-11 | 2003-02-04 | M-Biotech, Inc. | Hydrogel biosensor |
US6359444B1 (en) | 1999-05-28 | 2002-03-19 | University Of Kentucky Research Foundation | Remote resonant-circuit analyte sensing apparatus with sensing structure and associated method of sensing |
US6546268B1 (en) | 1999-06-02 | 2003-04-08 | Ball Semiconductor, Inc. | Glucose sensor |
DE19925910B4 (en) | 1999-06-07 | 2005-04-28 | Siemens Ag | Method for processing or processing data |
GB2351153B (en) | 1999-06-18 | 2003-03-26 | Abbott Lab | Electrochemical sensor for analysis of liquid samples |
US6423035B1 (en) | 1999-06-18 | 2002-07-23 | Animas Corporation | Infusion pump with a sealed drive mechanism and improved method of occlusion detection |
US6654625B1 (en) | 1999-06-18 | 2003-11-25 | Therasense, Inc. | Mass transport limited in vivo analyte sensor |
FI108986B (en) | 1999-07-01 | 2002-04-30 | Emfitech Oy | Process for producing a sensor element and a sensor element |
US6804558B2 (en) | 1999-07-07 | 2004-10-12 | Medtronic, Inc. | System and method of communicating between an implantable medical device and a remote computer system or health care provider |
US6514460B1 (en) | 1999-07-28 | 2003-02-04 | Abbott Laboratories | Luminous glucose monitoring device |
US6471689B1 (en) | 1999-08-16 | 2002-10-29 | Thomas Jefferson University | Implantable drug delivery catheter system with capillary interface |
US6923763B1 (en) | 1999-08-23 | 2005-08-02 | University Of Virginia Patent Foundation | Method and apparatus for predicting the risk of hypoglycemia |
US7113821B1 (en) | 1999-08-25 | 2006-09-26 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery |
US6343225B1 (en) | 1999-09-14 | 2002-01-29 | Implanted Biosystems, Inc. | Implantable glucose sensor |
AT408182B (en) | 1999-09-17 | 2001-09-25 | Schaupp Lukas Dipl Ing Dr Tech | DEVICE FOR VIVO MEASURING SIZES IN LIVING ORGANISMS |
US7045054B1 (en) | 1999-09-20 | 2006-05-16 | Roche Diagnostics Corporation | Small volume biosensor for continuous analyte monitoring |
US20050103624A1 (en) | 1999-10-04 | 2005-05-19 | Bhullar Raghbir S. | Biosensor and method of making |
US7073246B2 (en) | 1999-10-04 | 2006-07-11 | Roche Diagnostics Operations, Inc. | Method of making a biosensor |
US7317938B2 (en) | 1999-10-08 | 2008-01-08 | Sensys Medical, Inc. | Method of adapting in-vitro models to aid in noninvasive glucose determination |
CA2387124A1 (en) | 1999-10-08 | 2001-04-26 | Healthetech, Inc. | Integrated calorie management system |
US20060091006A1 (en) | 1999-11-04 | 2006-05-04 | Yi Wang | Analyte sensor with insertion monitor, and methods |
US6616819B1 (en) | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US6605201B1 (en) | 1999-11-15 | 2003-08-12 | Therasense, Inc. | Transition metal complexes with bidentate ligand having an imidazole ring and sensor constructed therewith |
US6658396B1 (en) | 1999-11-29 | 2003-12-02 | Tang Sharon S | Neural network drug dosage estimation |
US6418346B1 (en) | 1999-12-14 | 2002-07-09 | Medtronic, Inc. | Apparatus and method for remote therapy and diagnosis in medical devices via interface systems |
US6497655B1 (en) | 1999-12-17 | 2002-12-24 | Medtronic, Inc. | Virtual remote monitor, alert, diagnostics and programming for implantable medical device systems |
US7060031B2 (en) | 1999-12-17 | 2006-06-13 | Medtronic, Inc. | Method and apparatus for remotely programming implantable medical devices |
US7286894B1 (en) | 2000-01-07 | 2007-10-23 | Pasco Scientific | Hand-held computer device and method for interactive data acquisition, analysis, annotation, and calibration |
JP3449958B2 (en) | 2000-01-18 | 2003-09-22 | 理想科学工業株式会社 | Printing system, printing method, and computer-readable recording medium storing printing program |
EP1248661B1 (en) | 2000-01-21 | 2012-08-22 | Medtronic MiniMed, Inc. | Ambulatory medical apparatus and method having telemetry modifiable control software |
US7369635B2 (en) | 2000-01-21 | 2008-05-06 | Medtronic Minimed, Inc. | Rapid discrimination preambles and methods for using the same |
WO2001054753A2 (en) | 2000-01-21 | 2001-08-02 | Medical Research Group, Inc. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
US6873268B2 (en) | 2000-01-21 | 2005-03-29 | Medtronic Minimed, Inc. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
US7003336B2 (en) | 2000-02-10 | 2006-02-21 | Medtronic Minimed, Inc. | Analyte sensor method of making the same |
US20030060765A1 (en) | 2000-02-16 | 2003-03-27 | Arthur Campbell | Infusion device menu structure and method of using the same |
US6895263B2 (en) | 2000-02-23 | 2005-05-17 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US7890295B2 (en) | 2000-02-23 | 2011-02-15 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US7027931B1 (en) | 2000-02-24 | 2006-04-11 | Bionostics, Inc. | System for statistical analysis of quality control data |
US7025425B2 (en) | 2000-03-29 | 2006-04-11 | University Of Virginia Patent Foundation | Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data |
US6610012B2 (en) | 2000-04-10 | 2003-08-26 | Healthetech, Inc. | System and method for remote pregnancy monitoring |
US6440068B1 (en) | 2000-04-28 | 2002-08-27 | International Business Machines Corporation | Measuring user health as measured by multiple diverse health measurement devices utilizing a personal storage device |
AU2001263022A1 (en) | 2000-05-12 | 2001-11-26 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
US7181261B2 (en) | 2000-05-15 | 2007-02-20 | Silver James H | Implantable, retrievable, thrombus minimizing sensors |
US6442413B1 (en) | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
US6891936B2 (en) | 2000-05-31 | 2005-05-10 | Arkray, Inc. | Remote data control system and measuring data gathering method |
MXPA02012643A (en) | 2000-06-23 | 2004-09-10 | Bodymedia Inc | System for monitoring health, wellness and fitness. |
US7530964B2 (en) | 2000-06-30 | 2009-05-12 | Elan Pharma International Limited | Needle device and method thereof |
JP4055926B2 (en) | 2000-08-14 | 2008-03-05 | テルモ株式会社 | Infusion pump |
EP1309271B1 (en) | 2000-08-18 | 2008-04-16 | Animas Technologies LLC | Device for prediction of hypoglycemic events |
WO2002017210A2 (en) | 2000-08-18 | 2002-02-28 | Cygnus, Inc. | Formulation and manipulation of databases of analyte and associated values |
EP1311189A4 (en) | 2000-08-21 | 2005-03-09 | Euro Celtique Sa | Near infrared blood glucose monitoring system |
WO2002024065A1 (en) | 2000-09-22 | 2002-03-28 | Knobbe, Lim & Buckingham | Method and apparatus for real-time estimation and control of pysiological parameters |
EP1339312B1 (en) | 2000-10-10 | 2006-01-04 | Microchips, Inc. | Microchip reservoir devices using wireless transmission of power and data |
US6712025B2 (en) | 2000-10-13 | 2004-03-30 | Dogwatch, Inc. | Receiver/stimulus unit for an animal control system |
EP1333751A2 (en) | 2000-11-13 | 2003-08-13 | Nipro Diabetes Systems | Glucose sensor system |
US6695860B1 (en) | 2000-11-13 | 2004-02-24 | Isense Corp. | Transcutaneous sensor insertion device |
US7052483B2 (en) | 2000-12-19 | 2006-05-30 | Animas Corporation | Transcutaneous inserter for low-profile infusion sets |
US20020147135A1 (en) | 2000-12-21 | 2002-10-10 | Oliver Schnell | Method and device for producing an adapted travel treatment plan for administering a medicine in the event of a long-haul journey |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
KR20030079958A (en) | 2001-01-22 | 2003-10-10 | 에프. 호프만-라 로슈 아게 | Lancet device having capillary action |
CA2440799A1 (en) | 2001-03-14 | 2002-09-19 | Baxter International Inc. | Internet based therapy management system |
US6968294B2 (en) | 2001-03-15 | 2005-11-22 | Koninklijke Philips Electronics N.V. | Automatic system for monitoring person requiring care and his/her caretaker |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US6983176B2 (en) | 2001-04-11 | 2006-01-03 | Rio Grande Medical Technologies, Inc. | Optically similar reference samples and related methods for multivariate calibration models used in optical spectroscopy |
US6676816B2 (en) | 2001-05-11 | 2004-01-13 | Therasense, Inc. | Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes |
US6932894B2 (en) | 2001-05-15 | 2005-08-23 | Therasense, Inc. | Biosensor membranes composed of polymers containing heterocyclic nitrogens |
US6549796B2 (en) | 2001-05-25 | 2003-04-15 | Lifescan, Inc. | Monitoring analyte concentration using minimally invasive devices |
US6837988B2 (en) | 2001-06-12 | 2005-01-04 | Lifescan, Inc. | Biological fluid sampling and analyte measurement devices and methods |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US7179226B2 (en) | 2001-06-21 | 2007-02-20 | Animas Corporation | System and method for managing diabetes |
WO2003000127A2 (en) | 2001-06-22 | 2003-01-03 | Cygnus, Inc. | Method for improving the performance of an analyte monitoring system |
EP1405596B1 (en) | 2001-07-11 | 2010-10-06 | ARKRAY, Inc. | Lancet |
AUPR632301A0 (en) | 2001-07-11 | 2001-08-02 | Chee, Frederick Howe-Hui | Infusion apparatus for regulating blood glucose levels |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6544212B2 (en) | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
US6788965B2 (en) | 2001-08-03 | 2004-09-07 | Sensys Medical, Inc. | Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes |
WO2003014735A1 (en) | 2001-08-03 | 2003-02-20 | General Hospital Corporation | System, process and diagnostic arrangement establishing and monitoring medication doses for patients |
JP2004538078A (en) | 2001-08-20 | 2004-12-24 | インバネス・メディカル・リミテッド | Wireless diabetes management device and method of using wireless diabetes management device |
JP2003084101A (en) | 2001-09-17 | 2003-03-19 | Dainippon Printing Co Ltd | Resin composition for optical device, optical device and projection screen |
US7052591B2 (en) | 2001-09-21 | 2006-05-30 | Therasense, Inc. | Electrodeposition of redox polymers and co-electrodeposition of enzymes by coordinative crosslinking |
US6830562B2 (en) | 2001-09-27 | 2004-12-14 | Unomedical A/S | Injector device for placing a subcutaneous infusion set |
US20050137480A1 (en) | 2001-10-01 | 2005-06-23 | Eckhard Alt | Remote control of implantable device through medical implant communication service band |
AU2002346399A1 (en) | 2001-11-14 | 2003-05-26 | Medical Instill Technologies, Inc. | Intradermal delivery device and method |
US20060006141A1 (en) | 2001-11-16 | 2006-01-12 | Stefan Ufer | Biomedical electrochemical sensor array and method of fabrication |
US7382405B2 (en) | 2001-12-03 | 2008-06-03 | Nikon Corporation | Electronic apparatus having a user identification function and user identification method |
DE60239835D1 (en) * | 2001-12-06 | 2011-06-01 | Carefusion 303 Inc | Infusion device with CO2 monitoring |
US7729776B2 (en) | 2001-12-19 | 2010-06-01 | Cardiac Pacemakers, Inc. | Implantable medical device with two or more telemetry systems |
US7399277B2 (en) | 2001-12-27 | 2008-07-15 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US7022072B2 (en) | 2001-12-27 | 2006-04-04 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US20080255438A1 (en) | 2001-12-27 | 2008-10-16 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US7056302B2 (en) | 2002-02-26 | 2006-06-06 | Sterling Medivations, Inc. | Insertion device for an insertion set and method of using the same |
US20030212379A1 (en) | 2002-02-26 | 2003-11-13 | Bylund Adam David | Systems and methods for remotely controlling medication infusion and analyte monitoring |
US6830558B2 (en) | 2002-03-01 | 2004-12-14 | Insulet Corporation | Flow condition sensor assembly for patient infusion device |
US6998247B2 (en) | 2002-03-08 | 2006-02-14 | Sensys Medical, Inc. | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
US6936006B2 (en) | 2002-03-22 | 2005-08-30 | Novo Nordisk, A/S | Atraumatic insertion of a subcutaneous device |
GB2388898B (en) | 2002-04-02 | 2005-10-05 | Inverness Medical Ltd | Integrated sample testing meter |
US7027848B2 (en) | 2002-04-04 | 2006-04-11 | Inlight Solutions, Inc. | Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US7410468B2 (en) | 2002-04-19 | 2008-08-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7153265B2 (en) | 2002-04-22 | 2006-12-26 | Medtronic Minimed, Inc. | Anti-inflammatory biosensor for reduced biofouling and enhanced sensor performance |
US6960192B1 (en) | 2002-04-23 | 2005-11-01 | Insulet Corporation | Transcutaneous fluid delivery system |
US20040153032A1 (en) | 2002-04-23 | 2004-08-05 | Garribotto John T. | Dispenser for patient infusion device |
US6758835B2 (en) * | 2002-05-01 | 2004-07-06 | Medtg, Llc | Disposable needle assembly having sensors formed therein permitting the simultaneous drawing and administering of fluids and method of forming the same |
GB2388715B (en) | 2002-05-13 | 2005-08-03 | Splashpower Ltd | Improvements relating to the transfer of electromagnetic power |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US20080132842A1 (en) | 2002-06-06 | 2008-06-05 | Flaherty J Christopher | Plunger assembly for patient infusion device |
US20030236489A1 (en) * | 2002-06-21 | 2003-12-25 | Baxter International, Inc. | Method and apparatus for closed-loop flow control system |
US6865407B2 (en) | 2002-07-11 | 2005-03-08 | Optical Sensors, Inc. | Calibration technique for non-invasive medical devices |
US20040010207A1 (en) | 2002-07-15 | 2004-01-15 | Flaherty J. Christopher | Self-contained, automatic transcutaneous physiologic sensing system |
JP2004054394A (en) | 2002-07-17 | 2004-02-19 | Toshiba Corp | Radio information processing system, radio information recording medium, radio information processor and communication method for radio information processing system |
AU2003302720B9 (en) | 2002-07-19 | 2008-08-21 | Smiths Detection-Pasadena, Inc. | Non-specific sensor array detectors |
US7278983B2 (en) | 2002-07-24 | 2007-10-09 | Medtronic Minimed, Inc. | Physiological monitoring device for controlling a medication infusion device |
CA2495648C (en) | 2002-08-13 | 2014-07-22 | University Of Virginia Patent Foundation | Method, system, and computer program product for processing of self-monitoring blood glucose (smbg) data to enhance diabetic self-management |
US6865641B2 (en) | 2002-08-29 | 2005-03-08 | International Business Machines Corporation | Method and apparatus for non-volatile display of information for an electronic device |
US7404796B2 (en) | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
CN1723053A (en) | 2002-09-12 | 2006-01-18 | 儿童医院医疗中心 | Method and device for painless injection of medication |
US7144384B2 (en) | 2002-09-30 | 2006-12-05 | Insulet Corporation | Dispenser components and methods for patient infusion device |
US7128727B2 (en) | 2002-09-30 | 2006-10-31 | Flaherty J Christopher | Components and methods for patient infusion device |
US7192405B2 (en) | 2002-09-30 | 2007-03-20 | Becton, Dickinson And Company | Integrated lancet and bodily fluid sensor |
CN1859943B (en) | 2002-10-11 | 2010-09-29 | 贝克顿·迪金森公司 | System for controlling concentration of glucose in a patient |
AU2003287159A1 (en) | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Synchronization and calibration of clocks for a medical device and calibrated clock |
US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US7572237B2 (en) | 2002-11-06 | 2009-08-11 | Abbott Diabetes Care Inc. | Automatic biological analyte testing meter with integrated lancing device and methods of use |
US20060264926A1 (en) * | 2002-11-08 | 2006-11-23 | Kochamba Gary S | Cutaneous stabilization by vacuum for delivery of micro-needle array |
JP2006509593A (en) | 2002-12-16 | 2006-03-23 | メーガン メディカル アイエヌシー | Method and apparatus for depth control for percutaneous use |
US20040116866A1 (en) | 2002-12-17 | 2004-06-17 | William Gorman | Skin attachment apparatus and method for patient infusion device |
US20040122353A1 (en) | 2002-12-19 | 2004-06-24 | Medtronic Minimed, Inc. | Relay device for transferring information between a sensor system and a fluid delivery system |
EP1578262A4 (en) | 2002-12-31 | 2007-12-05 | Therasense Inc | Continuous glucose monitoring system and methods of use |
GB0304424D0 (en) | 2003-02-26 | 2003-04-02 | Glaxosmithkline Biolog Sa | Novel compounds |
US9872890B2 (en) | 2003-03-19 | 2018-01-23 | Paul C. Davidson | Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
US20040186373A1 (en) | 2003-03-21 | 2004-09-23 | Dunfield John Stephen | Method and device for targeted epithelial delivery of medicinal and related agents |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US20040204868A1 (en) | 2003-04-09 | 2004-10-14 | Maynard John D. | Reduction of errors in non-invasive tissue sampling |
CA2520880A1 (en) | 2003-04-18 | 2004-11-04 | Insulet Corporation | User interface for infusion pump remote controller and method of using the same |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US7258673B2 (en) | 2003-06-06 | 2007-08-21 | Lifescan, Inc | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
US20040249254A1 (en) | 2003-06-06 | 2004-12-09 | Joel Racchini | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US20040254433A1 (en) | 2003-06-12 | 2004-12-16 | Bandis Steven D. | Sensor introducer system, apparatus and method |
US7155290B2 (en) | 2003-06-23 | 2006-12-26 | Cardiac Pacemakers, Inc. | Secure long-range telemetry for implantable medical device |
US7510564B2 (en) | 2003-06-27 | 2009-03-31 | Abbott Diabetes Care Inc. | Lancing device |
US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
WO2005007223A2 (en) | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
US7651596B2 (en) | 2005-04-08 | 2010-01-26 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
WO2005019795A2 (en) | 2003-07-25 | 2005-03-03 | Dexcom, Inc. | Electrochemical sensors including electrode systems with increased oxygen generation |
EP1649260A4 (en) | 2003-07-25 | 2010-07-07 | Dexcom Inc | Electrode systems for electrochemical sensors |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7424318B2 (en) | 2003-12-05 | 2008-09-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7366556B2 (en) | 2003-12-05 | 2008-04-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20070173709A1 (en) | 2005-04-08 | 2007-07-26 | Petisce James R | Membranes for an analyte sensor |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20050176136A1 (en) | 2003-11-19 | 2005-08-11 | Dexcom, Inc. | Afinity domain for analyte sensor |
US7460898B2 (en) | 2003-12-05 | 2008-12-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7467003B2 (en) | 2003-12-05 | 2008-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
JP4708342B2 (en) | 2003-07-25 | 2011-06-22 | デックスコム・インコーポレーテッド | Oxygen augmentation membrane system for use in implantable devices |
US6931327B2 (en) | 2003-08-01 | 2005-08-16 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7925321B2 (en) | 2003-08-01 | 2011-04-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8626257B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | Analyte sensor |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
NZ580449A (en) | 2003-09-11 | 2011-06-30 | Theranos Inc | Ingestible medical device with biocompatible polymer coating, device with microarray to interact with disease marker |
DE10343863A1 (en) | 2003-09-23 | 2005-04-14 | Roche Diagnostics Gmbh | Method and device for continuously monitoring the concentration of an analyte |
JP3612324B1 (en) | 2003-09-29 | 2005-01-19 | 株式会社日立製作所 | Blood glucose level display method and apparatus |
DE602004026763D1 (en) | 2003-09-30 | 2010-06-02 | Roche Diagnostics Gmbh | SENSOR WITH IMPROVED BIOKOMPATIBILITY |
US20050090607A1 (en) | 2003-10-28 | 2005-04-28 | Dexcom, Inc. | Silicone composition for biocompatible membrane |
EP1683058A2 (en) | 2003-10-29 | 2006-07-26 | Novo Nordisk A/S | Medical advisory system |
US20050096516A1 (en) | 2003-10-30 | 2005-05-05 | Orhan Soykan | Optical detector of organic analyte |
US6928380B2 (en) | 2003-10-30 | 2005-08-09 | International Business Machines Corporation | Thermal measurements of electronic devices during operation |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
JP2005137416A (en) * | 2003-11-04 | 2005-06-02 | Sysmex Corp | Percutaneous analyte extraction system and percutaneous analyte analysis system |
JP4704351B2 (en) | 2003-11-06 | 2011-06-15 | ライフスキャン・インコーポレイテッド | Drug introduction pen with event notification means |
WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US20050113886A1 (en) | 2003-11-24 | 2005-05-26 | Fischell David R. | Implantable medical system with long range telemetry |
US8425416B2 (en) | 2006-10-04 | 2013-04-23 | Dexcom, Inc. | Analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US20080197024A1 (en) | 2003-12-05 | 2008-08-21 | Dexcom, Inc. | Analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8774886B2 (en) | 2006-10-04 | 2014-07-08 | Dexcom, Inc. | Analyte sensor |
EP2239566B1 (en) | 2003-12-05 | 2014-04-23 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
US20080200788A1 (en) | 2006-10-04 | 2008-08-21 | Dexcorn, Inc. | Analyte sensor |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8364230B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8425417B2 (en) | 2003-12-05 | 2013-04-23 | Dexcom, Inc. | Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device |
ES2646312T3 (en) | 2003-12-08 | 2017-12-13 | Dexcom, Inc. | Systems and methods to improve electromechanical analyte sensors |
WO2005057175A2 (en) | 2003-12-09 | 2005-06-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US7384397B2 (en) | 2003-12-30 | 2008-06-10 | Medtronic Minimed, Inc. | System and method for sensor recalibration |
US7637868B2 (en) | 2004-01-12 | 2009-12-29 | Dexcom, Inc. | Composite material for implantable device |
DK2611042T3 (en) | 2004-01-27 | 2015-04-20 | Altivera L L C | DIAGNOSTIC RADIO FREQUENCY IDENTIFICATION SENSORS AND APPLICATIONS THEREOF |
US7580812B2 (en) | 2004-01-28 | 2009-08-25 | Honeywell International Inc. | Trending system and method using window filtering |
US8165651B2 (en) | 2004-02-09 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte sensor, and associated system and method employing a catalytic agent |
US7699964B2 (en) | 2004-02-09 | 2010-04-20 | Abbott Diabetes Care Inc. | Membrane suitable for use in an analyte sensor, analyte sensor, and associated method |
US7364592B2 (en) | 2004-02-12 | 2008-04-29 | Dexcom, Inc. | Biointerface membrane with macro-and micro-architecture |
CA2556331A1 (en) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US20060154642A1 (en) | 2004-02-20 | 2006-07-13 | Scannell Robert F Jr | Medication & health, environmental, and security monitoring, alert, intervention, information and network system with associated and supporting apparatuses |
JP3590053B1 (en) | 2004-02-24 | 2004-11-17 | 株式会社日立製作所 | Blood glucose measurement device |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
CA2833776C (en) | 2004-02-26 | 2017-03-28 | Diabetes Tools Sweden Ab | Metabolic monitoring, a method and apparatus for indicating a health-related condition of a subject |
US7831828B2 (en) | 2004-03-15 | 2010-11-09 | Cardiac Pacemakers, Inc. | System and method for securely authenticating a data exchange session with an implantable medical device |
US6971274B2 (en) | 2004-04-02 | 2005-12-06 | Sierra Instruments, Inc. | Immersible thermal mass flow meter |
US20060009727A1 (en) | 2004-04-08 | 2006-01-12 | Chf Solutions Inc. | Method and apparatus for an extracorporeal control of blood glucose |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US20050245799A1 (en) | 2004-05-03 | 2005-11-03 | Dexcom, Inc. | Implantable analyte sensor |
US7651845B2 (en) | 2004-05-13 | 2010-01-26 | The Regents Of The University Of California | Method and apparatus for glucose control and insulin dosing for diabetics |
US7241266B2 (en) | 2004-05-20 | 2007-07-10 | Digital Angel Corporation | Transducer for embedded bio-sensor using body energy as a power source |
US7118667B2 (en) | 2004-06-02 | 2006-10-10 | Jin Po Lee | Biosensors having improved sample application and uses thereof |
EP1810185A4 (en) | 2004-06-04 | 2010-01-06 | Therasense Inc | Diabetes care host-client architecture and data management system |
US7289855B2 (en) | 2004-06-09 | 2007-10-30 | Medtronic, Inc. | Implantable medical device package antenna |
US20070060979A1 (en) | 2004-06-10 | 2007-03-15 | Ndi Medical, Llc | Implantable pulse generator systems and methods for providing functional and / or therapeutic stimulation of muscles and / or nerves and / or central nervous system tissue |
US7283867B2 (en) | 2004-06-10 | 2007-10-16 | Ndi Medical, Llc | Implantable system and methods for acquisition and processing of electrical signals from muscles and/or nerves and/or central nervous system tissue |
US20070100222A1 (en) | 2004-06-14 | 2007-05-03 | Metronic Minimed, Inc. | Analyte sensing apparatus for hospital use |
US7565197B2 (en) | 2004-06-18 | 2009-07-21 | Medtronic, Inc. | Conditional requirements for remote medical device programming |
DE102004031092A1 (en) | 2004-06-28 | 2006-01-12 | Giesecke & Devrient Gmbh | transponder unit |
US20060001538A1 (en) | 2004-06-30 | 2006-01-05 | Ulrich Kraft | Methods of monitoring the concentration of an analyte |
US20060001551A1 (en) | 2004-06-30 | 2006-01-05 | Ulrich Kraft | Analyte monitoring system with wireless alarm |
US8224669B2 (en) | 2004-07-01 | 2012-07-17 | Anchor Holdings, Inc. | Chronic disease management system |
US20060015020A1 (en) | 2004-07-06 | 2006-01-19 | Dexcom, Inc. | Systems and methods for manufacture of an analyte-measuring device including a membrane system |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20080242961A1 (en) | 2004-07-13 | 2008-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
EP3666187B1 (en) | 2004-07-13 | 2021-05-26 | DexCom, Inc. | Transcutaneous analyte sensor |
US20060016700A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7857760B2 (en) | 2004-07-13 | 2010-12-28 | Dexcom, Inc. | Analyte sensor |
US7344500B2 (en) | 2004-07-27 | 2008-03-18 | Medtronic Minimed, Inc. | Sensing system with auxiliary display |
US20080312859A1 (en) | 2004-09-03 | 2008-12-18 | Novo Nordisk A/S | Method of Calibrating a System for Measuring the Concentration of Substances in Body and an Apparatus for Exercising the Method |
US7468033B2 (en) | 2004-09-08 | 2008-12-23 | Medtronic Minimed, Inc. | Blood contacting sensor |
EP1794695A2 (en) | 2004-09-23 | 2007-06-13 | Novo Nordisk A/S | Device for self-care support |
ATE479387T1 (en) | 2004-11-02 | 2010-09-15 | Medtronic Inc | TECHNIQUES FOR USER-ACTIVATED DATA RETENTION IN AN IMPLANTABLE MEDICAL DEVICE |
US20060173712A1 (en) | 2004-11-12 | 2006-08-03 | Dirk Joubert | Portable medical information system |
US7237712B2 (en) | 2004-12-01 | 2007-07-03 | Alfred E. Mann Foundation For Scientific Research | Implantable device and communication integrated circuit implementable therein |
US20070010950A1 (en) | 2004-12-03 | 2007-01-11 | Abensour Daniel S | Method to determine the degree and stability of blood glucose control in patients with diabetes mellitus via the creation and continuous update of new statistical indicators in blood glucose monitors or free standing computers |
US7978063B2 (en) | 2004-12-13 | 2011-07-12 | Koninklijke Philips Electronics N.V. | Wireless network having body coupled communication for mobile patient monitoring |
US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
US20090082693A1 (en) | 2004-12-29 | 2009-03-26 | Therasense, Inc. | Method and apparatus for providing temperature sensor module in a data communication system |
US9636450B2 (en) * | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US20070027381A1 (en) | 2005-07-29 | 2007-02-01 | Therasense, Inc. | Inserter and methods of use |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US8029441B2 (en) | 2006-02-28 | 2011-10-04 | Abbott Diabetes Care Inc. | Analyte sensor transmitter unit configuration for a data monitoring and management system |
US7731657B2 (en) | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
US20060166629A1 (en) | 2005-01-24 | 2006-07-27 | Therasense, Inc. | Method and apparatus for providing EMC Class-B compliant RF transmitter for data monitoring an detection systems |
US7545272B2 (en) | 2005-02-08 | 2009-06-09 | Therasense, Inc. | RF tag on test strips, test strip vials and boxes |
US20060181695A1 (en) * | 2005-02-11 | 2006-08-17 | Sage Burton H Jr | Compensating liquid delivery system and method |
US7390663B2 (en) | 2005-02-23 | 2008-06-24 | Streck, Inc. | Process, composition and kit for providing a stable whole blood calibrator/control |
KR100638727B1 (en) | 2005-02-28 | 2006-10-30 | 삼성전기주식회사 | Concurrent transceiver for zigbee and bluetooth |
US20090076360A1 (en) | 2007-09-13 | 2009-03-19 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20060202805A1 (en) | 2005-03-14 | 2006-09-14 | Alfred E. Mann Foundation For Scientific Research | Wireless acquisition and monitoring system |
CN101180093B (en) | 2005-03-21 | 2012-07-18 | 雅培糖尿病护理公司 | Method and system for providing integrated medication infusion and analyte monitoring system |
US7889069B2 (en) | 2005-04-01 | 2011-02-15 | Codman & Shurtleff, Inc. | Wireless patient monitoring system |
WO2006108809A1 (en) | 2005-04-13 | 2006-10-19 | Novo Nordisk A/S | Medical skin mountable device and system |
US8700157B2 (en) | 2005-04-29 | 2014-04-15 | Medtronic, Inc. | Telemetry head programmer for implantable medical device and system and method |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
ATE478333T1 (en) | 2005-06-02 | 2010-09-15 | Isense Corp | USE OF MULTIPLE DATA POINTS AND FILTERING IN ONE ANALYTICAL SENSOR |
EP1893079B1 (en) | 2005-06-08 | 2012-06-27 | SHER, Philip Michael | Fluctuating blood glucose notification threshold profiles and methods of use |
US8251904B2 (en) | 2005-06-09 | 2012-08-28 | Roche Diagnostics Operations, Inc. | Device and method for insulin dosing |
EP1733676B1 (en) | 2005-06-17 | 2012-08-01 | F. Hoffmann-La Roche AG | Sensor system, arrangement and method for monitoring a compound, in particular glucose in body tissue. |
US20060293577A1 (en) | 2005-06-23 | 2006-12-28 | Morrison Andrew E | Glucose monitoring kit |
US20070016449A1 (en) | 2005-06-29 | 2007-01-18 | Gary Cohen | Flexible glucose analysis using varying time report deltas and configurable glucose target ranges |
US20070066956A1 (en) | 2005-07-27 | 2007-03-22 | Medtronic Minimed, Inc. | Systems and methods for entering temporary basal rate pattern in an infusion device |
US7606784B2 (en) | 2005-08-02 | 2009-10-20 | Northrop Grumman Corporation | Uncertainty management in a decision-making system |
US20070060869A1 (en) | 2005-08-16 | 2007-03-15 | Tolle Mike C V | Controller device for an infusion pump |
US20070093786A1 (en) | 2005-08-16 | 2007-04-26 | Medtronic Minimed, Inc. | Watch controller for a medical device |
US20090227855A1 (en) | 2005-08-16 | 2009-09-10 | Medtronic Minimed, Inc. | Controller device for an infusion pump |
CN101365374B (en) | 2005-08-31 | 2011-11-16 | 弗吉尼亚大学专利基金委员会 | Improving accuracy of continuous glucose sensors |
US9089713B2 (en) | 2005-08-31 | 2015-07-28 | Michael Sasha John | Methods and systems for semi-automatic adjustment of medical monitoring and treatment |
US8831735B2 (en) | 2005-08-31 | 2014-09-09 | Michael Sasha John | Methods and systems for semi-automatic adjustment of medical monitoring and treatment |
ES2575660T3 (en) | 2005-09-09 | 2016-06-30 | F. Hoffmann-La Roche Ag | System, tools, devices and program for diabetic care |
US8298389B2 (en) | 2005-09-12 | 2012-10-30 | Abbott Diabetes Care Inc. | In vitro analyte sensor, and methods |
DE502005009907D1 (en) | 2005-09-15 | 2010-08-26 | Roche Diagnostics Gmbh | Insertion head with handle |
US9072476B2 (en) | 2005-09-23 | 2015-07-07 | Medtronic Minimed, Inc. | Flexible sensor apparatus |
US7725148B2 (en) | 2005-09-23 | 2010-05-25 | Medtronic Minimed, Inc. | Sensor with layered electrodes |
US7846311B2 (en) | 2005-09-27 | 2010-12-07 | Abbott Diabetes Care Inc. | In vitro analyte sensor and methods of use |
US7761165B1 (en) | 2005-09-29 | 2010-07-20 | Boston Scientific Neuromodulation Corporation | Implantable stimulator with integrated plastic housing/metal contacts and manufacture and use |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
EP1772162A1 (en) * | 2005-10-08 | 2007-04-11 | Boehringer Mannheim Gmbh | Infusion system for delivery of a liquid drug |
CA2622986A1 (en) | 2005-10-20 | 2007-04-26 | Big Glucose Ltd. | Non-invasive glucose monitoring |
US20070095661A1 (en) | 2005-10-31 | 2007-05-03 | Yi Wang | Method of making, and, analyte sensor |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
WO2007056592A2 (en) | 2005-11-08 | 2007-05-18 | M2 Medical A/S | Method and system for manual and autonomous control of an infusion pump |
US20070173706A1 (en) | 2005-11-11 | 2007-07-26 | Isense Corporation | Method and apparatus for insertion of a sensor |
US7918975B2 (en) | 2005-11-17 | 2011-04-05 | Abbott Diabetes Care Inc. | Analytical sensors for biological fluid |
US7941200B2 (en) | 2005-12-08 | 2011-05-10 | Roche Diagnostics Operations, Inc. | System and method for determining drug administration information |
US8515518B2 (en) | 2005-12-28 | 2013-08-20 | Abbott Diabetes Care Inc. | Analyte monitoring |
CA2636034A1 (en) | 2005-12-28 | 2007-10-25 | Abbott Diabetes Care Inc. | Medical device insertion |
US8160670B2 (en) | 2005-12-28 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent |
US8102789B2 (en) | 2005-12-29 | 2012-01-24 | Medtronic, Inc. | System and method for synchronous wireless communication with a medical device |
US7574266B2 (en) | 2006-01-19 | 2009-08-11 | Medtronic, Inc. | System and method for telemetry with an implantable medical device |
US7872574B2 (en) | 2006-02-01 | 2011-01-18 | Innovation Specialists, Llc | Sensory enhancement systems and methods in personal electronic devices |
WO2007092637A2 (en) | 2006-02-09 | 2007-08-16 | Deka Products Limited Partnership | Patch-sized fluid delivery systems and methods |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US7981034B2 (en) | 2006-02-28 | 2011-07-19 | Abbott Diabetes Care Inc. | Smart messages and alerts for an infusion delivery and management system |
US7811430B2 (en) | 2006-02-28 | 2010-10-12 | Abbott Diabetes Care Inc. | Biosensors and methods of making |
US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US7887682B2 (en) | 2006-03-29 | 2011-02-15 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US20070233013A1 (en) | 2006-03-31 | 2007-10-04 | Schoenberg Stephen J | Covers for tissue engaging members |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
CA2649563C (en) | 2006-04-20 | 2015-02-17 | Manfred Ebner | Method for transmitting data in a blood glucose system and corresponding blood glucose system |
US7359837B2 (en) | 2006-04-27 | 2008-04-15 | Medtronic, Inc. | Peak data retention of signal data in an implantable medical device |
US20070258395A1 (en) | 2006-04-28 | 2007-11-08 | Medtronic Minimed, Inc. | Wireless data communication protocols for a medical device network |
US20070255126A1 (en) | 2006-04-28 | 2007-11-01 | Moberg Sheldon B | Data communication in networked fluid infusion systems |
US7496852B2 (en) | 2006-05-16 | 2009-02-24 | International Business Machines Corporation | Graphically manipulating a database |
WO2007143225A2 (en) | 2006-06-07 | 2007-12-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
US20080177149A1 (en) | 2006-06-16 | 2008-07-24 | Stefan Weinert | System and method for collecting patient information from which diabetes therapy may be determined |
US20070299617A1 (en) | 2006-06-27 | 2007-12-27 | Willis John P | Biofouling self-compensating biosensor |
US9119582B2 (en) | 2006-06-30 | 2015-09-01 | Abbott Diabetes Care, Inc. | Integrated analyte sensor and infusion device and methods therefor |
US7911010B2 (en) | 2006-07-17 | 2011-03-22 | Kwj Engineering, Inc. | Apparatus and method for microfabricated multi-dimensional sensors and sensing systems |
US7866026B1 (en) | 2006-08-01 | 2011-01-11 | Abbott Diabetes Care Inc. | Method for making calibration-adjusted sensors |
US8372015B2 (en) | 2006-08-28 | 2013-02-12 | Intuity Medical, Inc. | Body fluid sampling device with pivotable catalyst member |
US20080058626A1 (en) | 2006-09-05 | 2008-03-06 | Shinichi Miyata | Analytical meter with display-based tutorial module |
US20080058678A1 (en) | 2006-09-05 | 2008-03-06 | Shinichi Miyata | Kit for the determination of an analyte in a bodily fluid sample that includes a meter with a display-based tutorial module |
US20080071328A1 (en) | 2006-09-06 | 2008-03-20 | Medtronic, Inc. | Initiating medical system communications |
WO2008036516A1 (en) | 2006-09-22 | 2008-03-27 | Bayer Healthcare Llc | Biosensor system having enhanced stability and hematocrit performance |
US8449464B2 (en) | 2006-10-04 | 2013-05-28 | Dexcom, Inc. | Analyte sensor |
US8298142B2 (en) | 2006-10-04 | 2012-10-30 | Dexcom, Inc. | Analyte sensor |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8275438B2 (en) | 2006-10-04 | 2012-09-25 | Dexcom, Inc. | Analyte sensor |
US8447376B2 (en) | 2006-10-04 | 2013-05-21 | Dexcom, Inc. | Analyte sensor |
US8562528B2 (en) | 2006-10-04 | 2013-10-22 | Dexcom, Inc. | Analyte sensor |
US8478377B2 (en) | 2006-10-04 | 2013-07-02 | Dexcom, Inc. | Analyte sensor |
JP2010508091A (en) | 2006-10-26 | 2010-03-18 | アボット ダイアベティス ケア インコーポレイテッド | Method, system, and computer program product for detecting in real time a decrease in sensitivity of an analyte sensor |
US8439837B2 (en) | 2006-10-31 | 2013-05-14 | Lifescan, Inc. | Systems and methods for detecting hypoglycemic events having a reduced incidence of false alarms |
US7822557B2 (en) | 2006-10-31 | 2010-10-26 | Abbott Diabetes Care Inc. | Analyte sensors and methods |
US20080119705A1 (en) | 2006-11-17 | 2008-05-22 | Medtronic Minimed, Inc. | Systems and Methods for Diabetes Management Using Consumer Electronic Devices |
WO2008065646A1 (en) | 2006-11-28 | 2008-06-05 | Medingo Ltd. | An insertion device and method for inserting a subcutaneously insertable element into a body |
US20080139910A1 (en) | 2006-12-06 | 2008-06-12 | Metronic Minimed, Inc. | Analyte sensor and method of using the same |
WO2008071218A1 (en) | 2006-12-14 | 2008-06-19 | Egomedical Swiss Ag | Monitoring device |
US7802467B2 (en) | 2006-12-22 | 2010-09-28 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US7946985B2 (en) | 2006-12-29 | 2011-05-24 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
US20080161666A1 (en) | 2006-12-29 | 2008-07-03 | Abbott Diabetes Care, Inc. | Analyte devices and methods |
US7742747B2 (en) | 2007-01-25 | 2010-06-22 | Icera Canada ULC | Automatic IIP2 calibration architecture |
US9597019B2 (en) | 2007-02-09 | 2017-03-21 | Lifescan, Inc. | Method of ensuring date and time on a test meter is accurate |
WO2008115409A1 (en) | 2007-03-19 | 2008-09-25 | Bayer Healthcare Llc | Continuous analyte monitoring assembly and method of forming the same |
US20080234663A1 (en) | 2007-03-19 | 2008-09-25 | Ofer Yodfat | Method for Selecting Bolus Doses in a Drug Delivery System |
US20080269723A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
BRPI0810520A2 (en) | 2007-04-27 | 2014-10-21 | Abbott Diabetes Care Inc | TESTING IDENTIFICATION USING CONDUCTIVE MODELS |
US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7996158B2 (en) | 2007-05-14 | 2011-08-09 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
WO2008143943A1 (en) | 2007-05-14 | 2008-11-27 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20080300572A1 (en) | 2007-06-01 | 2008-12-04 | Medtronic Minimed, Inc. | Wireless monitor for a personal medical device system |
CA2688184A1 (en) | 2007-06-08 | 2008-12-18 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US20080312518A1 (en) | 2007-06-14 | 2008-12-18 | Arkal Medical, Inc | On-demand analyte monitor and method of use |
EP2166929B1 (en) | 2007-06-15 | 2012-12-19 | F. Hoffmann-La Roche AG | Visualization of a parameter which is measured on the human body |
AU2008265541B2 (en) | 2007-06-21 | 2014-07-17 | Abbott Diabetes Care, Inc. | Health management devices and methods |
US9754078B2 (en) | 2007-06-21 | 2017-09-05 | Immersion Corporation | Haptic health feedback monitoring |
EP2170159B8 (en) | 2007-06-29 | 2016-09-21 | Roche Diabetes Care GmbH | Combination communication device and medical device for communicating wirelessly with a remote medical device |
US7768386B2 (en) | 2007-07-31 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7731658B2 (en) | 2007-08-16 | 2010-06-08 | Cardiac Pacemakers, Inc. | Glycemic control monitoring using implantable medical device |
US8303545B2 (en) * | 2007-09-07 | 2012-11-06 | Stat Medical Devices, Inc. | Infusion device and method of using and making the same |
JP5109171B2 (en) | 2007-09-18 | 2012-12-26 | 株式会社ワコム | Position indicator, position input device, and computer system |
US20090085768A1 (en) | 2007-10-02 | 2009-04-02 | Medtronic Minimed, Inc. | Glucose sensor transceiver |
EP3868284A1 (en) | 2007-10-10 | 2021-08-25 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
US8216138B1 (en) | 2007-10-23 | 2012-07-10 | Abbott Diabetes Care Inc. | Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7783442B2 (en) | 2007-10-31 | 2010-08-24 | Medtronic Minimed, Inc. | System and methods for calibrating physiological characteristic sensors |
US9839395B2 (en) | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7757869B2 (en) * | 2007-12-26 | 2010-07-20 | Stephen Lawson | Hanger adaptable for use with a slatwall track and a retainer therefor |
WO2009097450A1 (en) | 2008-01-30 | 2009-08-06 | Dexcom. Inc. | Continuous cardiac marker sensor system |
CA2715624A1 (en) | 2008-02-20 | 2009-08-27 | Dexcom, Inc. | Continuous medicament sensor system for in vivo use |
CA2715628A1 (en) | 2008-02-21 | 2009-08-27 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US20090242399A1 (en) | 2008-03-25 | 2009-10-01 | Dexcom, Inc. | Analyte sensor |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
US20090247856A1 (en) | 2008-03-28 | 2009-10-01 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
WO2009124095A1 (en) | 2008-03-31 | 2009-10-08 | Abbott Diabetes Care Inc. | Shallow implantable analyte sensor with rapid physiological response |
US7826382B2 (en) | 2008-05-30 | 2010-11-02 | Abbott Diabetes Care Inc. | Close proximity communication device and methods |
US8394637B2 (en) | 2008-06-02 | 2013-03-12 | Roche Diagnostics Operations, Inc. | Handheld analyzer for testing a sample |
CN101621714B (en) | 2008-06-30 | 2013-06-12 | 华为技术有限公司 | Node and data processing system and data processing method |
US20100095229A1 (en) | 2008-09-18 | 2010-04-15 | Abbott Diabetes Care, Inc. | Graphical user interface for glucose monitoring system |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US9320470B2 (en) | 2008-12-31 | 2016-04-26 | Medtronic Minimed, Inc. | Method and/or system for sensor artifact filtering |
EP3714788B8 (en) | 2009-02-26 | 2023-06-14 | Abbott Diabetes Care, Inc. | Method of making improved analyte sensors |
US8062249B2 (en) | 2009-03-31 | 2011-11-22 | Abbott Diabetes Care Inc. | Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model |
EP2419015A4 (en) | 2009-04-16 | 2014-08-20 | Abbott Diabetes Care Inc | Analyte sensor calibration management |
US10376213B2 (en) | 2009-06-30 | 2019-08-13 | Waveform Technologies, Inc. | System, method and apparatus for sensor insertion |
US9131885B2 (en) | 2009-07-02 | 2015-09-15 | Dexcom, Inc. | Analyte sensors and methods of manufacturing same |
BR112012003078A2 (en) | 2009-08-17 | 2019-09-24 | Univ California | interrogable external sensor system for obtaining one or more biological characteristics of a patient's body internal tissue surface or region, method for obtaining one or more biological characteristics of a patient's internal tissue surface or region, transdermal sensor system for obtaining one or more biological characteristics of a patient's internal tissue region, method for obtaining one or more biological characteristics of a patient's internal tissue region, and interrogable sensor system for obtaining one or more biological characteristics of an internal tissue region of a patient |
US8932256B2 (en) | 2009-09-02 | 2015-01-13 | Medtronic Minimed, Inc. | Insertion device systems and methods |
CN102724913A (en) | 2009-09-30 | 2012-10-10 | 德克斯康公司 | Transcutaneous analyte sensor |
US9949672B2 (en) | 2009-12-17 | 2018-04-24 | Ascensia Diabetes Care Holdings Ag | Apparatus, systems and methods for determining and displaying pre-event and post-event analyte concentration levels |
US20110208027A1 (en) | 2010-02-23 | 2011-08-25 | Roche Diagnostics Operations, Inc. | Methods And Systems For Providing Therapeutic Guidelines To A Person Having Diabetes |
WO2011163519A2 (en) | 2010-06-25 | 2011-12-29 | Dexcom, Inc. | Systems and methods for communicating sensor data between communication devices |
US10143796B2 (en) * | 2010-08-25 | 2018-12-04 | Medtronic, Inc. | Fluid delivery device refill access |
US10231653B2 (en) | 2010-09-29 | 2019-03-19 | Dexcom, Inc. | Advanced continuous analyte monitoring system |
EP2632334B1 (en) | 2010-10-27 | 2020-09-09 | Dexcom, Inc. | Continuous analyte monitor data recording device operable in a blinded mode |
-
2008
- 2008-02-15 US US12/032,593 patent/US9636450B2/en active Active
- 2008-02-16 CN CN2012105685237A patent/CN103055378A/en active Pending
- 2008-02-16 CN CN2008800053887A patent/CN101631586B/en not_active Expired - Fee Related
- 2008-02-16 WO PCT/US2008/054186 patent/WO2008103620A2/en active Application Filing
- 2008-02-16 BR BRPI0807515-8A patent/BRPI0807515A2/en not_active IP Right Cessation
- 2008-02-16 EP EP08730066A patent/EP2125096A4/en not_active Withdrawn
- 2008-02-16 CA CA002678565A patent/CA2678565A1/en not_active Abandoned
- 2008-02-16 RU RU2009135048/14A patent/RU2480251C2/en not_active IP Right Cessation
-
2010
- 2010-06-29 US US12/826,662 patent/US20100274112A1/en not_active Abandoned
-
2017
- 2017-05-01 US US15/582,878 patent/US20170296740A1/en not_active Abandoned
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6068613A (en) * | 1989-06-16 | 2000-05-30 | Kriesel; Marshall S. | Fluid delivery device |
US5800420A (en) * | 1994-11-04 | 1998-09-01 | Elan Medical Technologies Limited | Analyte-controlled liquid delivery device and analyte monitor |
US5858001A (en) * | 1995-12-11 | 1999-01-12 | Elan Medical Technologies Limited | Cartridge-based drug delivery device |
US6186982B1 (en) * | 1998-05-05 | 2001-02-13 | Elan Corporation, Plc | Subcutaneous drug delivery device with improved filling system |
US6589229B1 (en) * | 2000-07-31 | 2003-07-08 | Becton, Dickinson And Company | Wearable, self-contained drug infusion device |
US20020072733A1 (en) * | 2000-09-08 | 2002-06-13 | Flaherty J. Christopher | Devices, systems and methods for patient infusion |
US20020040208A1 (en) * | 2000-10-04 | 2002-04-04 | Flaherty J. Christopher | Data collection assembly for patient infusion system |
US20020123740A1 (en) * | 2000-11-09 | 2002-09-05 | Flaherty J. Christopher | Transcutaneous delivery means |
US20020169439A1 (en) * | 2001-02-22 | 2002-11-14 | Flaherty J. Christopher | Modular infusion device and method |
US20030055380A1 (en) * | 2001-09-19 | 2003-03-20 | Flaherty J. Christopher | Plunger for patient infusion device |
US20050148865A1 (en) * | 2001-11-09 | 2005-07-07 | Scimed Life Systems, Inc. | Ceramic reinforcement member for MRI devices |
US20040015131A1 (en) * | 2002-07-16 | 2004-01-22 | Flaherty J. Christopher | Flow restriction system and method for patient infusion device |
US20060253086A1 (en) * | 2005-05-06 | 2006-11-09 | Medtronic Minimed, Inc. | Medical needles for damping motion |
US20060253085A1 (en) * | 2005-05-06 | 2006-11-09 | Medtronic Minimed, Inc. | Dual insertion set |
Also Published As
Publication number | Publication date |
---|---|
US9636450B2 (en) | 2017-05-02 |
US20100274112A1 (en) | 2010-10-28 |
CN101631586A (en) | 2010-01-20 |
WO2008103620A2 (en) | 2008-08-28 |
CN103055378A (en) | 2013-04-24 |
RU2480251C2 (en) | 2013-04-27 |
WO2008103620A3 (en) | 2008-10-16 |
US20080200897A1 (en) | 2008-08-21 |
EP2125096A2 (en) | 2009-12-02 |
BRPI0807515A2 (en) | 2014-06-03 |
EP2125096A4 (en) | 2012-11-07 |
CN101631586B (en) | 2013-01-09 |
CA2678565A1 (en) | 2008-08-28 |
RU2009135048A (en) | 2011-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170296740A1 (en) | Modular combination of medication infusion and analyte monitoring | |
US8029459B2 (en) | Method and system for providing integrated medication infusion and analyte monitoring system | |
US20240033429A1 (en) | Integrated analyte sensor and infusion device and methods therefo | |
US20230317276A1 (en) | Closed loop control system interface and methods | |
EP1250087B2 (en) | Handheld personal data assistant with a medical device | |
JP2002536038A (en) | Holter monitor system with analyte sensor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT DIABETES CARE INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HOSS, UDO;STAFFORD, GARY A.;REEL/FRAME:046756/0119 Effective date: 20090313 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |